

**(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. AU 2013242403 B2

(54) Title
Artificial nucleic acid molecules

(51) International Patent Classification(s)
C12N 15/67 (2006.01) **C12N 15/85** (2006.01)

(21) Application No: **2013242403** (22) Date of Filing: **2013.03.27**

(87) WIPO No: **WO13/143698**

(30) Priority Data

(31) Number (32) Date (33) Country
PCT/EP2012/002446 **2012.06.08** **EP**
PCT/EP2012/001337 **2012.03.27** **EP**

(43) Publication Date: **2013.10.03**
(44) Accepted Journal Date: **2018.10.18**

(71) Applicant(s)
CureVac AG

(72) Inventor(s)
Thess, Andreas;Kallen, Karl-Josef

(74) Agent / Attorney
Allens Patent & Trade Mark Attorneys, Deutsche Bank Place Corner Hunter and Phillip Streets, SYDNEY, NSW, 2000, AU

(56) Related Art
US 20100120152 A1
CHRISTINE I. WOODDELL ET AL, THE JOURNAL OF GENE MEDICINE, (2008-05-01), vol. 10, no. 5, pages 551 - 563
KRISTINE A PARTRIDGE ET AL, CYTOTECHNOLOGY (1999-05-01), vol. 30, no. 1-3, pages 37 - 47
WO 9913090 A1
US 20030143740 A1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2013/143698 A1

(43) International Publication Date
3 October 2013 (03.10.2013)(51) International Patent Classification:
C12N 15/67 (2006.01) *C12N 15/85* (2006.01)(74) Agents: **GRAF VON STOSCH, Andreas** et al.; Graf von Stosch Patentanwaltsgesellschaft mbH, Prinzregentenstrasse 22, 80538 München (DE).

(21) International Application Number:

PCT/EP2013/000936

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date:

27 March 2013 (27.03.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2012/001337 27 March 2012 (27.03.2012) EP
PCT/EP2012/002446 8 June 2012 (08.06.2012) EP(71) Applicant: **CUREVAC GMBH** [DE/DE]; Paul-Ehrlich-Str. 15, 72076 Tübingen (DE).

(72) Inventors; and

(71) Applicants (for US only): **THESS, Andreas** [DE/DE]; Hindenburgstr. 9, 72127 Kusterdingen (DE). **KALLEN, Karl-Josef** [DE/DE]; Philipp-von-Heck-Strasse 1, 72076 Tübingen (DE).


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

[Continued on next page]

(54) Title: ARTIFICIAL NUCLEIC ACID MOLECULES

PpLuc from mRNAs with different 3'-UTRs (HeLa)

PpLuc(GC)..



(57) Abstract: The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3'UTR element comprising a nucleic acid sequence which is derived from the 3'UTR of an albumin gene or from a variant of the 3'UTR of an albumin gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. Furthermore, the invention relates to the use of a 3'UTR element comprising a nucleic acid sequence which is derived from the 3'UTR of an albumin gene or from a variant of the 3'UTR of an albumin gene for the stabilization and/or prolongation of protein expression from a nucleic acid sequence comprising such 3'UTR element.

Fig. 1



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, **Published:**
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

5

Artificial nucleic acid molecules

The invention relates to artificial nucleic acid molecules comprising an open reading frame, a 3'-UTR element and optionally a poly(A) sequence and/or a polyadenylation-signal. The invention relates further to a vector comprising a 3'-UTR element, to a pharmaceutical composition comprising an artificial nucleic acid molecule and to a kit comprising an artificial nucleic acid molecule, a vector and/or a pharmaceutical composition comprising an artificial nucleic acid molecule, preferably for use in the field of gene therapy and/or genetic vaccination.

Gene therapy and genetic vaccination belong to the most promising and quickly developing methods of modern medicine. They may provide highly specific and individual options for therapy of a large variety of diseases. Particularly, inherited genetic diseases but also autoimmune diseases, cancerous or tumour-related diseases as well as inflammatory diseases may be the subject of such treatment approaches. Also, it is envisaged to prevent (early) onset of such diseases by these approaches.

The main conceptual rational behind gene therapy is appropriate modulation of impaired gene expression associated with pathological conditions of specific diseases. Pathologically altered gene expression may result in lack or overproduction of essential gene products, for example, signalling factors such as hormones, housekeeping factors, metabolic enzymes, structural proteins or the like. Altered gene expression may not only be due to misregulation of transcription and/or translation, but also due to mutations within the ORF coding for a particular protein. Pathological mutations may be caused by e.g. chromosomal aberration, or by more specific mutations, such as point or frame-shift-mutations, all of them resulting in limited functionality and, potentially, total loss of function of the gene product.

However, misregulation of transcription or translation may also occur, if mutations affect genes encoding proteins which are involved in the transcriptional or translational machinery of the cell. Such mutations may lead to pathological up- or down-regulation of genes which are – as such – functional. Genes encoding gene products which exert such regulating functions, may be, e.g., transcription factors, signal receptors, messenger proteins or the like. However, loss of function of such genes encoding regulatory proteins may, under certain circumstances, be reversed by artificial introduction of other factors acting further downstream of the impaired gene product. Such gene defects may also be compensated by gene therapy via substitution of the affected gene itself.

10 Genetic vaccination allows to evoke a desired immune response to selected antigens, such as characteristic components of bacterial surfaces, viral particles, tumour antigens or the like. Generally, vaccination is one of the pivotal achievements of modern medicine. However, effective vaccines are currently available only for a smaller number of diseases. Accordingly, infections that are not preventable by vaccination still affect millions of people
15 every year.

Commonly, vaccines may be subdivided into “first”, “second” and “third” generation vaccines. “First generation” vaccines are, typically, whole-organism vaccines. They are based on either live and attenuated or killed pathogens, e.g. viruses, bacteria or the like. The major drawback of live and attenuated vaccines is the risk for a reversion to life-
20 threatening variants. Thus, although attenuated, such pathogens may still intrinsically bear unpredictable risks. Killed pathogens may not be as effective as desired for generating a specific immune response. In order to minimize these risks, “second generation” vaccines were developed. These are, typically, subunit vaccines, consisting of defined antigens or recombinant protein components which are derived from pathogens.

25 Genetic vaccines, i.e. vaccines for genetic vaccination, are usually understood as “third generation” vaccines. They are typically composed of genetically engineered nucleic acid molecules which allow expression of peptide or protein (antigen) fragments characteristic for a pathogen or a tumor antigen *in vivo*. Genetic vaccines are expressed upon administration to a patient an uptake by competent cells. Expression of the administered
30 nucleic acids results in production of the encoded proteins. In the event these proteins are recognized as foreign by the patient’s immune system, an immune response is triggered.

As can be seen from the above, both methods, gene therapy and genetic vaccination, are essentially based on the administration of nucleic acid molecules to a patient and subsequent transcription and/or translation of the encoded genetic information. Alternatively, genetic vaccination or gene therapy may also comprise methods which 5 include isolation of specific body cells from a patient to be treated, subsequent *in vitro* transfection of such cells, and re-administration of the treated cells to the patient.

DNA as well as RNA may be used as nucleic acid molecules for administration in the context of gene therapy or genetic vaccination. DNA is known to be relatively stable and easy to handle. However, the use of DNA bears the risk of undesired insertion of the 10 administered DNA-fragments into the patient's genome potentially resulting in loss of function of the impaired genes. As a further risk, the undesired generation of anti-DNA antibodies has emerged. Another drawback is the limited expression level of the encoded peptide or protein that is achievable upon DNA administration and its transcription/translation. Among other reasons, the expression level of the administered 15 DNA will be dependent on the presence of specific transcription factors which regulate DNA transcription. In the absence of such factors, DNA transcription will not yield satisfying amounts of RNA. As a result, the level of translated peptide or protein obtained is limited.

By using RNA instead of DNA for gene therapy or genetic vaccination, the risk of undesired 20 genomic integration and generation of anti-DNA antibodies is minimized or avoided. However, RNA is considered to be a rather unstable molecular species which may readily be degraded by ubiquitous RNases.

In vivo, RNA-degradation contributes to the regulation of the RNA half-life time. That effect was considered and proven to fine tune the regulation of eukaryotic gene expression 25 (Friedel *et al.*, Conserved principles of mammalian transcriptional regulation revealed by RNA half-life, Nucleic Acid Research, 2009, 1-12). Accordingly, each naturally occurring mRNA has its individual half-life depending on the gene from which the mRNA is derived. It contributes to the regulation of the expression level of this gene. Unstable RNAs are important to realize transient gene expression at distinct points in time. However, long-lived 30 RNAs may be associated with accumulation of distinct proteins or continuous expression of genes. *In vivo*, the half life of mRNAs may also be dependent on environmental factors,

such as hormonal treatment, as has been shown, e.g., for insulin-like growth factor I, actin, and albumin mRNA (Johnson *et al.*, Newly synthesized RNA: Simultaneous measurement in intact cells of transcription rates and RNA stability of insulin-like growth factor I, actin, and albumin in growth hormone-stimulated hepatocytes, Proc. Natl. Acad. Sci., Vol. 88, pp.

5 5287-5291, 1991).

For gene therapy and genetic vaccination, usually stable RNA is desired. This is, on the one hand, due to the fact that the product encoded by the RNA-sequence shall accumulate *in vivo*. On the other hand, the RNA has to maintain its structural and functional integrity when prepared for a suitable dosage form, in the course of its storage, and when 10 administered. Thus, considerable attention was dedicated to provide stable RNA molecules for gene therapy or genetic vaccination in order to prevent them from being subject to early degradation or decay.

It has been reported that the G/C-content of nucleic acid molecules may influence their stability. Thus, nucleic acids comprising an increased amount of guanine (G) and/or

15 cytosine (C) residues may be functionally more stable than nucleic acids containing a large amount of adenine (A) and thymine (T) or uracil (U) nucleotides. In this context, WO02/098443 provides a pharmaceutical composition containing an mRNA that is stabilised by sequence modifications in the translated region. Such a sequence modification takes advantage of the degeneracy of the genetic code. Accordingly, codons which contain

20 a less favourable combination of nucleotides (less favourable in terms of RNA stability) may be substituted by alternative codons without altering the encoded amino acid sequence.

This method of RNA stabilization is limited by the provisions of the specific nucleotide sequence of each single RNA molecule which is not allowed to leave the space of the desired amino acid sequence. Also, that approach is restricted to coding regions of the

25 RNA.

As an alternative option for mRNA stabilisation, it has been found that naturally occurring eukaryotic mRNA molecules contain characteristic stabilising elements. For example, they may comprise so-called untranslated regions (UTR) at their 5'-end (5'-UTR) and/or at their

30 3'-end (3'-UTR) as well as other structural features, such as a 5'-cap structure or a 3'- poly(A) tail. Both, 5'-UTR and 3'-UTR are typically transcribed from the genomic DNA and are, thus, an element of the premature mRNA. Characteristic structural features of mature

mRNA, such as the 5'-cap and the 3'-poly(A) tail (also called poly(A) tail or poly(A) sequence) are usually added to the transcribed (premature) mRNA during mRNA processing.

A 3'-poly(A) tail is typically a monotonous sequence stretch of adenine nucleotides added to the 3'-end of the transcribed mRNA. It may comprise up to about 400 adenine nucleotides. It was 5 found that the length of such a 3'-poly(A) tail is a potentially critical element for the stability of the individual mRNA.

Also, it was shown that the 3'UTR of α -globin mRNA may be an important factor for the well-known stability of α -globin mRNA (Rodgers *et al.*, Regulated α -globin mRNA decay is a cytoplasmic event proceeding through 3'-to-5' exosome-dependent decapping, *RNA*, 8, pp. 1526-10 1537, 2002). The 3'UTR of α -globin mRNA is obviously involved in the formation of a specific ribonucleoprotein-complex, the α -complex, whose presence correlates with mRNA stability *in vitro* (Wang *et al.*, An mRNA stability complex functions with poly(A)-binding protein to stabilize mRNA *in vitro*, *Molecular and Cellular biology*, Vol 19, No. 7, July 1999, p. 4552-4560).

Irrespective of factors influencing mRNA stability, effective translation of the administered 15 nucleic acid molecules by the target cells or tissue is crucial for any approach using nucleic acid molecules for gene therapy or genetic vaccination. Along with the regulation of stability, also translation of the majority of mRNAs is regulated by structural features like UTRs, 5'-cap and 3'-poly(A) tail. In this context, it has been reported that the length of the poly(A) tail may play an important role for translational efficiency as well. Stabilizing 3'-elements, however, may also 20 have an attenuating effect on translation.

There is provided herein nucleic acid molecules which may be suitable for application in gene therapy and/or genetic vaccination. Particularly, it is the object of the invention to provide an mRNA species which is stabilized against preterm degradation or decay without exhibiting significant functional loss in translational efficiency. Also provided are nucleic acid molecules 25 coding for such a superior mRNA species which may be amenable for use in gene therapy and/or genetic vaccination. Further provided is a pharmaceutical composition for use in gene therapy and/or genetic vaccination. In summary, there is provided improved nucleic acid species which overcome the

above discussed disadvantages of the prior art by a cost-effective and straight-forward approach.

For the sake of clarity and readability the following definitions are provided. Any technical feature mentioned for these definitions may be read on each and every embodiment of the invention. Additional definitions and explanations may be specifically provided in the context of these embodiments.

Adaptive immune response: The adaptive immune response is typically understood to be an antigen-specific response of the immune system. Antigen specificity allows for the generation of responses that are tailored to specific pathogens or pathogen-infected cells. The ability to mount these tailored responses is usually maintained in the body by "memory cells". Should a pathogen infect the body more than once, these specific memory cells are used to quickly eliminate it. In this context, the first step of an adaptive immune response is the activation of naïve antigen-specific T cells or different immune cells able to induce an antigen-specific immune response by antigen-presenting cells. This occurs in the lymphoid tissues and organs through which naïve T cells are constantly passing. The three cell types that may serve as antigen-presenting cells are dendritic cells, macrophages, and B cells. Each of these cells has a distinct function in eliciting immune responses. Dendritic cells may take up antigens by phagocytosis and macropinocytosis and may become stimulated by contact with e.g. a foreign antigen to migrate to the local lymphoid tissue, where they differentiate into mature dendritic cells. Macrophages ingest particulate antigens such as bacteria and are induced by infectious agents or other appropriate stimuli to express MHC molecules. The unique ability of B cells to bind and internalize soluble protein antigens via their receptors may also be important to induce T cells. MHC-molecules are, typically, responsible for presentation of an antigen to T-cells. Therein, presenting the antigen on MHC molecules leads to activation of T cells which induces their proliferation and differentiation into armed effector T cells. The most important function of effector T cells is the killing of infected cells by CD8+ cytotoxic T cells and the activation of macrophages by Th1 cells which together make up cell-mediated immunity, and the activation of B cells by both Th2 and Th1 cells to produce different classes of antibody, thus driving the humoral immune response. T cells recognize an antigen by their T cell receptors which do not

recognize and bind the antigen directly, but instead recognize short peptide fragments e.g. of pathogen-derived protein antigens, e.g. so-called epitopes, which are bound to MHC molecules on the surfaces of other cells.

Adaptive immune system: The adaptive immune system is essentially dedicated to eliminate or prevent pathogenic growth. It typically regulates the adaptive immune response by providing the vertebrate immune system with the ability to recognize and remember specific pathogens (to generate immunity), and to mount stronger attacks each time the pathogen is encountered. The system is highly adaptable because of somatic hypermutation (a process of accelerated somatic mutations), and V(D)J recombination (an irreversible genetic recombination of antigen receptor gene segments). This mechanism allows a small number of genes to generate a vast number of different antigen receptors, which are then uniquely expressed on each individual lymphocyte. Because the gene rearrangement leads to an irreversible change in the DNA of each cell, all of the progeny (offspring) of such a cell will then inherit genes encoding the same receptor specificity, including the Memory B cells and Memory T cells that are the keys to long-lived specific immunity.

Adjuvant/adjuvant component: An adjuvant or an adjuvant component in the broadest sense is typically a pharmacological and/or immunological agent that may modify, e.g. enhance, the effect of other agents, such as a drug or vaccine. It is to be interpreted in a broad sense and refers to a broad spectrum of substances. Typically, these substances are able to increase the immunogenicity of antigens. For example, adjuvants may be recognized by the innate immune systems and, e.g., may elicit an innate immune response. "Adjuvants" typically do not elicit an adaptive immune response. Insofar, "adjuvants" do not qualify as antigens. Their mode of action is distinct from the effects triggered by antigens resulting in an adaptive immune response.

Antigen: In the context of the present invention "antigen" refers typically to a substance which may be recognized by the immune system, preferably by the adaptive immune system, and is capable of triggering an antigen-specific immune response, e.g. by formation of antibodies and/or antigen-specific T cells as part of an adaptive immune response. Typically, an antigen may be or may comprise a peptide or protein which may be presented by the MHC to T-cells.

Artificial nucleic acid molecule: An artificial nucleic acid molecule may typically be understood to be a nucleic acid molecule, e.g. a DNA or an RNA, that does not occur naturally. In other words, an artificial nucleic acid molecule may be understood as a non-natural nucleic acid molecule. Such nucleic acid molecule may be non-natural due to its 5 individual sequence (which does not occur naturally) and/or due other modifications, e.g. structural modifications of nucleotides which do not occur naturally. An artificial nucleic acid molecule may be a DNA molecule, an RNA molecule or a hybrid-molecule comprising DNA and RNA portions. Typically, artificial nucleic acid molecules may be designed and/or generated by genetic engineering methods to correspond to a desired 10 artificial sequence of nucleotides (heterologous sequence). In this context an artificial sequence is usually a sequence that may not occur naturally, i.e. it differs from the wild type sequence by at least one nucleotide. The term "wild type" may be understood as a sequence occurring in nature. Further, the term "artificial nucleic acid molecule" is not restricted to mean "one single molecule" but is, typically, understood to comprise an 15 ensemble of identical molecules. Accordingly, it may relate to a plurality of identical molecules contained in an aliquot.

Bicistronic RNA, multicistronic RNA: A bicistronic or multicistronic RNA is typically an RNA, preferably an mRNA, that typically may have two (bicistronic) or more (multicistronic) open reading frames (ORF). An open reading frame in this context is a 20 sequence of codons that is translatable into a peptide or protein.

Carrier / polymeric carrier: A carrier in the context of the invention may typically be a compound that facilitates transport and/or complexation of another compound (cargo). A polymeric carrier is typically a carrier that is formed of a polymer. A carrier may be associated to its cargo by covalent or non-covalent interaction. A carrier may transport 25 nucleic acids, e.g. RNA or DNA, to the target cells. The carrier may – for some embodiments – be a cationic component.

Cationic component: The term "cationic component" typically refers to a charged molecule, which is positively charged (cation) at a pH value typically from 1 to 9, preferably at a pH value of or below 9 (e.g. from 5 to 9), of or below 8 (e.g. from 5 to 8), of 30 or below 7 (e.g. from 5 to 7), most preferably at a physiological pH, e.g. from 7.3 to 7.4. Accordingly, a cationic component may be any positively charged compound or polymer,

preferably a cationic peptide or protein which is positively charged under physiological conditions, particularly under physiological conditions *in vivo*. A "cationic peptide or protein" may contain at least one positively charged amino acid, or more than one positively charged amino acid, e.g. selected from Arg, His, Lys or Orn. Accordingly, 5 "polycationic" components are also within the scope exhibiting more than one positive charge under the conditions given.

5'-cap: A 5'-cap is an entity, typically a modified nucleotide entity, which generally "caps" the 5'-end of a mature mRNA. A 5'-cap may typically be formed by a modified nucleotide, particularly by a derivative of a guanine nucleotide. Preferably, the 5'-cap is 10 linked to the 5'-terminus via a 5'-5'-triphosphate linkage. A 5'-cap may be methylated, e.g. m7GpppN, wherein N is the terminal 5' nucleotide of the nucleic acid carrying the 5'-cap, typically the 5'-end of an RNA. . Further examples of 5'cap structures include glyceryl, inverted deoxy abasic residue (moiety), 4',5' methylene nucleotide, 1-(beta-D-erythrofuranosyl) nucleotide, 4'-thio nucleotide, carbocyclic nucleotide, 1,5-anhydrohexitol 15 nucleotide, L-nucleotides, alpha-nucleotide, modified base nucleotide, threo-pentofuranosyl nucleotide, acyclic 3',4'-seco nucleotide, acyclic 3,4-dihydroxybutyl nucleotide, acyclic 3,5 dihydroxypentyl nucleotide, 3'-3'-inverted nucleotide moiety, 3'-3'-inverted abasic moiety, 3'-2'-inverted nucleotide moiety, 3'-2'-inverted abasic moiety, 1,4-butanediol phosphate, 3'-phosphoramidate, hexylphosphate, aminohexyl phosphate, 3'-phosphate, 20 3'phosphorothioate, phosphorodithioate, or bridging or non-bridging methylphosphonate moiety.

Cellular immunity/cellular immune response: Cellular immunity relates typically to the activation of macrophages, natural killer cells (NK), antigen-specific cytotoxic T-lymphocytes, and the release of various cytokines in response to an antigen. In more 25 general terms, cellular immunity is not based on antibodies, but on the activation of cells of the immune system. Typically, a cellular immune response may be characterized e.g. by activating antigen-specific cytotoxic T-lymphocytes that are able to induce apoptosis in cells, e.g. specific immune cells like dendritic cells or other cells, displaying epitopes of foreign antigens on their surface. Such cells may be virus-infected or infected with 30 intracellular bacteria, or cancer cells displaying tumor antigens. Further characteristics may be activation of macrophages and natural killer cells, enabling them to destroy pathogens

and stimulation of cells to secrete a variety of cytokines that influence the function of other cells involved in adaptive immune responses and innate immune responses.

DNA: DNA is the usual abbreviation for deoxy-ribonucleic-acid. It is a nucleic acid molecule, i.e. a polymer consisting of nucleotides. These nucleotides are usually deoxy-

5 adenosine-monophosphate, deoxy-thymidine-monophosphate, deoxy-guanosine-monophosphate and deoxy-cytidine-monophosphate monomers which are – by themselves – composed of a sugar moiety (deoxyribose), a base moiety and a phosphate moiety, and polymerise by a characteristic backbone structure. The backbone structure is, typically, formed by phosphodiester bonds between the sugar moiety of the nucleotide, i.e. deoxyribose, of a first and a phosphate moiety of a second, adjacent monomer. The specific order of the monomers, i.e. the order of the bases linked to the sugar/phosphate-backbone, is called the DNA-sequence. DNA may be single stranded or double stranded. In the double stranded form, the nucleotides of the first strand typically hybridize with the nucleotides of the second strand, e.g. by A/T-base-pairing and G/C-base-pairing.

10 Epitope: (also called “antigen determinant”) can be distinguished in T cell epitopes and B cell epitopes. T cell epitopes or parts of the proteins in the context of the present invention may comprise fragments preferably having a length of about 6 to about 20 or even more amino acids, e.g. fragments as processed and presented by MHC class I molecules, preferably having a length of about 8 to about 10 amino acids, e.g. 8, 9, or 10, (or even 11, 20 or 12 amino acids), or fragments as processed and presented by MHC class II molecules, preferably having a length of about 13 or more amino acids, e.g. 13, 14, 15, 16, 17, 18, 19, 25 20 or even more amino acids, wherein these fragments may be selected from any part of the amino acid sequence. These fragments are typically recognized by T cells in form of a complex consisting of the peptide fragment and an MHC molecule, i.e. the fragments are typically not recognized in their native form. B cell epitopes are typically fragments located on the outer surface of (native) protein or peptide antigens as defined herein, preferably having 5 to 15 amino acids, more preferably having 5 to 12 amino acids, even more preferably having 6 to 9 amino acids, which may be recognized by antibodies, i.e. in their native form.

30 Such epitopes of proteins or peptides may furthermore be selected from any of the herein mentioned variants of such proteins or peptides. In this context antigenic determinants can be conformational or discontinuous epitopes which are composed of segments of the pro-

teins or peptides as defined herein that are discontinuous in the amino acid sequence of the proteins or peptides as defined herein but are brought together in the three-dimensional structure or continuous or linear epitopes which are composed of a single polypeptide chain.

5 Fragment of a sequence: A fragment of a sequence may typically be a shorter portion of a full-length sequence of e.g. a nucleic acid molecule or an amino acid sequence. Accordingly, a fragment, typically, consists of a sequence that is identical to the corresponding stretch within the full-length sequence. A preferred fragment of a sequence in the context of the present invention, consists of a continuous stretch of entities, such as 10 nucleotides or amino acids corresponding to a continuous stretch of entities in the molecule the fragment is derived from, which represents at least 20%, preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, and most preferably at least 80% of the total (i.e. full-length) molecule from which the fragment is derived.

15 G/C modified: A G/C-modified nucleic acid may typically be a nucleic acid, preferably an artificial nucleic acid molecule as defined herein, based on a modified wild-type sequence comprising a preferably increased number of guanosine and/or cytosine nucleotides as compared to the wild-type sequence. Such an increased number may be generated by substitution of codons containing adenosine or thymidine nucleotides by 20 codons containing guanosine or cytosine nucleotides. If the enriched G/C content occurs in a coding region of DNA or RNA, it makes use of the degeneracy of the genetic code. Accordingly, the codon substitutions preferably do not alter the encoded amino acid residues, but exclusively increase the G/C content of the nucleic acid molecule.

25 Gene therapy: Gene therapy may typically be understood to mean a treatment of a patient's body or isolated elements of a patient's body, for example isolated tissues/cells, by nucleic acids encoding a peptide or protein. It typically may comprise at least one of the steps of a) administration of a nucleic acid, preferably an artificial nucleic acid molecule as defined herein, directly to the patient - by whatever administration route - or *in vitro* to isolated cells/tissues of the patient, which results in transfection of the patient's cells either *in vivo/ex vivo* or *in vitro*; b) transcription and/or translation of the introduced nucleic acid molecule;

and optionally c) re-administration of isolated, transfected cells to the patient, if the nucleic acid has not been administered directly to the patient.

Genetic vaccination: Genetic vaccination may typically be understood to be vaccination by administration of a nucleic acid molecule encoding an antigen or an immunogen or fragments thereof. The nucleic acid molecule may be administered to a subject's body or to isolated cells of a subject. Upon transfection of certain cells of the body or upon transfection of the isolated cells, the antigen or immunogen may be expressed by those cells and subsequently presented to the immune system, eliciting an adaptive, i.e. antigen-specific immune response. Accordingly, genetic vaccination typically comprises at least one of the steps of a) administration of a nucleic acid, preferably an artificial nucleic acid molecule as defined herein, to a subject, preferably a patient, or to isolated cells of a subject, preferably a patient, which usually results in transfection of the subject's cells either *in vivo* or *in vitro*; b) transcription and/or translation of the introduced nucleic acid molecule; and optionally c) re-administration of isolated, transfected cells to the subject, preferably the patient, if the nucleic acid has not been administered directly to the patient.

Heterologous sequence: Two sequences are typically understood to be 'heterologous' if they are not derivable from the same gene. I.e., although heterologous sequences may be derivable from the same organism, they naturally (in nature) do not occur in the same nucleic acid molecule, such as in the same mRNA.

Humoral immunity/humoral immune response: Humoral immunity refers typically to antibody production and optionally to accessory processes accompanying antibody production. A humoral immune response may be typically characterized, e.g., by Th2 activation and cytokine production, germinal center formation and isotype switching, affinity maturation and memory cell generation. Humoral immunity also typically may refer to the effector functions of antibodies, which include pathogen and toxin neutralization, classical complement activation, and opsonin promotion of phagocytosis and pathogen elimination.

Immunogen: In the context of the present invention an immunogen may be typically understood to be a compound that is able to stimulate an immune response. Preferably, an immunogen is a peptide, polypeptide, or protein. In a particularly preferred embodiment, an immunogen in the sense of the present invention is the product of translation of a provided

nucleic acid molecule, preferably an artificial nucleic acid molecule as defined herein. Typically, an immunogen elicits at least an adaptive immune response.

Immunostimulatory composition: In the context of the invention, an immunostimulatory composition may be typically understood to be a composition containing at least one

5 component which is able to induce an immune response or from which a component which is able to induce an immune response is derivable. Such immune response may be preferably an innate immune response or a combination of an adaptive and an innate immune response. Preferably, an immunostimulatory composition in the context of the invention contains at least one artificial nucleic acid molecule, more preferably an RNA, for
10 example an mRNA molecule. The immunostimulatory component, such as the mRNA may be complexed with a suitable carrier. Thus, the immunostimulatory composition may comprise an mRNA/carrier-complex. Furthermore, the immunostimulatory composition may comprise an adjuvant and/or a suitable vehicle for the immunostimulatory component, such as the mRNA.

15 Immune response: An immune response may typically be a specific reaction of the adaptive immune system to a particular antigen (so called specific or adaptive immune response) or an unspecific reaction of the innate immune system (so called unspecific or innate immune response), or a combination thereof.

20 Immune system: The immune system may protect organisms from infection. If a pathogen succeeds in passing a physical barrier of an organism and enters this organism, the innate immune system provides an immediate, but non-specific response. If pathogens evade this innate response, vertebrates possess a second layer of protection, the adaptive immune system. Here, the immune system adapts its response during an infection to improve its recognition of the pathogen. This improved response is then retained after the pathogen has
25 been eliminated, in the form of an immunological memory, and allows the adaptive immune system to mount faster and stronger attacks each time this pathogen is encountered. According to this, the immune system comprises the innate and the adaptive immune system. Each of these two parts typically contains so called humoral and cellular components.

30 Immunostimulatory RNA: An immunostimulatory RNA (isRNA) in the context of the invention may typically be an RNA that is able to induce an innate immune response. It

usually does not have an open reading frame and thus does not provide a peptide-antigen or immunogen but elicits an immune response e.g. by binding to a specific kind of Toll-like-receptor (TLR) or other suitable receptors. However, of course also mRNAs having an open reading frame and coding for a peptide/protein may induce an innate immune response and, thus, may be immunostimulatory RNAs.

Innate immune system: The innate immune system, also known as non-specific (or unspecific) immune system, typically comprises the cells and mechanisms that defend the host from infection by other organisms in a non-specific manner. This means that the cells of the innate system may recognize and respond to pathogens in a generic way, but unlike

10 the adaptive immune system, it does not confer long-lasting or protective immunity to the host. The innate immune system may be, e.g., activated by ligands of Toll-like receptors (TLRs) or other auxiliary substances such as lipopolysaccharides, TNF-alpha, CD40 ligand, or cytokines, monokines, lymphokines, interleukins or chemokines, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IFN-alpha, IFN-beta, IFN-gamma, GM-CSF, G-CSF, M-CSF, LT-beta, TNF-alpha, growth factors, and hGH, a ligand of human Toll-like receptor TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, a ligand of murine Toll-like receptor TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12 or TLR13, a ligand of a NOD-like receptor,

15 a ligand of a RIG-I like receptor, an immunostimulatory nucleic acid, an immunostimulatory RNA (isRNA), a CpG-DNA, an antibacterial agent, or an anti-viral agent. The pharmaceutical composition according to the present invention may comprise one or more such substances. Typically, a response of the innate immune system includes recruiting immune cells to sites of infection, through the production of chemical factors, including

20 specialized chemical mediators, called cytokines; activation of the complement cascade; identification and removal of foreign substances present in organs, tissues, the blood and lymph, by specialized white blood cells; activation of the adaptive immune system; and/or acting as a physical and chemical barrier to infectious agents.

Cloning site: A cloning site is typically understood to be a segment of a nucleic acid molecule, which is suitable for insertion of a nucleic acid sequence, e.g., a nucleic acid sequence comprising an open reading frame. Insertion may be performed by any molecular biological method known to the one skilled in the art, e.g. by restriction and ligation. A

cloning site typically comprises one or more restriction enzyme recognition sites (restriction sites). These one or more restrictions sites may be recognized by restriction enzymes which cleave the DNA at these sites. A cloning site which comprises more than one restriction site may also be termed a multiple cloning site (MCS) or a polylinker.

5 Nucleic acid molecule: A nucleic acid molecule is a molecule comprising, preferably consisting of nucleic acid components. The term nucleic acid molecule preferably refers to DNA or RNA molecules. It is preferably used synonymous with the term "polynucleotide". Preferably, a nucleic acid molecule is a polymer comprising or consisting of nucleotide monomers which are covalently linked to each other by phosphodiester-bonds of a 10 sugar/phosphate-backbone. The term "nucleic acid molecule" also encompasses modified nucleic acid molecules, such as base-modified, sugar-modified or backbone-modified etc. DNA or RNA molecules.

15 Open reading frame: An open reading frame (ORF) in the context of the invention may typically be a sequence of several nucleotide triplets which may be translated into a peptide or protein. An open reading frame preferably contains a start codon, i.e. a combination of three subsequent nucleotides coding usually for the amino acid methionine (ATG), at its 5'-end and a subsequent region which usually exhibits a length which is a multiple of 3 nucleotides. An ORF is preferably terminated by a stop-codon (e.g., TAA, TAG, TGA). Typically, this is the only stop-codon of the open reading frame. Thus, an open reading 20 frame in the context of the present invention is preferably a nucleotide sequence, consisting of a number of nucleotides that may be divided by three, which starts with a start codon (e.g. ATG) and which preferably terminates with a stop codon (e.g., TAA, TGA, or TAG). The open reading frame may be isolated or it may be incorporated in a longer nucleic acid sequence, for example in a vector or an mRNA. An open reading frame may also be termed 25 "protein coding region".

30 Peptide: A peptide or polypeptide is typically a polymer of amino acid monomers, linked by peptide bonds. It typically contains less than 50 monomer units. Nevertheless, the term peptide is not a disclaimer for molecules having more than 50 monomer units. Long peptides are also called polypeptides, typically having between 50 and 600 monomeric units.

Pharmaceutically effective amount: A pharmaceutically effective amount in the context of the invention is typically understood to be an amount that is sufficient to induce a pharmaceutical effect, such as an immune response, altering a pathological level of an expressed peptide or protein, or substituting a lacking gene product, e.g., in case of a pathological situation.

Protein A protein typically comprises one or more peptides or polypeptides. A protein is typically folded into 3-dimensional form, which may be required for the protein to exert its biological function.

Poly(A) sequence: A poly(A) sequence, also called poly(A) tail or 3'-poly(A) tail, is typically understood to be a sequence of adenine nucleotides, e.g., of up to about 400 adenine nucleotides, e.g. from about 20 to about 400, preferably from about 50 to about 400, more preferably from about 50 to about 300, even more preferably from about 50 to about 250, most preferably from about 60 to about 250 adenine nucleotides. A poly(A) sequence is typically located at the 3'end of an mRNA. In the context of the present invention, a poly(A) sequence may be located within an mRNA or any other nucleic acid molecule, such as, e.g., in a vector, for example, in a vector serving as template for the generation of an RNA, preferably an mRNA, e.g., by transcription of the vector.

Polyadenylation: Polyadenylation is typically understood to be the addition of a poly(A) sequence to a nucleic acid molecule, such as an RNA molecule, e.g. to a premature mRNA. Polyadenylation may be induced by a so called polyadenylation signal. This signal is preferably located within a stretch of nucleotides at the 3'-end of a nucleic acid molecule, such as an RNA molecule, to be polyadenylated. A polyadenylation signal typically comprises a hexamer consisting of adenine and uracil/thymine nucleotides, preferably the hexamer sequence AAUAAA. Other sequences, preferably hexamer sequences, are also conceivable. Polyadenylation typically occurs during processing of a pre-mRNA (also called premature-mRNA). Typically, RNA maturation (from pre-mRNA to mature mRNA) comprises the step of polyadenylation.

Restriction site: A restriction site, also termed restriction enzyme recognition site, is a nucleotide sequence recognized by a restriction enzyme. A restriction site is typically a short, preferably palindromic nucleotide sequence, e.g. a sequence comprising 4 to 8 nucleotides. A restriction site is preferably specifically recognized by a restriction enzyme.

The restriction enzyme typically cleaves a nucleotide sequence comprising a restriction site at this site. In a double-stranded nucleotide sequence, such as a double-stranded DNA sequence, the restriction enzyme typically cuts both strands of the nucleotide sequence.

RNA, mRNA: RNA is the usual abbreviation for ribonucleic-acid. It is a nucleic acid molecule, i.e. a polymer consisting of nucleotides. These nucleotides are usually adenosine-monophosphate, uridine-monophosphate, guanosine-monophosphate and cytidine-monophosphate monomers which are connected to each other along a so-called backbone. The backbone is formed by phosphodiester bonds between the sugar, i.e. ribose, of a first and a phosphate moiety of a second, adjacent monomer. The specific succession of the monomers is called the RNA-sequence. Usually RNA may be obtainable by transcription of a DNA-sequence, e.g., inside a cell. In eukaryotic cells, transcription is typically performed inside the nucleus or the mitochondria. In vivo, transcription of DNA usually results in the so-called premature RNA which has to be processed into so-called messenger-RNA, usually abbreviated as mRNA. Processing of the premature RNA, e.g. in eukaryotic organisms, comprises a variety of different posttranscriptional-modifications such as splicing, 5'-capping, polyadenylation, export from the nucleus or the mitochondria and the like. The sum of these processes is also called maturation of RNA. The mature messenger RNA usually provides the nucleotide sequence that may be translated into an amino-acid sequence of a particular peptide or protein. Typically, a mature mRNA comprises a 5'-cap, a 5'UTR, an open reading frame, a 3'UTR and a poly(A) sequence. Aside from messenger RNA, several non-coding types of RNA exist which may be involved in regulation of transcription and/or translation.

Sequence of a nucleic acid molecule: The sequence of a nucleic acid molecule is typically understood to be the particular and individual order, i.e. the succession of its nucleotides. The sequence of a protein or peptide is typically understood to be the order, i.e. the succession of its amino acids.

Sequence identity: Two or more sequences are identical if they exhibit the same length and order of nucleotides or amino acids. The percentage of identity typically describes the extent to which two sequences are identical, i.e. it typically describes the percentage of nucleotides that correspond in their sequence position with identical nucleotides of a reference-sequence. For determination of the degree of identity, the sequences to be

compared are considered to exhibit the same length, i.e. the length of the longest sequence of the sequences to be compared. This means that a first sequence consisting of 8 nucleotides is 80% identical to a second sequence consisting of 10 nucleotides comprising the first sequence. In other words, in the context of the present invention, identity of sequences preferably relates to the percentage of nucleotides of a sequence which have the same position in two or more sequences having the same length. Gaps are usually regarded as non-identical positions, irrespective of their actual position in an alignment.

Stabilized nucleic acid molecule: A stabilized nucleic acid molecule is a nucleic acid molecule, preferably a DNA or RNA molecule that is modified such, that it is more stable to disintegration or degradation, e.g., by environmental factors or enzymatic digest, such as by an exo- or endonuclease degradation, than the nucleic acid molecule without the modification. Preferably, a stabilized nucleic acid molecule in the context of the present invention is stabilized in a cell, such as a prokaryotic or eukaryotic cell, preferably in a mammalian cell, such as a human cell. The stabilization effect may also be exerted outside of cells, e.g. in a buffer solution etc., for example, in a manufacturing process for a pharmaceutical composition comprising the stabilized nucleic acid molecule.

Transfection: The term “transfection” refers to the introduction of nucleic acid molecules, such as DNA or RNA (e.g. mRNA) molecules, into cells, preferably into eukaryotic cells. In the context of the present invention, the term “transfection” encompasses any method known to the skilled person for introducing nucleic acid molecules into cells, preferably into eukaryotic cells, such as into mammalian cells. Such methods encompass, for example, electroporation, lipofection, e.g. based on cationic lipids and/or liposomes, calcium phosphate precipitation, nanoparticle based transfection, virus based transfection, or transfection based on cationic polymers, such as DEAE-dextran or polyethylenimine etc.

25 Preferably, the introduction is non-viral.

Vaccine: A vaccine is typically understood to be a prophylactic or therapeutic material providing at least one antigen, preferably an immunogen. The antigen or immunogen may be derived from any material that is suitable for vaccination. For example, the antigen or immunogen may be derived from a pathogen, such as from bacteria or virus particles etc., or from a tumor or cancerous tissue. The antigen or immunogen stimulates the body's adaptive immune system to provide an adaptive immune response.

Vector: The term "vector" refers to a nucleic acid molecule, preferably to an artificial nucleic acid molecule. A vector in the context of the present invention is suitable for incorporating or harboring a desired nucleic acid sequence, such as a nucleic acid sequence comprising an open reading frame. Such vectors may be storage vectors, 5 expression vectors, cloning vectors, transfer vectors etc. A storage vector is a vector which allows the convenient storage of a nucleic acid molecule, for example, of an mRNA molecule. Thus, the vector may comprise a sequence corresponding, e.g., to a desired mRNA sequence or a part thereof, such as a sequence corresponding to the open reading frame and the 3'UTR of an mRNA. An expression vector may be used for production of 10 expression products such as RNA, e.g. mRNA, or peptides, polypeptides or proteins. For example, an expression vector may comprise sequences needed for transcription of a sequence stretch of the vector, such as a promoter sequence, e.g. an RNA promoter sequence. A cloning vector is typically a vector that contains a cloning site, which may be used to incorporate nucleic acid sequences into the vector. A cloning vector may be, e.g., a 15 plasmid vector or a bacteriophage vector. A transfer vector may be a vector which is suitable for transferring nucleic acid molecules into cells or organisms, for example, viral vectors. A vector in the context of the present invention may be, e.g., an RNA vector or a DNA vector. Preferably, a vector is a DNA molecule. Preferably, a vector in the sense of the present application comprises a cloning site, a selection marker, such as an antibiotic 20 resistance factor, and a sequence suitable for multiplication of the vector, such as an origin of replication. Preferably, a vector in the context of the present application is a plasmid vector.

Vehicle: A vehicle is typically understood to be a material that is suitable for storing, transporting, and/or administering a compound, such as a pharmaceutically active 25 compound. For example, it may be a physiologically acceptable liquid which is suitable for storing, transporting, and/or administering a pharmaceutically active compound.

3'-untranslated region (3'UTR): A 3'UTR is typically the part of an mRNA which is located between the protein coding region (open reading frame (ORF) or coding sequence (CDS)) and the poly(A) sequence of the mRNA. A 3'UTR of the mRNA is not translated into 30 an amino acid sequence. The 3'UTR sequence is generally encoded by the gene which is transcribed into the respective mRNA during the gene expression process. The genomic sequence is first transcribed into pre-mature mRNA, which comprises optional introns. The

pre-mature mRNA is then further processed into mature mRNA in a maturation process. This maturation process comprises the steps of 5'capping, splicing the pre-mature mRNA to excise optional introns and modifications of the 3'-end, such as polyadenylation of the 3'-end of the pre-mature mRNA and optional endo- / or exonuclease cleavages etc.. In the context of the present invention, a 3'UTR corresponds to the sequence of a mature mRNA which is located 3' to the stop codon of the protein coding region, preferably immediately 3' to the stop codon of the protein coding region, and which extends to the 5'-side of the poly(A) sequence, preferably to the nucleotide immediately 5' to the poly(A) sequence. The term "corresponds to" means that the 3'UTR sequence may be an RNA sequence, such as in the mRNA sequence used for defining the 3'UTR sequence, or a DNA sequence which corresponds to such RNA sequence. In the context of the present invention, the term "a 3'UTR of a gene", such as "a 3'UTR of an albumin gene", is the sequence which corresponds to the 3'UTR of the mature mRNA derived from this gene, i.e. the mRNA obtained by transcription of the gene and maturation of the pre-mature mRNA. The term "3'UTR of a gene" encompasses the DNA sequence and the RNA sequence of the 3'UTR.

15

In a first aspect, the present invention relates to an artificial nucleic acid molecule comprising

- a. at least one open reading frame (ORF); and
- b. at least one 3'-untranslated region element (3'UTR element) comprising or consisting of a nucleic acid sequence which is derived from the 3'UTR of an albumin gene or from a variant of the 3'UTR of an albumin gene.

In a first embodiment there is provided an artificial nucleic acid molecule comprising

- a. at least one open reading frame (ORF); and
- b. at least one 3'-untranslated region element (3'UTR element) comprising or consisting of a nucleic acid sequence which is derived from the 3'UTR of an albumin gene or from a variant of the 3'UTR of an albumin gene, and a histone stem-loop.

In a second embodiment there is provided a vector comprising

- a. an open reading frame and/or a cloning site;
- b. at least one 3'-untranslated region element (3'UTR element) comprising a nucleic acid sequence which is derived from the 3'UTR of an albumin gene or from a variant of the 3'UTR of an albumin gene; and
- c. a histone stem-loop.

In a third embodiment there is provided a cell comprising the artificial nucleic acid molecule according to any one of the first embodiment or the vector according to the second embodiment.

In a fourth embodiment there is provided a pharmaceutical composition comprising the artificial nucleic acid molecule according to the first embodiment, the vector according to the second embodiment, or the cell according to the third embodiment.

In a fifth embodiment there is provided use of the artificial nucleic acid molecule according to the first embodiment, the vector according to the second embodiment, the cell according to the third embodiment, or the pharmaceutical composition according to the fourth embodiment for the manufacture of a medicament for use as a vaccine or in gene therapy.

10 In a sixth embodiment there is provided a method for treating or preventing a disorder comprising administering the artificial nucleic acid molecule according to the first embodiment, the vector according to the second embodiment, the cell according to the third embodiment, or the pharmaceutical composition according to the fourth embodiment to a subject in need thereof.

15 In a seventh embodiment there is provided a method of treating or preventing a disorder comprising transfection of a cell with an artificial nucleic acid molecule according to the first embodiment or with the vector according to the second embodiment.

20 In an eighth embodiment there is provided a method for stabilizing and/or prolonging protein production from a nucleic acid molecule, the method comprising the step of associating the nucleic acid molecule, with a 3'UTR element and a histone stem-loop, wherein the 3'UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'UTR of an albumin gene or from a variant of the 3'UTR of an albumin gene.

25 In a ninth aspect there is provided use of a 3'UTR element and a histone stem-loop for stabilizing and/or prolonging protein production from a nucleic acid molecule, wherein the 3'UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'UTR of an albumin gene or from a variant of the 3'UTR of an albumin gene.

In a tenth aspect there is provided a kit comprising an artificial nucleic acid molecule according to the first embodiment, a vector according to the second embodiment, a cell according to any the third embodiment, and/or a pharmaceutical composition according to the fourth embodiment.

The term “3'UTR element” refers to a nucleic acid sequence which comprises or consists of a nucleic acid sequence that is derived from a 3'UTR or from a variant of a 3'UTR. A ‘3'-UTR element’ preferably refers to a nucleic acid sequence which represents a 3'UTR of an artificial nucleic acid sequence, such as an artificial mRNA, or which codes for a 3'UTR of an artificial nucleic acid molecule. Accordingly, in the sense of the present invention, preferably, a 3'UTR element may be the 3'UTR of an mRNA, preferably of an artificial mRNA, or it may be the transcription template for a 3'UTR of an mRNA. Thus, a 3'UTR element preferably is a nucleic acid sequence which corresponds to the 3'UTR of an mRNA, preferably to the 3'UTR of an artificial mRNA, such as an mRNA obtained by transcription of a genetically engineered vector construct. Preferably, a 3'UTR element in

the sense of the present invention functions as a 3'UTR or codes for a nucleotide sequence that fulfils the function of a 3'UTR.

Preferably, the at least one open reading frame and the at least one 3'UTR element are 5 heterologous. The term "heterologous" in this context means that the open reading frame and the 3'UTR element are not occurring naturally (in nature) in this combination. Preferably, the 3'UTR element is derived from a different gene than the open reading frame. For example, the ORF may be derived from a different gene than the 3'UTR element, e.g. 10 encoding a different protein or the same protein but of a different species etc. Preferably, the open reading frame does not code for human albumin, preferably the open reading frame does not code for albumin. It is preferred that the open reading frame does not code for a reporter protein, e.g., selected from the group consisting of globin proteins (particularly beta-globin), luciferase protein, GFP proteins or variants thereof, for example, variants 15 exhibiting at least 70% sequence identity to a globin protein, a luciferase protein, or a GFP protein. Particularly, it is preferred, in a specific embodiment, that the open reading frame does not code for beta-globin, or, more specifically, for rabbit beta-globin, or variants thereof, in particular in case the 3'UTR element is derived from the rat albumin 3'UTR or 20 variants thereof. Furthermore, in a specific embodiment, the artificial nucleic acid molecule of the invention does not code for a signal sequence (and therefore does not contain a segment coding for such a signal sequence), which is synonymously also designated a localization signal or targeting signal. Such a signal sequence is typically provided at the 5' terminus of the encoded amino acid sequence. Particularly, the artificial nucleic acid of the 25 invention does not code for a protein which (artificially or naturally) contains a "signal amino acid sequence", in particular not a signal sequence directing the encoded protein to polysomes bound to the membrane of the endoplasmic reticulum and/or translocating the 30 protein of interest encoded by the inventive nucleic acid across the membrane of the endoplasmic reticulum. In particular, the encoded protein of the inventive nucleic acid molecule does not contain an albumin signal sequence, more specifically not the rat albumin signal sequence. Typically, the protein encoded by the inventive artificial nucleic acid molecule does also not contain a milk protein or growth hormone signal sequence, in particular if the coding region codes for globin, more specifically for beta-globin, even more 35 specifically for rabbit beta-globin. In another embodiment, the artificial nucleic acid sequence of the invention does not contain a globin 5'-UTR sequence, in particular not a

5' -UTR sequence from beta-globin or, more particularly, not a rabbit globin 5' -UTR sequence, in particular if the coding region codes for a globin sequence, more specifically for beta-globin or variants thereof. If the artificial nucleic acid molecule contains a 5' -UTR sequence, that 5' -UTR sequence may be selected such that it is not the 5' -UTR-sequence
5 from an albumin gene, in particular not from the rat albumin gene. In case the artificial nucleic acid molecule of the invention contains more than one 3' -UTR, the other 3' -UTR(s) is/are preferably not selected from the group consisting of a globin 3' -UTR and a c-myc 3' -UTR. In another embodiment, the 3'UTR of the inventive nucleic acid molecule does not correspond to the rat albumin 3' -UTR, in particular if the coding region codes for a globin,
10 more specifically a beta-globin.

Furthermore, it is particularly preferred that the open reading frame does not code for human factor IX or variants thereof, for example, variants exhibiting at least 70% sequence identity to human factor IX. The nucleic acid molecule does not contain an albumin
15 promoter, in particular an albumin promoter with a point mutation, more specifically with a G52A point mutation, in particular if the coding region of the inventive nucleic acid molecule codes for human factor IX or variants thereof as described above.

In another embodiment, the artificial nucleic acid molecule of the invention does not
20 correspond to a transposon element, e.g. a transposon plasmid, or does not contain a transposon (in particular not a Tn5 transposon or does not contain TN5 mosaic elements), in particular if the coding region codes for a resistance gene, in particular a neomycin resistance gene. The nucleic acid molecule of the invention cannot functionally interact with a transposase, in particular not with a Tn5 transposase, under such circumstances.
25 Functionally speaking, the inventive nucleic acid molecule shall typically not form a complex between the nucleic acid (as the inventive artificial nucleic acid does not contain a transposon) and a transposase specific for whatever transposon. The coding region (ORF) of the nucleic acid molecule of the invention does not code for an siRNA, in particular if the nucleic acid molecule of the invention functionally interacts with a transposase.

30

In this context it is particularly preferred in a specific embodiment that the open reading frame does not contain an intron, particularly in case the open reading frame codes for human factor IX or variants thereof.

Furthermore, it is preferred in this context that in a specific embodiment the open reading frame does not code for human factor IX or variants thereof, in particular in case the 3'UTR element is derived from the human albumin 3'UTR or variants thereof.

5 The inventive artificial nucleic acid molecule is – as a specific embodiment of the invention – not an expression cassette. Accordingly, the inventive nucleic acid molecule does e.g. not contain a 3' promoter or a promoter 3' end. In terms of that embodiment, the inventive nucleic acid molecule is also not a “secretion cassette”, as it does not contain a signal sequence and, preferably, does not contain 3' promoter. In particular, the inventive nucleic acid molecule is composed of one single nucleic acid molecule comprising the ORF and the 3'UTR region and optionally a 5' UTR region. Accordingly, the inventive nucleic acid molecule does not correspond to a secretion cassette which is composed of more than one separate genetic elements, in particular does not correspond to a first genetic element representing the region upstream of the coding region (ORF) and a separate second genetic element representing the region downstream of the ORF, which are provided independently, e.g. as parts of a kit.

Preferably, the at least one 3'UTR element is functionally linked to the ORF. This means preferably that the 3'UTR element is associated with the ORF such that it may exert a function, such as a stabilizing function on the expression of the ORF or a stabilizing function on the artificial nucleic acid molecule. Preferably, the ORF and the 3'UTR element are associated in 5'→3' direction. Thus, preferably, the artificial nucleic acid molecule comprises the structure 5'-ORF-(optional)linker-3'UTR element-3', wherein the linker may be present or absent. For example, the linker may be one or more nucleotides, such as a stretch of 1-50 or 1-20 nucleotides, e.g., comprising or consisting of one or more restriction enzyme recognition sites (restriction sites).

Preferably, the at least one 3'UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'UTR of a vertebrate albumin gene or from a variant thereof, preferably from the 3'UTR of a mammalian albumin gene such as e.g. the 3'UTR of the mouse albumin gene, the albumin gene of *Olive baboon* or the human albumin gene or from a variant thereof. More preferably the at least one 3'UTR element comprises or consists of a nucleic acid sequence derived from the 3'UTR of a primate albumin gene, particularly

of a human albumin gene or of an albumin gene of *Olive baboon* or from a variant thereof, even more preferably from the 3'UTR of the human albumin gene according to GenBank Accession number NM_000477.5 or from a variant thereof. In a preferred embodiment, the 3'UTR element is not derived from the 3'UTR of a *Xenopus* albumin gene. Preferably, the 5 3'UTR element does not comprise a poly(A) limiting element B (PLEB) of a 3'UTR from a *Xenopus* albumin gene. Preferably, the 3'UTR element does not consist of a PLEB of a 3'UTR from a *Xenopus* albumin gene.

The term "a nucleic acid sequence which is derived from the 3'UTR of an [...] albumin 10 gene" preferably refers to a nucleic acid sequence which is based on the 3'UTR sequence of an albumin gene or on a fragment or part thereof. This term includes sequences corresponding to the entire 3'UTR sequence, i.e. the full length 3'UTR sequence of an albumin gene, and sequences corresponding to a fragment of the 3'UTR sequence of an albumin gene. Preferably, a fragment of a 3'UTR of an albumin gene consists of a 15 continuous stretch of nucleotides corresponding to a continuous stretch of nucleotides in the full-length 3'UTR of an albumin gene, which represents at least 20%, preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, and most preferably at least 90% of the full-length 3'UTR of an albumin gene. Such a fragment, in the 20 sense of the present invention, is preferably a functional fragment as described herein. The term "3'UTR of an albumin gene" preferably refers to the 3'UTR of a naturally occurring albumin gene.

The terms "variant of the 3'UTR of an albumin gene" and "variant thereof" in the context of 25 a 3'UTR of an albumin gene refers to a variant of the 3'UTR of a naturally occurring albumin gene, preferably to a variant of the 3'UTR of a vertebrate albumin gene, more preferably to a variant of the 3'UTR of a mammalian albumin gene such as the 3'UTR of a mouse albumin gene, even more preferably to a variant of the 3'UTR of a primate albumin gene, particular a human albumin gene or an albumin gene of *Olive baboon* as described 30 above. Such variant may be a modified 3'UTR of an albumin gene. For example, a variant 3'UTR may exhibit one or more nucleotide deletions, insertions, additions and/or substitutions compared to the naturally occurring 3'UTR from which the variant is derived. Preferably, a variant of a 3'UTR of an albumin gene is at least 40%, preferably at least 50%,

more preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, most preferably at least 95% identical to the naturally occurring 3'UTR the variant is derived from. Preferably, the variant is a functional variant as described herein.

5

The term "a nucleic acid sequence which is derived from a variant of the 3'UTR of an albumin gene" preferably refers to a nucleic acid sequence which is based on a variant of the 3'UTR sequence of an albumin gene or on a fragment or part thereof as described above. This term includes sequences corresponding to the entire sequence of the variant of 10 the 3'UTR of an albumin gene, i.e. the full length variant 3'UTR sequence of an albumin gene, and sequences corresponding to a fragment of the variant 3'UTR sequence of an albumin gene. Preferably, a fragment of a variant of the 3'UTR of an albumin gene consists of a continuous stretch of nucleotides corresponding to a continuous stretch of nucleotides in the full-length variant of the 3'UTR of an albumin gene, which represents at least 20%, 15 preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, and most preferably at least 90% of the full-length variant of the 3'UTR of an albumin gene. Such a fragment of a variant, in the sense of the present invention, is preferably a functional fragment of a variant as described herein.

20

The terms "functional variant", "functional fragment", and "functional fragment of a variant" (also termed "functional variant fragment") in the context of the present invention, mean that the fragment of the 3'UTR, the variant of the 3'UTR, or the fragment of a variant of the 3'UTR of an albumin gene fulfils at least one, preferably more than one function of the 25 naturally occurring 3'UTR of an albumin gene of which the variant, the fragment, or the fragment of a variant is derived. Such function may be, for example, stabilizing mRNA and/or stabilizing and/or prolonging protein production from an mRNA and/or increasing protein expression or total protein production from an mRNA, preferably in a mammalian cell, such as in a human cell. It is particularly preferred that the variant, the fragment, and 30 the variant fragment in the context of the present invention fulfil the function of stabilizing an mRNA, preferably in a mammalian cell, such as a human cell, compared to an mRNA comprising a reference 3'UTR or lacking a 3'UTR, and/or the function of stabilizing and/or prolonging protein production from an mRNA, preferably in a mammalian cell, such as in a

human cell, compared to an mRNA comprising a reference 3'UTR or lacking a 3'UTR, and/or the function of increasing protein production from an mRNA, preferably in a mammalian cell, such as in a human cell, compared to an mRNA comprising a reference 3'UTR or lacking a 3'UTR. A reference 3'UTR may be, for example, a 3'UTR naturally occurring in combination with the ORF. Furthermore, a functional variant, a functional fragment, or a functional variant fragment of a 3'UTR of an albumin gene preferably does not have a substantially diminishing effect on the efficiency of translation of the mRNA which comprises such variant, fragment, or variant fragment of a 3'UTR compared to the wild type 3'UTR from which the variant, the fragment, or the variant fragment is derived. A particularly preferred function of a "functional fragment", a "functional variant" or a "functional fragment of a variant" of the 3'UTR of an albumin gene in the context of the present invention is the stabilization and/or prolongation of protein production by expression of an mRNA carrying the functional fragment, functional variant or functional fragment of a variant as described above.

15

Preferably, the efficiency of the one or more functions exerted by the functional variant, the functional fragment, or the functional variant fragment, such as mRNA and/or protein production stabilizing efficiency and/or the protein production increasing efficiency, is at least 40%, more preferably at least 50%, more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, most preferably at least 90% of the mRNA and/or protein production stabilizing efficiency and/or the protein production increasing efficiency exhibited by the naturally occurring 3'UTR of an albumin gene from which the variant, the fragment or the variant fragment is derived.

25

In the context of the present invention, a fragment of the 3'UTR of an albumin gene or of a variant of the 3'UTR of an albumin gene preferably exhibits a length of at least about 50 nucleotides, preferably of at least about 75 nucleotides, more preferably of at least about 100 nucleotides, even more preferably of at least about 125 nucleotides, most preferably of at least about 150 nucleotides. Preferably, such fragment of the 3'UTR of an albumin gene or of a variant of the 3'UTR of an albumin gene is a functional fragment as described above.

30

Preferably, the at least one 3'UTR element of the artificial nucleic acid molecule according to the present invention comprises or consists of a "functional fragment", a "functional variant" or a "functional fragment of a variant" of the 3'UTR of an albumin gene.

- 5 Preferably, the at least one 3'UTR element of the artificial nucleic acid molecule according to the present invention increases the stability of the artificial nucleic acid molecule, e.g. increases the stability of an mRNA according to the present invention, compared to a respective mRNA (reference mRNA) lacking a 3'UTR or comprising a reference 3'UTR, such as a 3'UTR naturally occurring in combination with the ORF. Preferably, the at least one
- 10 3'UTR element of the artificial nucleic acid molecule according to the present invention increases the stability of protein production from the artificial nucleic acid molecule according to the present invention, e.g. from an mRNA according to the present invention, compared to a respective mRNA lacking a 3'UTR or comprising a reference 3'UTR, such as a 3'UTR naturally occurring in combination with the ORF. Preferably, the at least one
- 15 3'UTR element of the artificial nucleic acid molecule according to the present invention prolongs protein production from the artificial nucleic acid molecule according to the present invention, e.g. from an mRNA according to the present invention, compared to a respective mRNA lacking a 3'UTR or comprising a reference 3'UTR, such as a 3'UTR naturally occurring in combination with the ORF. Preferably, the at least one 3'UTR
- 20 element of the artificial nucleic acid molecule according to the present invention increases the protein expression and/or total protein production from the artificial nucleic acid molecule according to the present invention, e.g. from an mRNA according to the present invention, compared to a respective mRNA lacking a 3'UTR or comprising a reference 3'UTR, such as a 3'UTR naturally occurring in combination with the ORF. Preferably, the at
- 25 least one 3'UTR element of the artificial nucleic acid molecule according to the present invention does not negatively influence translational efficiency of an mRNA compared to the translational efficiency of a respective mRNA lacking a 3'UTR or comprising a reference 3'UTR, such as a 3'UTR naturally occurring in combination with the ORF. The term "respective mRNA" in this context means that - apart from the different 3'UTRs - the
- 30 reference mRNA is comparable, preferably identical, to the mRNA comprising the inventive 3'UTR element.

The term "stabilizing and/or prolonging protein production" from an artificial nucleic acid molecule such as an artificial mRNA preferably means that the protein production from the artificial nucleic acid molecule such as the artificial mRNA is stabilized and/or prolonged compared to the protein production from a reference nucleic acid molecule such as a reference mRNA, e.g. comprising a reference 3'UTR or lacking a 3'UTR, preferably in a mammalian expression system, such as in HeLa or HDF cells. Thus, protein produced from the artificial nucleic acid molecule such as the artificial mRNA is observable for a longer period of time than what may be seen for a protein produced from a reference nucleic acid molecule. In other words, the amount of protein produced from the artificial nucleic acid molecule such as the artificial mRNA measured over time undercuts a threshold value at a later time point than the amount of protein produced from a reference nucleic acid molecule such as a reference mRNA measured over time. Such a threshold value may be, for example, the amount of protein measured in the initial phase of expression, such as 1, 2, 3, 4, 5, or 6 hours post initiation of expression, such as post transfection of the nucleic acid molecule (Figure 17).

For example, the protein production from the artificial nucleic acid molecule such as the artificial mRNA - in an amount which is at least the amount observed in the initial phase of expression, such as 1, 2, 3, 4, 5, or 6 hours post initiation of expression, such as post transfection of the nucleic acid molecule - is prolonged by at least about 5 hours, preferably by at least about 10 hours, more preferably by at least about 24 hours compared to the protein production from a reference nucleic acid molecule, such as a reference mRNA, in a mammalian expression system, such as in mammalian cells, e.g. in HeLa or HDF cells. Thus, the artificial nucleic acid molecule according to the present invention preferably allows for prolonged protein production in an amount which is at least the amount observed in the initial phase of expression, such as 1, 2, 3, 4, 5, or 6 hours post initiation of expression, such as post transfection, by at least about 5 hours, preferably by at least about 10 hours, more preferably by at least about 24 hours compared to a reference nucleic acid molecule lacking a 3'UTR or comprising a reference 3'UTR.

30

In preferred embodiments, the protein production from the artificial nucleic acid molecule according to the present invention is prolonged at least 1.5 fold, preferably at least 2 fold,

more preferably at least 2.5 fold compared to the protein production from a reference nucleic acid molecule lacking a 3'UTR or comprising a reference 3'UTR.

This effect of prolonging protein production may be determined by (i) measuring protein amounts, e.g. obtained by expression of an ORF encoding a reporter protein such as luciferase, preferably in a mammalian expression system such as in HeLa or HDF cells, over time, (ii) determining the time point at which the protein amount undercuts the amount of protein observed, e.g., at 1, 2, 3, 4, 5, or 6 hours post initiation of expression, e.g. 1, 2, 3, 4, 5, or 6 hours post transfection of the artificial nucleic acid molecule, and (iii) comparing the time point at which the protein amount undercuts the protein amount observed at 1, 2, 3, 4, 5, or 6 hours post initiation of expression to said time point determined for a nucleic acid molecule lacking a 3'UTR or comprising a reference 3'UTR (Figure 17).

Preferably, this stabilizing and/or prolonging effect on protein production is achieved, while the total amount of protein produced from the artificial nucleic acid molecule according to the present invention, e.g. within a time span of 48 or 72 hours, is at least the amount of protein produced from a reference nucleic acid molecule lacking a 3'UTR or comprising a reference 3'UTR, such as a 3'UTR naturally occurring with the ORF of the artificial nucleic acid molecule. Thus, the present invention provides an artificial nucleic acid molecule which allows for prolonged and/or stabilized protein production in a mammalian expression system, such as in mammalian cells, e.g. in HeLa or HDF cells, as specified above, wherein the total amount of protein produced from said artificial nucleic acid molecule, e.g. within a time span of 48 or 72 hours, is at least the total amount of protein produced, e.g. within said time span, from a reference nucleic acid molecule lacking a 3'UTR or comprising a reference 3'UTR, such as a 3'UTR naturally occurring with the ORF of the artificial nucleic acid molecule.

Thus, "stabilized protein expression" preferably means that there is more uniform protein production from the artificial nucleic acid molecule according to the present invention over a predetermined period of time, such as over 24 hours, more preferably over 48 hours, even more preferably over 72 hours, when compared to a reference nucleic acid molecule, for example, an mRNA comprising a reference 3'UTR or lacking a 3'UTR. Accordingly, the level of protein production, e.g. in a mammalian system, from the artificial nucleic acid

molecule comprising a 3'UTR element according to the present invention, e.g. from an mRNA according to the present invention, preferably does not drop to the extent observed for a reference nucleic acid molecule, such as a reference mRNA as described above. For example, the amount of a protein (encoded by the ORF) observed 6 hours after initiation of expression, e.g. 6 hours post transfection of the artificial nucleic acid molecule according to the present invention into a cell, such as a mammalian cell, may be comparable to the amount of protein observed 48 hours after initiation of expression, e.g. 48 hours post transfection. Thus, the ratio of the amount of protein encoded by the ORF, such as of a reporter protein, e.g., luciferase, observed at 48 hours post initiation of expression, e.g. 48 hours post transfection, to the amount of protein observed 6 hours after initiation of expression, e.g. 6 hours post transfection, is preferably at least about 0.4, more preferably at least about 0.5, more preferably at least about 0.6, even more preferably at least about 0.7. Preferably, the ratio is between about 0.4 and about 4, preferably between about 0.65 and about 3, more preferably between about 0.7 and 2 for a nucleic acid molecule according to the present invention. For a respective reference nucleic acid molecule, e.g. an mRNA comprising a reference 3'UTR or lacking a 3'UTR, said ratio may be, e.g. between about 0.05 and about 0.3.

Thus, the present invention provides an artificial nucleic acid molecule comprising an ORF and a 3'UTR element as described above, wherein the ratio of the (reporter) protein amount, e.g. the amount of luciferase, observed 48 hours after initiation of expression to the (reporter) protein amount observed 6 hours after initiation of expression, preferably in a mammalian expression system, such as in mammalian cells, e.g. in HeLa cells, is preferably above about 0.4, more preferably above about 0.5, more preferably above about 0.6, even more preferably above about 0.7, e.g. between about 0.4 and about 4, preferably between about 0.65 and about 3, more preferably between about 0.7 and 2, wherein preferably the total amount of protein produced from said artificial nucleic acid molecule, e.g. within a time span of 48 hours, is at least the total amount of protein produced, e.g. within said time span, from a reference nucleic acid molecule lacking a 3'UTR or comprising a reference 3'UTR, such as a 3'UTR naturally occurring with the ORF of the artificial nucleic acid molecule. In a preferred embodiment, the present invention provides an artificial nucleic acid molecule comprising an ORF and a 3'UTR element as described above, wherein the ratio of the (reporter) protein amount, e.g. the amount of luciferase, observed 72 hours after

initiation of expression to the (reporter) protein amount observed 6 hours after initiation of expression, preferably in a mammalian expression system, such as in mammalian cells, e.g. in HeLa cells, is preferably above about 0.4, more preferably above about 0.5, more preferably above about 0.6, even more preferably above about 0.7, e.g. between about 0.4
5 and 1.5, preferably between about 0.65 and about 1.15, more preferably between about 0.7 and 1.0, wherein preferably the total amount of protein produced from said artificial nucleic acid molecule, e.g. within a time span of 72 hours, is at least the total amount of protein produced, e.g. within said time span, from a reference nucleic acid molecule lacking a 3'UTR or comprising a reference 3'UTR, such as a 3'UTR naturally occurring with the ORF
10 of the artificial nucleic acid molecule.

“Increased protein expression” in the context of the present invention preferably means an increased protein expression at one time point after initiation of expression compared to a reference molecule. Thus, the protein level observed at a certain time point after initiation
15 of expression, e.g. after transfection, of the artificial nucleic acid molecule according to the present invention, e.g. after transfection of an mRNA according to the present invention, for example, 48 or 72 hours post transfection, is preferably higher than the protein level observed at the same time point after initiation of expression, e.g. after transfection, of a reference nucleic acid molecule, such as a reference mRNA comprising a reference 3'UTR
20 or lacking a 3'UTR.

“Increased total protein production” from an artificial nucleic acid molecule refers to an increased protein production over the time span, in which protein is produced from an artificial nucleic acid molecule, preferably in a mammalian expression system, such as in
25 mammalian cells, e.g. in HeLa or HDF cells. Thus, “total protein production” preferably refers to the area under the curve (AUC) representing protein production over time.

Said increase in stability of the artificial nucleic acid molecule, said increase in stability of protein production, said prolongation of protein production and/or said increase in protein
30 expression and/or total protein production is preferably determined by comparison with a respective reference nucleic acid molecule lacking a 3'UTR, e.g. an mRNA lacking a 3'UTR, or a reference nucleic acid molecule comprising a reference 3'UTR, such as a 3'UTR naturally occurring with the ORF as described above.

The mRNA and/or protein production stabilizing effect and efficiency and/or the protein production increasing effect and efficiency of the variants, fragments and/or variant fragments of the 3'UTR of an albumin gene as well as the mRNA and/or protein production 5 stabilizing effect and efficiency and/or the protein production increasing effect and efficiency of the at least one 3'UTR element of the artificial nucleic acid molecule according to the present invention may be determined by any method suitable for this purpose known to skilled person. For example, artificial mRNA molecules may be generated comprising a coding sequence for a reporter protein, such as luciferase, and no 10 3'UTR, a 3'UTR derived from a naturally occurring albumin gene, a 3'UTR derived from a reference gene (i.e., a reference 3'UTR, such as a 3'UTR naturally occurring with the ORF), as 3'UTR a variant of a 3'UTR of an albumin gene, as 3'UTR a fragment of a naturally occurring albumin gene, or as 3'UTR a fragment of a variant of a 3'UTR of an albumin gene. Such mRNAs may be generated, for example, by *in vitro* transcription of respective 15 vectors such as plasmid vectors, e.g. comprising a T7 promoter and a sequence encoding the respective mRNA sequences. The generated mRNA molecules may be transfected into cells by any transfection method suitable for transfecting mRNA, for example they may be electroporated into mammalian cells, such as HELA cells, and samples may be analyzed certain time points after transfection, for example, 6 hours, 24 hours, 48 hours, and 72 20 hours post transfection. Said samples may be analyzed for mRNA quantities and/or protein quantities by methods well known to the skilled person. For example, the quantities of reporter mRNA present in the cells at the sample time points may be determined by quantitative PCR methods. The quantities of reporter protein encoded by the respective mRNAs may be determined, e.g., by ELISA assays or reporter assays such as luciferase 25 assays depending on the reporter protein used. The effect of stabilizing protein expression and/or prolonging protein expression may be, for example, analyzed by determining the ratio of the protein level observed 48 hours post transfection and the protein level observed 6 hours post transfection. The closer said value is to 1, the more stable the protein expression is within this time period. Such measurements may of course also be performed 30 at 72 or more hours and the ratio of the protein level observed 72 hours post transfection and the protein level observed 6 hours post transfection may be determined to determine stability of protein expression.

Preferably, the at least one 3'UTR element of the artificial nucleic acid molecule according to the present invention comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99%, most preferably of 100% to the nucleic acid sequence of a 3'UTR of an albumin gene, such as to the nucleic acid sequence according to SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 32, SEQ ID No. 33, SEQ ID No. 34 or SEQ ID No. 35 as shown below, wherein the variants of the sequences (e.g. at least 40% identical) are preferably functional variants as described above:

CATCACATT AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA
AAGCTTATTC ATCTGTTTT CTTTTCGTT GGTGTAAAGC CAACACCCCTG TCTAAAAAAC
ATAAATTTCT TTAATCATT TGCTCTTT CTCTGTGCTT CAATTAATAA AAAATGGAAA
15 GAATCT (SEQ ID No. 1)

CAUCACAUUU AAAAGCAUCU CAGCCUACCA UGAGAAUAAG AGAAAGAAAA UGAAGAUCAA
AAGCUUAUUC AUCUGUUUUU CUUUUUCGUU GGUGUAAAGC CAACACCCUG UCUAAAAAAC
AUAAAUUUCU UUAAUCAUUU UGCCUCUUUU CUCUGUGCUU CAAUUAUAUA AAAAUGGAAA
GAAUCU (SEQ ID No. 2).

AAACATCACA ATTAAGAAC A TCTCAGCCTA CCATGAGAAC AAGAGAAATA AAATGAAGAT
CAAAAGCTTA TTCATCTGTT TTTCTTTTC ATTGGTATAA AGCCAACACC CTGTCTAAAA
AACTATAAAAT TTCTTTAAC C ATTTGCCTC TTTTCTCTGT GCTTCAATTA ATAAAAAAATG
GAAAGAATCT AGATCTAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA
AAAA (SEQ ID No. 32)

AAACAUACACA AUUAAGAAC A UCUCAGCCUA CCAUGAGAAC AAGAGAAUA AAAUGAAGAU
CAAAAGCUUA UUCAUCUGUU UUUUUUUUUC AUUGGUUAAG AGCCAACACC CUGUCUAAAA
AAUCUAAAUAU UUCUUUAUC AUUUUGCCUC UUUUCUCUGU GCUUCAAUUA AUAAAAAAUG
GAAAGAAUCU AGAUCUAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA
AAAA (SEQ ID No. 33)

ACACATCACA ACCACAACCT TCTCAGGCTA CCCTGAGAAA AAAAGACATG AAGACTCAGG
ACTCATCTT TCTGTTGGTG TAAAATCAAC ACCCTAAGGA ACACAAATT CTTTAAACAT
TTGACTTCTT GTCTCTGTGC TGCAATTAAT AAAAAATGGA AAGAATCTAC AGATCTAAA
AAAA (SEQ ID No. 34)

ACACAUCACA ACCACAACCU UCUCAGGCUA CCCUGAGAAA AAAAGACAUG AAGACUCAGG
ACUCAUCUU UCUGUUGGUG UAAAAUCAAC ACCCUAAGGA ACACAAAUU CUUUAACAU
UUGACUUCUU GUCUCUGUGC UGCAAUUAAU AAAAAAUGGA AAGAAUCUAC AGAUCUAAA
AAAA (SEQ ID No. 35)

The at least one 3'UTR element of the artificial nucleic acid molecule according to the present invention may also comprise or consist of a fragment of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of

5 at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99%, most preferably of 100% to the nucleic acid sequence of the 3'UTR of an albumin gene, such as to the nucleic acid sequence according to SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 32, SEQ ID No. 33, SEQ ID No. 34 or SEQ ID No. 35, wherein the fragment is preferably a functional fragment or a functional variant fragment as described above. Such fragment preferably exhibits a length of at least about 50 nucleotides, preferably of at least about 75 nucleotides, more preferably of at least about 100 nucleotides, even more preferably of at least about 125 nucleotides, most preferably of at least about 150 nucleotides.

15

For example, such fragment may exhibit a nucleic acid sequence according to SEQ ID Nos. 18-30, such as

AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA AAGCTTATTC
20 ATCTGTTTT CTTTTCGTT GGTGTAAAGC CAACACCCTG TCTAAAAAAC ATAAATTCT
TTAACATTT TGCCTCTTT CTCTGTGCTT CAATT (SEQ ID No. 18)

CATCACATTT AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA
AAGCTTATTC ATCTGTTTT CTTTTCGTT GGTGTAAAGC CAACACCCTG (SEQ ID No.
19)

5 AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA AAGCTTATTC
ATCTGTTTT CTTTTCGTT GGTGTAAAGC CAACACCCTG TCTAAAAAAC (SEQ ID No.
20)

10 CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA AAGCTTATTC ATCTGTTTT
CTTTTCGTT GGTGTAAAGC CAACACCCTG TCTAAAAAAC ATAAATTCT (SEQ ID No.
21)

15 TGAGAATAAG AGAAAGAAAA TGAAGATCAA AAGCTTATTC ATCTGTTTT CTTTTCGTT
GGTGTAAAGC CAACACCCTG TCTAAAAAAC ATAAATTCT TTAATCATT (SEQ ID No.
22)

20 AGAAAGAAAA TGAAGATCAA AAGCTTATTC ATCTGTTTT CTTTTCGTT GGTGTAAAGC
CAACACCCTG TCTAAAAAAC ATAAATTCT TTAATCATT TGCCTCTTT (SEQ ID No.
23)

25 AAGCTTATTC ATCTGTTTT CTTTTCGTT GGTGTAAAGC CAACACCCTG TCTAAAAAAC
ATAAATTCT TTAATCATT TGCCTCTTT CTCTGTGCTT (SEQ ID No.
24)

30 ATCTGTTTT CTTTTCGTT GGTGTAAAGC CAACACCCTG TCTAAAAAAC ATAAATTCT
TTAATCATT TGCCTCTTT CTCTGTGCTT CAATTAATAA (SEQ ID No.
26)

CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA AAGCTTATTC ATCTGTTTT
CTTTTCGTT GGTGTAAAGC CAACACCCCTG TCTAAAAAAC ATAAATTCT TTAATCATT
TGCCTCTTT CTCTGTGCTT CAATTAATAA A (SEQ ID No. 27)

5 TGAAGATCAA AAGCTTATTC ATCTGTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCCTG
TCTAAAAAAC ATAAATTCT TTAATCATT TGCCTCTTT CTCTGTGCTT CAATTAATAA
A (SEQ ID No. 28)

10 CTTTTTCGTT GGTGTAAAGC CAACACCCCTG TCTAAAAAAC ATAAATTCT TTAATCATT
TGCCTCTTT CTCTGTGCTT CAATTAATAA A (SEQ ID No. 29)

AAGCTTATTC ATCTGTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCCTG TCTAAAAAAC
(SEQ ID No. 30)

15 or the corresponding RNA sequence, or a nucleic acid sequence which is at least 40%,
preferably at least about 50%, preferably at least about 60%, preferably at least about 70%,
more preferably at least about 80%, more preferably at least about 90%, even more
preferably at least about 95%, even more preferably at least about 99% identical to said
nucleic acid sequences or the corresponding RNA sequence. Thus, the at least one 3'UTR
20 element of the artificial nucleic acid molecule according to the present invention may
comprise of consist of a nucleic acid fragment as described above. Obviously, the
thymidine nucleotides comprised in the fragments according to SEQ ID No. 18-30 can be
replaced by uridine nucleotides.

25 Preferably, said variants, fragments or variant fragments are functional variants, functional
fragments, or functional variant fragments as described above, exhibiting at least one
function of the nucleic acid sequence according to SEQ ID No. 1, SEQ ID No. 2, SEQ ID
No. 32, SEQ ID No. 33, SEQ ID No. 34 or SEQ ID No. 35, such as stabilization of the
artificial nucleic acid molecule according to the invention, stabilizing and/or prolonging
30 protein expression from the artificial nucleic acid molecule according to the invention,
and/or increasing protein production, preferably with an efficiency of at least 40%, more
preferably of at least 50%, more preferably of at least 60%, even more preferably of at least
70%, even more preferably of at least 80%, most preferably of at least 90% of the stabilizing
efficiency and/or protein production increasing efficiency exhibited by the nucleic acid

sequence according to SEQ ID No. 1, SEQ ID NO. 2, SEQ ID No. 32, SEQ ID No. 33, SEQ ID No. 34 or SEQ ID No. 35.

Preferably, the at least one 3'UTR element of the artificial nucleic acid molecule according
5 to the present invention exhibits a length of at least about 50 nucleotides, preferably of at
least about 75 nucleotides, more preferably of at least about 100 nucleotides, even more
preferably of at least about 125 nucleotides, most preferably of at least about 150
nucleotides. For example, the 3'UTR element may exhibit a length of about 50 to about 300
nucleotides, preferably of about 100 to about 250 nucleotides, more preferably of about
10 150 to about 200 nucleotides.

Furthermore, the artificial nucleic acid molecule according to the present invention may
comprise more than one 3'UTR elements as described above. For example, the artificial
nucleic acid molecule according to the present invention may comprise one, two, three,
15 four or more 3'UTR elements, wherein the individual 3'UTR elements may be the same or
they may be different. For example, the artificial nucleic acid molecule according to the
present invention may comprise two essentially identical 3'UTR elements as described
above, e.g. two 3'UTR elements comprising or consisting of a nucleic acid sequence which
is derived from the 3'UTR of an albumin gene or from a variant of the 3'UTR of an albumin
20 gene, such as a nucleic acid sequence according to SEQ ID No. 1, 2, 32, 33, 34 or 35
functional variants thereof, functional fragments thereof, or functional variant fragments
thereof as described above.

Surprisingly, the inventors found that an artificial nucleic acid molecule comprising a 3'UTR
25 as described above may represent or may provide an mRNA molecule which allows for
prolonged and/or stabilized protein production. Thus, a 3'UTR as described herein may
improve stability of protein expression from an mRNA molecule and/or improve
translational efficiency.

30 The artificial nucleic acid molecule according to the present invention may be RNA, such
as mRNA, DNA, such as a DNA vector, or may be a modified RNA or DNA molecule. It
may be provided as a double-stranded molecule having a sense strand and an anti-sense
strand, for example, as a DNA molecule having a sense strand and an anti-sense strand.

The artificial nucleic acid according to the present invention may further comprise optionally a 5'UTR and/or a 5'-cap. The optional 5'-cap and/or the 5'UTR are preferably located 5' to the ORF within the artificial nucleic acid molecule according to the present

5 invention.

Preferably, the artificial nucleic acid molecule according to the present invention further comprises a poly(A) sequence and/or a polyadenylation signal. Preferably, the optional poly(A) sequence is located 3' to the at least one 3'UTR element, preferably is connected to

10 the 3'-end of the 3'UTR element. The connection may be direct or indirect, for example, via a stretch of 2, 4, 6, 8, 10, 20 etc. nucleotides, such as via a linker of 1-50, preferably of 1-20 nucleotides, e.g. comprising or consisting of one or more restriction sites.

In one embodiment, the optional polyadenylation signal is located within the 3'UTR element. Preferably, the polyadenylation signal comprises the consensus sequence NN(U/T)ANA, with N = A or U, preferably AA(U/T)AAA or A(U/T)(U/T)AAA. Such consensus sequence may be recognised by most animal and bacterial cell-systems, for example by the polyadenylation-factors, such as cleavage/polyadenylation specificity factor (CPSF) cooperating with CstF, PAP, PAB2, CFI and/or CFII. Preferably, the polyadenylation signal, preferably the consensus sequence NNUANA, is located less than about 50 nucleotides, more preferably less than about 30 bases, most preferably less than about 25 bases, for example 21 bases, upstream of the 3'-end of the 3'UTR element.

Transcription of an artificial nucleic acid molecule according to the present invention, e.g. of an artificial DNA molecule, comprising a polyadenylation signal within the 3'UTR element will result in a premature-RNA containing the polyadenylation signal in its 3'UTR element. For example, transcription of a DNA molecule comprising a 3'UTR element according to SEQ ID No. 1

30 CATCACATTT AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA
AAGCTTATTC ATCTGTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCTG TCTAAAAAAC
ATAAATTTCT TTAATCATTT TGCCTCTTT CTCTGTGCTT CAATTAATAA AAAATGGAAA
GAATCT (SEQ ID No. 1)

will result in an RNA having a 3'UTR element according to the sequence

CAUCACAUUU AAAAGCAUCU CAGCCUACCA UGAGAAUAAG AGAAAGAAAA UGAAGAUCAA
5 AAGCUUAUUC AUCUGUUUUU CUUUUUCGUU GGUGUAAAGC CAACACCCUG UCUAAAAAAC
AUAAAUUUCU UUAAUCAUUU UGCCUCUUUU CUCUGUGCUU CAAUUAUAAA AAAAUGGAAA
GAAUCU (SEQ ID No. 2).

Using an appropriate transcription system will then lead to attachment of a poly(A) sequence to the premature-RNA. For example, the inventive artificial nucleic acid molecule may be a DNA molecule comprising a 3'UTR element as described above and a polyadenylation signal, which may result in polyadenylation of an RNA upon transcription of this DNA molecule. Accordingly, a resulting RNA may comprise a combination of the inventive 3'UTR element followed by a poly(A) sequence.

15 Potential transcription systems are *in vitro* transcription systems or cellular transcription systems etc. Accordingly, transcription of an artificial nucleic acid molecule according to the invention, e.g. transcription of an artificial nucleic acid molecule comprising an open reading frame, a 3'UTR element and a polyadenylation-signal, may result in an mRNA 20 molecule comprising an open reading frame, a 3'UTR element and a poly(A) sequence.

Accordingly, the invention also provides an artificial nucleic acid molecule which is an mRNA molecule comprising an open reading frame, a 3'UTR element as described above and a poly(A) sequence.

25 In one embodiment, the invention provides an artificial nucleic acid molecule which is an artificial DNA molecule comprising an open reading frame and a sequence according to SEQ ID No. 1 or a sequence having an identity of at least about 40% or more to SEQ ID No. 1 or a fragment thereof as described above. Furthermore, the invention provides 30 an artificial nucleic acid molecule which is an artificial RNA molecule comprising an open reading frame and a sequence according to SEQ ID NO. 2 or a sequence having an identity of at least about 40 % or more to SEQ ID No. 2 or a fragment thereof as described above.

In one further embodiment, the invention provides an artificial nucleic acid molecule which is an artificial DNA molecule comprising an open reading frame and a sequence according to SEQ ID No. 32 or a sequence having an identity of at least about 40% or more to SEQ ID No. 32 or a fragment thereof as described above. Furthermore, the invention

5 provides an artificial nucleic acid molecule which is an artificial RNA molecule comprising an open reading frame and a sequence according to SEQ ID NO. 33 or a sequence having an identity of at least about 40 % or more to SEQ ID No. 33 or a fragment thereof as described above.

10 Furthermore, the invention provides an artificial nucleic acid molecule which is an artificial DNA molecule comprising an open reading frame and a sequence according to SEQ ID No. 34 or a sequence having an identity of at least about 40% or more to SEQ ID No. 34 or a fragment thereof as described above. Furthermore, the invention provides an artificial nucleic acid molecule which is an artificial RNA molecule comprising 15 an open reading frame and a sequence according to SEQ ID NO. 35 or a sequence having an identity of at least about 40 % or more to SEQ ID No. 35 or a fragment thereof as described above.

Accordingly, the invention provides an artificial nucleic acid molecule which may be a 20 template for an RNA molecule, preferably for an mRNA molecule, which is stabilised and optimized with respect to translation efficiency. In other words, the artificial nucleic acid molecule may be a DNA or RNA which may be used for production of an mRNA. The obtainable mRNA, may, in turn, be translated for production of a desired peptide or protein encoded by the open reading frame. If the artificial nucleic acid molecule is a DNA, it may, 25 for example, be used as a double-stranded storage form for continued and repetitive *in vitro* or *in vivo* production of mRNA.

In one embodiment, the artificial nucleic acid molecule according to the present invention further comprises a poly(A) sequence. The length of the poly(A) sequence may vary. For example, the poly(A) sequence may have a length of about 20 adenine nucleotides up to 30 about 300 adenine nucleotides, preferably of about 40 to about 200 adenine nucleotides, more preferably from about 50 to about 100 adenine nucleotides, such as about 60, 70, 80, 90 or 100 adenine nucleotides.

For example, the artificial nucleic acid molecule according to the present invention may comprise a nucleic acid sequence corresponding to the DNA-sequences

CATCACATT AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA

5 AAGCTTATTC ATCTGTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCCTG TCTAAAAAAC
ATAAATTTCT TTAATCATT TGCTCTTTT CTCTGTGCTT CAATTAATAA AAAATGGAAA
GAATCTAGAT CTAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA
AAAAAAA AAAAAA (SEQ ID No. 3),

AAACATCACA ATTAAGAAC A TCTCAGCCTA CCATGAGAAC AAGAGAAATA AAATGAAGAT

CAAAAGCTTA TTCATCTGTT TTTCTTTTC ATTGGTATAA AGCCAACACC CTGTCTAAAA

AACTATAAAAT TTCTTTAAC TTTTGCCCTC TTTTCTCTGT GCTTCAATTA ATAAAAAAATG

GAAAGAATCT AGATCTAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA

AAAAAAA AAAAAAAA (SEQ ID No. 36)

or

ACACATCACA ACCACAACCT TCTCAGGCTA CCCTGAGAAA AAAAGACATG AAGACTCAGG

ACTCATCTT TCTGTTGGTG TAAAATCAAC ACCCTAAGGA ACACAAATT CTTTAAACAT

TTGACTCTT GTCTCTGTGC TGCAATTAAT AAAAAATGGA AAGAATCTAC AGATCTAAA

AAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA

(SEQ ID No. 38)

10 Transcription of such sequences may result in artificial nucleic acid molecules comprising the sequences

CAUCACAUU AAAAGCAUCU CAGCCUACCA UGAGAAUAAG AGAAAGAAAA UGAAGAUCAA

AAGCUUAUUC AUCUGUUUUU CUUUUUCGUU GGUGUAAAGC CAACACCCUG UCUAAAAAAC

15 AUAAAUUUCU UUAAUCAUUU UGCCUCUUU CUCUGUGCUU CAAUUAUAA AAAAUGGAAA

GAAUCUAGAU CUAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA

AAAAAAA AAAAAA (SEQ ID No. 4),

AAACAUACACA AUUAAGAAC A UCUCAGCCUA CCAUGAGAAC AAGAGAAUA AAAUGAAGAU

CAAAAGCUUA UUCAUCUGUU UUUCUUUUUC AUUGGUUAAGC CAACACCCUG CUGUCUAAA

AACUUAUAAU UUCUTTAATC ATTTGCCTC TTTTCTCTGT GCTTCAATTA ATAAAAAAATG

GAAAGAATCT AGATCTAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA
AAAAAAA (SEQ ID No. 37)

or

ACACAUCACA ACCACAACCU UCUCAGGCUA CCCUGAGAAA AAAAGACAUG AAGACUCAGG
ACUCAUCUUU UCUGUUGGUG UAAAAUCAAC ACCCUAAGGA ACACAAUUU CUUUAACAU
UUGACUUUU GUCUCUGUGC UGCAAUUAAU AAAAAAUGGA AAGAAUCUAC AGAUCUAAA
AAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA (SEQ ID No. 39)

Such artificial RNA-molecules, i.e. artificial nucleic acid molecules comprising a sequence according to SEQ ID No. 4, 37 or 39 may also be obtainable *in vitro* by common methods of chemical-synthesis without being necessarily transcribed from a DNA-progenitor.

5

In a particularly preferred embodiment, the artificial nucleic acid molecule according to the present invention is an RNA molecule, preferably an mRNA molecule comprising in 5'-to-3'-direction an open reading frame, a 3'UTR element as described above and a poly(A) sequence.

10

In a preferred embodiment, the open reading frame does not code for albumin, particularly not for human albumin, mouse albumin or albumin from *Olive baboon*, provided that the 3'UTR element is identical to the 3'UTR of human albumin, mouse albumin or albumin from *Olive baboon*, respectively.. In some further embodiments, it may be preferred if the

15

open reading frame does not code for human albumin according to GenBank Accession number NM_000477.5 provided that the 3'UTR element is identical to the 3'UTR of human albumin. In some further embodiments, it may be preferred if the open reading frame does not code for albumin or variants thereof that the 3'UTR element is a sequence which is identical to SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 32, SEQ ID No. 33, SEQ ID No. 34 or

20

SEQ ID No. 35. Furthermore, in some embodiments it is preferred that the open reading frame does not code for human factor IX or a reporter protein, e.g., selected from the group consisting of globin proteins, (particularly beta-globin), luciferase proteins, GFP proteins or variants thereof, for example, variants exhibiting at least 70% sequence identity to a globin protein, a luciferase protein, or a GFP protein. Additionally, in specific embodiments it is

preferred that the open reading frame does not contain an intron, particularly in case the open reading frame codes for human factor IX.

In one embodiment, the invention provides an artificial DNA molecule comprising an open reading frame, preferably an open reading frame which encodes a peptide or protein other than albumin; a 3'UTR element comprising or consisting of a sequence which has at least about 60%, preferably at least about 70%, more preferably at least about 80%, more preferably at least about 90%, even more preferably at least about 95%; even more preferably at least 99%; even more preferably 100% sequence identity to SEQ ID No. 1, 32 or 34; and a polyadenylation signal and/or a poly(A) sequence. Furthermore, the invention provides an artificial DNA molecule comprising an open reading frame, preferably an open reading frame which encodes any peptide or protein other than albumin; a 3'UTR element comprising or consisting of a sequence which has at least about 60%, preferably at least about 70%, more preferably at least about 80%, more preferably at least about 90%, even more preferably at least about 95%; even more preferably at least 99%; even more preferably 100% sequence identity to SEQ ID No. 3, 36 or 38.

Furthermore, the invention provides an artificial RNA molecule, preferably an artificial mRNA molecule or an artificial viral RNA molecule, comprising an open reading frame, preferably an open reading frame which encodes a peptide or protein other than albumin; a 3'UTR element comprising or consisting of a sequence which has at least about 60%, preferably at least about 70%, more preferably at least about 80%, more preferably at least about 90%, even more preferably at least about 95%; even more preferably at least 99%; even more preferably 100% sequence identity to SEQ ID No. 2, 33 or 35; and a polyadenylation signal and/or a poly(A) sequence. Furthermore, the invention provides an artificial RNA molecule, preferably an artificial mRNA molecule or an artificial viral RNA molecule, comprising an open reading frame, preferably an open reading frame which encodes a peptide or protein other than albumin; a 3'UTR element comprising or consisting of a sequence which has at least about 60%, preferably at least about 70%, more preferably at least about 80%, more preferably at least about 90%, even more preferably at least about 95%; even more preferably at least 99%; even more preferably 100% sequence identity to SEQ ID No. 4, 37 or 39.

The invention provides an artificial nucleic acid molecule, preferably an artificial mRNA, which may be characterized by enhanced stability and prolonged expression of the encoded peptide or protein. Without being bound by any theory, enhanced stability of protein expression and thus prolonged protein expression may result from reduction in degradation of the artificial nucleic acid molecule, such as an artificial mRNA molecule according to the present invention. Accordingly, the inventive 3'UTR element may prevent the artificial nucleic acid from degradation and decay.

In some embodiments, it is preferred that the 3'UTR element does not consist of a histone stem-loop, preferably does not comprise a histone stem-loop. In one embodiment, the artificial nucleic acid molecule according to the present invention does not comprise a histone stem-loop. However, in some embodiments, the artificial nucleic acid molecule may comprise a histone stem-loop in addition to the nucleic acid sequence derived from the 3'UTR of an albumin gene. Such artificial nucleic acid molecule according to the present invention, for example, may comprise in 5'-to-3'-direction an ORF, an inventive 3'UTR element, preferably comprising a polyadenylation signal, an optional histone stem-loop and an optional poly(A) sequence. It may also comprise in 5'-to-3'-direction an ORF, an inventive 3'UTR element, e.g. comprising a polyadenylation-signal, a poly(A) sequence and an optional histone stem-loop.

In the context of the present invention, such a histone stem-loop is typically derived from a histone gene and comprises an intramolecular base pairing of two neighbored entirely or partially reverse complementary sequences, thereby forming a stem-loop. A stem-loop can occur in single-stranded DNA or, more commonly, in RNA. The structure is also known as a hairpin or hairpin loop and usually consists of a stem and a (terminal) loop within a consecutive sequence, wherein the stem is formed by two neighbored entirely or partially reverse complementary sequences separated by a short sequence as sort of spacer, which builds the loop of the stem-loop structure. The two neighbored entirely or partially reverse complementary sequences may be defined as e.g. stem-loop elements stem1 and stem2. The stem loop is formed when these two neighbored entirely or partially reverse complementary sequences, e.g. stem-loop elements stem1 and stem2, form base-pairs with each other, leading to a double stranded nucleic acid sequence comprising an unpaired loop at its terminal ending formed by the short sequence located between stem-loop elements stem1 and stem2 on the consecutive sequence. The unpaired loop thereby

typically represents a region of the nucleic acid which is not capable of base pairing with either of these stem-loop elements. The resulting lollipop-shaped structure is a key building block of many RNA secondary structures. The formation of a stem-loop structure is thus dependent on the stability of the resulting stem and loop regions, wherein the first 5 prerequisite is typically the presence of a sequence that can fold back on itself to form a paired double strand. The stability of paired stem-loop elements is determined by the length, the number of mismatches or bulges it contains (a small number of mismatches is typically tolerable, especially in a long double strand), and the base composition of the paired region. In the context of the present invention, optimal loop length is 3-10 bases, 10 more preferably 3 to 8, 3 to 7, 3 to 6 or even more preferably 4 to 5 bases, and most preferably 4 bases.

An example for a histone stem-loop sequence is the sequence according to SEQ ID NO: 31 (CAAAGGCTTTTCAGAGCCACCA) or the corresponding RNA sequence.

15

Thus, in some embodiments, the artificial nucleic acid molecule according to the present invention comprises (a.) at least one open reading frame; (b.) at least one 3'UTR element as described herein, and (d.) at least one histone-stem loop which may, for example, comprise or consist of a sequence having a sequence identity of at least about 75%, preferably of at 20 least about 80%, preferably at least about 85%, more preferably at least about 90%, even more preferably at least about 95% to the sequence according to SEQ ID NO. 31 or the corresponding RNA sequence, wherein preferably positions 6, 13 and 20 of the sequence having a sequence identity of at least about 75%, preferably of at least about 80%, preferably at least about 85%, more preferably at least about 90%, even more preferably at least 25 about 95% to the sequence according to SEQ ID NO. 31 or the corresponding RNA sequence are conserved, i.e. are identical to the nucleotides at positions 6, 13 and 20 of SEQ ID NO. 31.

In some embodiments, the artificial nucleic acid molecule comprises further elements such 30 as a 5'-cap, a poly(C) sequence and/or an IRES-motif. A 5'-cap may be added post-transcriptionally to the 5'end of an RNA. Furthermore, the inventive artificial nucleic acid molecule, particularly if the nucleic acid is in the form of an mRNA or codes for an mRNA, may be modified by a sequence of at least 10 cytidines, preferably at least 20 cytidines,

more preferably at least 30 cytidines (so-called "poly(C) sequence"). Particularly, the inventive nucleic acid molecule may contain, especially if the nucleic acid is in the form of an (m)RNA or codes for an mRNA, a poly(C) sequence of typically about 10 to 200 cytidine nucleotides, preferably about 10 to 100 cytidine nucleotides, more preferably about 10 to 5 70 cytidine nucleotides or even more preferably about 20 to 50 or even 20 to 30 cytidine nucleotides. Thus, preferably the artificial nucleic acid molecule according to the present invention comprises, preferably in 5'-to-3' direction, an ORF, at least one 3'UTR element as described above, a poly(A) sequence or a polyadenylation signal, and a poly(C) sequence.

10 An internal ribosome entry side (IRES) sequence or IRES-motif may separate several open reading frames, for example if the artificial nucleic acid molecule encodes for two or more peptides or proteins. An IRES-sequence may be particularly helpful if the mRNA is a bi- or multicistronic RNA.

15 Furthermore, the artificial nucleic acid molecule may comprise additional 5'-elements, preferably a 5'UTR, a promoter, or a 5'-UTR and a promoter containing-sequence. The promoter may drive and/or regulate transcription of the artificial nucleic acid molecule according to the present invention, for example of an artificial DNA-molecule according to the present invention. Furthermore, the 5'UTR may interact with the inventive 3'UTR 20 element and thus may support the stabilising effect of the inventive 3'UTR element. Such elements may further support stability and translational efficiency. Accordingly, in some embodiments, the invention provides artificial nucleic acid molecules, preferably mRNA-molecules, comprising in 5'-to-3'-direction at least one of the following structures

25 5'-cap – 5'UTR – ORF – 3'UTR element – histone stem-loop – poly(A) sequence

5'-cap – 5'UTR – ORF – 3'UTR element – poly(A) sequence – histone stem-loop

5'-cap – 5'UTR – ORF – IRES – ORF – 3'-UTR element – histone stem-loop – poly(A) sequence

5'-cap – 5'UTR – ORF – IRES – ORF – 3'-UTR element – histone stem-loop – 30 poly(A) sequence – poly(C) sequence

5'-cap – 5'UTR – ORF – IRES – ORF – 3'UTR element – poly(A) sequence – histone stem-loop

5'-cap – 5'UTR – ORF – IRES – ORF – 3'UTR element – poly(A) sequence – poly(C) sequence – histone stem-loop

5 5'-cap – 5'UTR – ORF – 3'UTR element – poly(A) sequence – poly(C) sequence

5'-cap – 5'UTR – ORF – 3'UTR element – poly(A) sequence – poly(C) sequence – histone stem loop

10 Preferably, the artificial nucleic acid molecule according to the present invention, preferably the open reading frame, is at least partially G/C modified. Thus, the inventive artificial nucleic acid molecule may be thermodynamically stabilized by modifying the G (guanosine)/C (cytidine) content of the molecule. The G/C content of the open reading frame of an artificial nucleic acid molecule according to the present invention may be increased compared to the G/C content of the open reading frame of a corresponding wild type sequence, preferably by using the degeneration of the genetic code. Thus, the encoded amino acid sequence of the nucleic acid molecule is preferably not modified by the G/C modification compared to the coded amino acid sequence of the particular wild type sequence. The codons of a coding sequence or a whole nucleic acid molecule, e.g. an mRNA, may therefore be varied compared to the wild type coding sequence, such that they 15 include an increased amount of G/C nucleotides while the translated amino acid sequence is maintained. In respect to the fact that several codons code for one and the same amino acid (so-called degeneration of the genetic code), the most favourable codons for the stability can be determined (so-called alternative codon usage).

25 Depending on the amino acid to be encoded by the coding region of the inventive nucleic acid molecule as defined herein, there are various possibilities for modification of the nucleic acid sequence, e.g. the open reading frame, compared to its wild type coding region. In the case of amino acids which are encoded by codons which contain exclusively G or C nucleotides, no modification of the codon is necessary. Thus, the codons for Pro (CCC or 30 CCG), Arg (CGC or CGG), Ala (GCC or GCG) and Gly (GGC or GGG) require no modifica-

tion, since no A or U/T is present.

In contrast, codons which contain A and/or U/T nucleotides may be modified by substitution of other codons which code for the same amino acids but contain no A and/or U/T. For

5 example

the codons for Pro can be modified from CC(U/T) or CCA to CCC or CCG;

the codons for Arg can be modified from CG(U/T) or CGA or AGA or AGG to CGC or CGG;

the codons for Ala can be modified from GC(U/T) or GCA to GCC or GCG;

10 the codons for Gly can be modified from GG(U/T) or GGA to GGC or GGG.

In other cases, although A or (U/T) nucleotides cannot be eliminated from the codons, it is however possible to decrease the A and (U/T) content by using codons which contain a lower content of A and/or (U/T) nucleotides. Examples of these are:

15

The codons for Phe can be modified from (U/T)(U/T)(U/T) to (U/T) (U/T)C;

the codons for Leu can be modified from (U/T) (U/T)A, (U/T) (U/T)G, C(U/T) (U/T) or C(U/T)A to C(U/T)C or C(U/T)G;

the codons for Ser can be modified from (U/T)C(U/T) or (U/T)CA or AG(U/T) to (U/T)CC,

20 (U/T)CG or AGC;

the codon for Tyr can be modified from (U/T)A(U/T) to (U/T)AC;

the codon for Cys can be modified from (U/T)G(U/T) to (U/T)GC;

the codon for His can be modified from CA(U/T) to CAC;

the codon for Gln can be modified from CAA to CAG;

25 the codons for Ile can be modified from A(U/T)(U/T) or A(U/T)A to A(U/T)C;

the codons for Thr can be modified from AC(U/T) or ACA to ACC or ACG;

the codon for Asn can be modified from AA(U/T) to AAC;

the codon for Lys can be modified from AAA to AAC;

the codons for Val can be modified from G(U/T)(U/T) or G(U/T)A to G(U/T)C or G(U/T)G;

30 the codon for Asp can be modified from GA(U/T) to GAC;

the codon for Glu can be modified from GAA to GAG;

the stop codon (U/T)AA can be modified to (U/T)AG or (U/T)GA.

In the case of the codons for Met (A(U/T)G) and Trp ((U/T)GG), on the other hand, there is no possibility of sequence modification without altering the encoded amino acid sequence.

The substitutions listed above can be used either individually or in all possible combinations to increase the G/C content of the open reading frame of the inventive nucleic acid sequence as defined herein, compared to its particular wild type open reading frame (i.e. the original sequence). Thus, for example, all codons for Thr occurring in the wild type sequence can be modified to ACC (or ACG).

Preferably, the G/C content of the open reading frame of the inventive artificial nucleic acid molecule as defined herein is increased by at least 7%, more preferably by at least 15%, particularly preferably by at least 20%, compared to the G/C content of the wild type coding region without altering the encoded amino acid sequence, i.e. using the degeneracy of the genetic code. According to a specific embodiment at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, more preferably at least 70 %, even more preferably at least 80% and most preferably at least 90%, 95% or even 100% of the substitutable codons in the open reading frame of the inventive artificial nucleic acid molecule or a fragment, variant or derivative thereof are substituted, thereby increasing the G/C content of said open reading frame.

In this context, it is particularly preferable to increase the G/C content of the open reading frame of the inventive nucleic acid sequence as defined herein, to the maximum (i.e. 100% of the substitutable codons), compared to the wild type open reading frame, without altering the encoded amino acid sequence.

Furthermore, the open reading frame is preferably at least partially codon-optimized. Codon-optimization is based on the finding that the translation efficiency may be determined by a different frequency in the occurrence of transfer RNAs (tRNAs) in cells. Thus, if so-called "rare codons" are present in the coding region of the inventive artificial nucleic acid molecule as defined herein, to an increased extent, the translation of the corresponding modified nucleic acid sequence is less efficient than in the case where codons coding for relatively "frequent" tRNAs are present.

Thus, the open reading frame of the inventive nucleic acid sequence is preferably modified compared to the corresponding wild type coding region such that at least one codon of the wild type sequence which codes for a tRNA which is relatively rare in the cell is exchanged

for a codon which codes for a tRNA which is comparably frequent in the cell and carries the same amino acid as the relatively rare tRNA. By this modification, the open reading frame of the inventive artificial nucleic acid molecule as defined herein, is modified such that codons for which frequently occurring tRNAs are available may replace codons which 5 correspond to rare tRNAs. In other words, according to the invention, by such a modification all codons of the wild type open reading frame which code for a rare tRNA may be exchanged for a codon which codes for a tRNA which is more frequent in the cell and which carries the same amino acid as the rare tRNA. Which tRNAs occur relatively frequently in the cell and which, in contrast, occur relatively rarely is known to a person 10 skilled in the art; cf. e.g. Akashi, Curr. Opin. Genet. Dev. 2001, 11(6): 660-666. Accordingly, preferably, the open reading frame is codon-optimized, preferably with respect to the system in which the nucleic acid molecule according to the present invention is to be expressed, preferably with respect to the system in which the nucleic acid molecule according 15 to the present invention is to be translated. Preferably, the codon usage of the open reading frame is codon-optimized according to mammalian codon usage, more preferably according to human codon usage. Preferably, the open reading frame is codon-optimized and G/C-content modified.

For further improving degradation resistance, e.g. resistance to *in vivo* degradation by an 20 exo- or endonuclease, and/or for further improving stability of protein expression from the artificial nucleic acid molecule according to the present invention, the artificial nucleic acid molecule may further comprise modifications, such as backbone modifications, sugar modifications and/or base modifications, e.g., lipid-modifications or the like. Preferably, the transcription and/or the translation of the artificial nucleic acid molecule according to the present invention is not significantly impaired by said modifications.

25 Nucleotide analogues/modifications that may be used in the context of the present invention may be selected, for example, from 2-amino-6-chloropurineriboside-5'-triphosphate, 2-aminoadenosine-5'-triphosphate, 2-thiocytidine-5'-triphosphate, 2-thiouridine-5'-triphosphate, 4-thiouridine-5'-triphosphate, 5-aminoallylcytidine-5'-triphosphate, 5-aminoallyluridine-5'-triphosphate, 5-bromocytidine-5'-triphosphate, 5-bromouridine-5'-triphosphate, 5-iodocytidine-5'-triphosphate, 5-iodouridine-5'-triphosphate, 5-methylcytidine-5'-triphosphate, 5-methyluridine-5'-triphosphate, 6-azacytidine-5'-triphosphate, 6-azauridine-5'-triphosphate, 6-chloropurineriboside-5'-triphosphate, 7-

deazaadenosine-5'-triphosphate, 7-deazaguanosine-5'-triphosphate, 8-azaadenosine-5'-triphosphate, 8-azidoadenosine-5'-triphosphate, benzimidazole-riboside-5'-triphosphate, N1-methyladenosine-5'-triphosphate, N1-methylguanosine-5'-triphosphate, N6-methyladenosine-5'-triphosphate, O6-methylguanosine-5'-triphosphate, pseudouridine-5'-triphosphate, or puromycin-5'-triphosphate, xanthosine-5'-triphosphate. Particular preference is given to nucleotides for base modifications selected from the group of base-modified nucleotides consisting of 5-methylcytidine-5'-triphosphate, 7-deazaguanosine-5'-triphosphate, 5-bromocytidine-5'-triphosphate, and pseudouridine-5'-triphosphate.

Further, lipid-modified artificial nucleic acid molecules may typically comprise at least one

linker which is covalently linked with the artificial nucleic acid molecule, and at least one lipid which is covalently linked with this linker. Alternatively, a lipid-modified artificial nucleic acid molecule may comprise at least one artificial nucleic acid molecule as defined herein and at least one, preferably bifunctional lipid which is covalently linked, preferably without a linker, with that artificial nucleic acid molecule. According to a third alternative,

a lipid-modified artificial nucleic acid molecule may comprise an artificial nucleic acid molecule as defined herein, at least one linker which is covalently linked with that artificial nucleic acid molecule, at least one lipid which is covalently linked with this linker, and additionally at least one, preferably bifunctional lipid which is covalently linked, preferably without a linker, with the artificial nucleic acid molecule.

20

In a further aspect, the present invention provides a vector comprising

- a. an open reading frame (ORF) and/or a cloning site, e.g. for insertion of an open reading frame or a sequence comprising an open reading frame; and
- b. at least one 3'-untranslated region element (3'UTR element) comprising a nucleic acid sequence which is derived from the 3'UTR of an albumin gene or from a variant of the 3'UTR of an albumin gene.

The at least one 3'UTR element and the ORF are as described above for the artificial nucleic acid molecule according to the present invention. The cloning site may be any sequence

30 that is suitable for introducing an open reading frame or a sequence comprising an open reading frame, such as one or more restriction sites. Thus, the vector comprising a cloning site is preferably suitable for inserting an open reading frame into the vector, preferably for inserting an open reading frame 5' to the 3'UTR element. Preferably the cloning site or the

ORF is located 5' to the 3'UTR element, preferably in close proximity to the 5'-end of the 3'UTR element. For example, the cloning site or the ORF may be directly connected to the 5'-end of the 3'UTR element or they may be connected via a stretch of nucleotides, such as by a stretch of 2, 4, 6, 8, 10, 20 etc. nucleotides as described above for the artificial nucleic acid molecule according to the present invention.

Preferably, the vector according to the present invention is suitable for producing the artificial nucleic acid molecule according to the present invention, preferably for producing an artificial mRNA according to the present invention, for example, by optionally inserting an open reading frame or a sequence comprising an open reading frame into the vector and transcribing the vector. Thus, preferably, the vector comprises elements needed for transcription, such as a promoter, e.g. an RNA polymerase promoter. Preferably, the vector is suitable for transcription using eukaryotic, prokaryotic, viral or phage transcription systems, such as eukaryotic cells, prokaryotic cells, or eukaryotic, prokaryotic, viral or phage *in vitro* transcription systems. Thus, for example, the vector may comprise a promoter sequence, which is recognized by a polymerase, such as by an RNA polymerase, e.g. by a eukaryotic, prokaryotic, viral, or phage RNA polymerase. In a preferred embodiment, the vector comprises a phage RNA polymerase promoter such as an SP6 or T7, preferably a T7 promoter. Preferably, the vector is suitable for *in vitro* transcription using a phage based *in vitro* transcription system, such as a T7 RNA polymerase based *in vitro* transcription system.

The vector may further comprise a poly(A) sequence and/or a polyadenylation signal as described above for the artificial nucleic acid molecule according to the present invention.

The vector may be an RNA vector or a DNA vector. Preferably, the vector is a DNA vector. The vector may be any vector known to the skilled person, such as a viral vector or a plasmid vector. Preferably, the vector is a plasmid vector, preferably a DNA plasmid vector.

In a preferred embodiment, the vector according to the present invention comprises the artificial nucleic acid molecule according to the present invention.

Preferably, a DNA vector according to the present invention comprises a sequence according to SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 32, SEQ ID No. 34, SEQ ID No. 36

or SEQ ID No. 38, or a sequence having an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%; even more preferably of at least about 99% sequence identity to the nucleic acid sequence according to SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 32, SEQ ID No. 34, SEQ ID No. 36 or SEQ ID No. 38, or a fragment thereof as described above, preferably a functional fragment thereof.

Preferably, an RNA vector according to the present invention comprises a sequence

according to SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 33, SEQ ID No. 35, SEQ ID No. 37 or SEQ ID No. 39 or a sequence having an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%; even more preferably of at least about 99% sequence identity to the nucleic acid sequence according to SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 33, SEQ ID No. 35, SEQ ID No. 37 or SEQ ID No. 39 or a fragment thereof, preferably a functional fragment thereof.

Preferably, the vector is a circular molecule. Preferably, the vector is a double-stranded molecule, such as a double stranded DNA molecule. Such circular, preferably double stranded DNA molecule may be used conveniently as a storage form for the inventive artificial nucleic acid molecule. Furthermore, it may be used for transfection of cells, for example, cultured cells. Also it may be used for *in vitro* transcription for obtaining an artificial RNA molecule according to the invention.

Preferably, the vector, preferably the circular vector, is linearizable, for example, by restriction enzyme digestion. In a preferred embodiment, the vector comprises a cleavage site, such as a restriction site, preferably a unique cleavage site, located immediately 3' to the 3'UTR element, or - if present - located 3' to the poly(A) sequence or polyadenylation signal, or - if present - located 3' to the poly(C) sequence, or - if present located 3' to the histone stem-loop. Thus, preferably, the product obtained by linearizing the vector terminates at the 3'end with the 3'-end of the 3'UTR element, or - if present - with the 3'-

end of the poly(A) sequence or polyadenylation signal, or - if present - with the 3'-end of the poly(C) sequence. In the embodiment, wherein the vector according to the present invention comprises the artificial nucleic acid molecule according to the present invention, a restriction site, preferably a unique restriction site, is preferably located immediately 3' to the 3'-end of the artificial nucleic acid molecule.

In a further aspect, the present invention relates to a cell comprising the artificial nucleic acid molecule according to the present invention or the vector according to present invention. The cell may be any cell, such as a bacterial cell, insect cell, plant cell,

vertebrate cell, e.g. a mammalian cell. Such cell may be, e.g., used for replication of the vector of the present invention, for example, in a bacterial cell. Furthermore, the cell may be used for transcribing the artificial nucleic acid molecule or the vector according to the present invention and/or translating the open reading frame of the artificial nucleic acid molecule or the vector according to the present invention. For example, the cell may be used for recombinant protein production.

The cells according to the present invention are, for example, obtainable by standard nucleic acid transfer methods, such as standard transfection, transduction or transformation methods. For example, the artificial nucleic acid molecule or the vector according to the present invention may be transferred into the cell by electroporation, lipofection, e.g. based

on cationic lipids and/or liposomes, calcium phosphate precipitation, nanoparticle based transfection, virus based transfection, or based on cationic polymers, such as DEAE-dextran or polyethylenimine etc..

Preferably, the cell is a mammalian cell, such as a cell of human subject, a domestic animal, a laboratory animal, such as a mouse or rat cell. Preferably the cell is a human cell.

The cell may be a cell of an established cell line, such as a CHO, BHK, 293T, COS-7, HELA, HEK, etc. or the cell may be a primary cell, such as a HDF cell etc., preferably a cell isolated from an organism. In a preferred embodiment, the cell is an isolated cell of a mammalian subject, preferably of a human subject. For example, the cell may be an immune cell, such as a dendritic cell, a cancer or tumor cell, or any somatic cell etc., preferably of a mammalian subject, preferably of a human subject.

In a further aspect, the present invention provides a pharmaceutical composition comprising the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, or the cell according to the present invention. The pharmaceutical composition according to the invention may be used, e.g., as a vaccine, for example, for 5 genetic vaccination. Thus, the ORF may, e.g., encode an antigen to be administered to a patient for vaccination. Thus, in a preferred embodiment, the pharmaceutical composition according to the present invention is a vaccine. Furthermore, the pharmaceutical composition according to the present invention may be used, e.g., for gene therapy.

10 Preferably, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients, vehicles, fillers and/or diluents. In the context of the present invention, a pharmaceutically acceptable vehicle typically includes a liquid or non-liquid basis for the inventive pharmaceutical composition. In one embodiment, the pharmaceutical composition is provided in liquid form. In this context, preferably, the vehicle is based 15 on water, such as pyrogen-free water, isotonic saline or buffered (aqueous) solutions, e.g. phosphate, citrate etc. buffered solutions. The buffer may be hypertonic, isotonic or hypotonic with reference to the specific reference medium, i.e. the buffer may have a higher, identical or lower salt content with reference to the specific reference medium, wherein preferably such concentrations of the afore mentioned salts may be used, which do not lead 20 to damage of mammalian cells due to osmosis or other concentration effects. Reference media are e.g. liquids occurring in "*in vivo*" methods, such as blood, lymph, cytosolic liquids, or other body liquids, or e.g. liquids, which may be used as reference media in "*in vitro*" methods, such as common buffers or liquids. Such common buffers or liquids are known to a skilled person. Ringer-Lactate solution is particularly preferred as a liquid basis.

25 One or more compatible solid or liquid fillers or diluents or encapsulating compounds suitable for administration to a patient may be used as well for the inventive pharmaceutical composition. The term "compatible" as used herein preferably means that these components of the inventive pharmaceutical composition are capable of being mixed with the inventive 30 nucleic acid, vector or cells as defined herein in such a manner that no interaction occurs which would substantially reduce the pharmaceutical effectiveness of the inventive pharmaceutical composition under typical use conditions.

The pharmaceutical composition according to the present invention may optionally further comprise one or more additional pharmaceutically active components. A pharmaceutically active component in this context is a compound that exhibits a therapeutic effect to heal, ameliorate or prevent a particular indication or disease. Such compounds include, without 5 implying any limitation, peptides or proteins, nucleic acids, (therapeutically active) low molecular weight organic or inorganic compounds (molecular weight less than 5000, preferably less than 1000), sugars, antigens or antibodies, therapeutic agents already known in the prior art, antigenic cells, antigenic cellular fragments, cellular fractions, cell wall components (e.g. polysaccharides), modified, attenuated or de-activated (e.g. chemically or by 10 irradiation) pathogens (virus, bacteria etc.).


Furthermore, the inventive pharmaceutical composition may comprise a carrier for the artificial nucleic acid molecule or the vector. Such a carrier may be suitable for mediating dissolution in physiological acceptable liquids, transport and cellular uptake of the pharmaceutical active artificial nucleic acid molecule or the vector. Accordingly, such a carrier 15 may be a component which may be suitable for depot and delivery of an artificial nucleic acid molecule or vector according to the invention. Such components may be, for example, cationic or polycationic carriers or compounds which may serve as transfection or complexation agent.

20 Particularly preferred transfection or complexation agents in this context are cationic or polycationic compounds, including protamine, nucleoline, spermine or spermidine, or other cationic peptides or proteins, such as poly-L-lysine (PLL), poly-arginine, basic poly-peptides, cell penetrating peptides (CPPs), including HIV-binding peptides, HIV-1 Tat (HIV), Tat-derived peptides, Penetratin, VP22 derived or analog peptides, HSV VP22 (Herpes simplex), MAP, KALA or protein transduction domains (PTDs), PpT620, prolin-rich peptides, 25 arginine-rich peptides, lysine-rich peptides, MPG-peptide(s), Pep-1, L-oligomers, Calcitonin peptide(s), Antennapedia-derived peptides (particularly from *Drosophila antennapedia*), pAntp, plsl, FGF, Lactoferrin, Transportan, Buforin-2, Bac715-24, SynB, SynB(1), pVEC, hCT-derived peptides, SAP, or histones.

30

Furthermore, such cationic or polycationic compounds or carriers may be cationic or polycationic peptides or proteins, which preferably comprise or are additionally modified to


comprise at least one $-SH$ moiety. Preferably, a cationic or polycationic carrier is selected from cationic peptides having the following sum formula (I):




5

wherein $l + m + n + o + x = 3-100$, and l, m, n or o independently of each other is any number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90 and 91-100 provided that the overall content of Arg (Arginine), Lys (Lysine), His (Histidine) and Orn (Ornithine) represents at least 10% of all amino acids of the oligopeptide; and Xaa is any amino acid selected from native (= naturally occurring) or non-native amino acids except of Arg, Lys, His or Orn; and x is any number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90, provided, that the overall content of Xaa does not exceed 90 % of all amino acids of the oligopeptide. Any of amino acids Arg, Lys, His, Orn and Xaa may be positioned at any place of the peptide. In this context cationic peptides or proteins in the range of 7-30 amino acids are particular preferred.

Further, the cationic or polycationic peptide or protein, when defined according to formula $\{(Arg)_l;(Lys)_m;(His)_n;(Orn)_o;(Xaa)_x\}$ (formula (I)) as shown above and which comprise or are 20 additionally modified to comprise at least one $-SH$ moiety, may be, without being restricted thereto, selected from subformula (Ia):



25 wherein $(Arg)_l;(Lys)_m;(His)_n;(Orn)_o$; and x are as defined herein, Xaa' is any amino acid selected from native (= naturally occurring) or non-native amino acids except of Arg, Lys, His, Orn or Cys and y is any number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80 and 81-90, provided that the overall content of Arg (Arginine), Lys (Lysine), His (Histidine) and Orn (Ornithine) represents at least 10% of all amino acids of the oligopeptide. Further, the cationic or polycationic peptide may be selected from subformula (Ib):



wherein empirical formula $\{(Arg)_i;(Lys)_m;(His)_n;(Orn)_o;(Xaa)_x\}$ (formula (III)) is as defined herein and forms a core of an amino acid sequence according to (semiempirical) formula (III) and wherein Cys_1 and Cys_2 are Cysteines proximal to, or terminal to 5 $(Arg)_i;(Lys)_m;(His)_n;(Orn)_o;(Xaa)_x$.

Further preferred cationic or polycationic compounds, which can be used as transfection or complexation agent may include cationic polysaccharides, for example chitosan, polybrene, cationic polymers, e.g. polyethyleneimine (PEI), cationic lipids, e.g. DOTMA: [1-10 (2,3-sioleyloxy)propyl]-N,N,N-trimethylammonium chloride, DMRIE, di-C14-amidine, DOTIM, SAINT, DC-Chol, BGTC, CTAP, DOPC, DODAP, DOPE: Dioleyl phosphatidylethanol-amine, DOSPA, DODAB, DOIC, DMEPC, DOGS: Dioctadecylamidoglycylspermin, DIMRI: Dimyristo-oxypropyl dimethyl hydroxyethyl ammonium bromide, DOTAP: dioleyloxy-3-(trimethylammonio)propane, DC-6-14: O,O-ditetradecanoyl-N-(α -trimethylammonioacetyl)diethanolamine chloride, CLIP1: rac-[(2,3-dioctadecyloxypropyl)(2-hydroxyethyl)]-dimethylammonium chloride, CLIP6: rac-[2(2,3-dihexadecyloxypropyl-oxymethyloxy)ethyl]trimethylammonium, CLIP9: rac-[2(2,3-dihexadecyloxypropyl-oxysuccinyl)ethyl]-trimethylammonium, oligofectamine, or cationic or polycationic polymers, e.g. modified polyaminoacids, such as β -aminoacid-20 polymers or reversed polyamides, etc., modified polyethylenes, such as PVP (poly(N-ethyl-4-vinylpyridinium bromide)), etc., modified acrylates, such as pDMAEMA (poly(dimethylaminoethyl methylacrylate)), etc., modified Amidoamines such as pAMAM (poly(amidoamine)), etc., modified polybetaaminoester (PBAE), such as diamine end modified 1,4 butanediol diacrylate-co-5-amino-1-pentanol polymers, etc., dendrimers, such as 25 polypropylamine dendrimers or pAMAM based dendrimers, etc., polyimine(s), such as PEI: poly(ethyleneimine), poly(propyleneimine), etc., polyallylamine, sugar backbone based polymers, such as cyclodextrin based polymers, dextran based polymers, chitosan, etc., silan backbone based polymers, such as PMOXA-PDMS copolymers, etc., blockpolymers 30 consisting of a combination of one or more cationic blocks (e.g. selected from a cationic polymer as mentioned above) and of one or more hydrophilic or hydrophobic blocks (e.g polyethyleneglycole); etc.

In this context it is particularly preferred that the inventive artificial nucleic acid molecule or the inventive vector is complexed at least partially with a cationic or polycationic compound, preferably cationic proteins or peptides. Partially means that only a part of the inventive artificial nucleic acid molecule or the inventive vector is complexed with a cationic or polycationic compound and that the rest of the inventive artificial nucleic acid molecule or the inventive vector is in uncomplexed form ("free"). Preferably the ratio of complexed nucleic acid to: free nucleic acid is selected from a range of about 5:1 (w/w) to about 1:10 (w/w), more preferably from a range of about 4:1 (w/w) to about 1:8 (w/w), even more preferably from a range of about 3:1 (w/w) to about 1:5 (w/w) or 1:3 (w/w), and most preferably the ratio of complexed nucleic acid to free nucleic acid is selected from a ratio of about 1:1 (w/w).

The pharmaceutical composition according to the present invention may optionally further comprise one or more adjuvants, for example, adjuvants for stimulating the innate immune system or for enhancing cellular uptake of the artificial nucleic acid molecule or vector. In this context, an adjuvant may be understood as any compound, which is suitable to initiate or increase an immune response of the innate immune system, i.e. a non-specific immune response. In other words, when administered, the inventive pharmaceutical composition preferably elicits an innate immune response due to the adjuvant, optionally contained therein. Preferably, such an adjuvant may be an adjuvant supporting the induction of an innate immune response in a mammal. Such an adjuvant may be, for example, an immunostimulatory nucleic acid, i.e. a nucleic acid that may bind to a Toll-like-receptor or the like, preferably an immunostimulatory RNA.

Such adjuvants, preferably such immunostimulatory nucleic acids, may induce an innate, i.e. unspecific, immune response which may support a specific, i.e. adaptive, immune response to the peptide or protein, i.e. the antigen, encoded by the artificial nucleic acid molecule of the pharmaceutical composition, preferably the vaccine.

The inventive pharmaceutical composition may also additionally comprise any further compound, which is known to be immunostimulating due to its binding affinity (as ligands) to human Toll-like receptors TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9,

TLR10, or due to its binding affinity (as ligands) to murine Toll-like receptors TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12 or TLR13.

Further additives which may be included in the inventive pharmaceutical composition are,

5 e.g., emulsifiers, such as, for example, Tween®; wetting agents, such as, for example, sodium lauryl sulfate; colouring agents; taste-imparting agents, pharmaceutical carriers; tablet-forming agents; stabilizers; antioxidants; preservatives etc.

The pharmaceutical composition according to the present invention preferably comprises a

10 "safe and effective amount" of the components of the pharmaceutical composition, particularly of the inventive nucleic acid sequence, the vector and/or the cells as defined herein. As used herein, a "safe and effective amount" means an amount sufficient to significantly induce a positive modification of a disease or disorder as defined herein. At the same time, however, a "safe and effective amount" preferably avoids serious side-effects and permits a
15 sensible relationship between advantage and risk. The determination of these limits typically lies within the scope of sensible medical judgment.

In a further aspect, the present invention provides the artificial nucleic acid molecule

20 according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention for use as a medicament, for example, as vaccine (in genetic vaccination) or in gene therapy.

The artificial nucleic acid molecule according to the present invention, the vector according

25 to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention are particularly suitable for any medical application which makes use of the therapeutic action or effect of peptides, polypeptides or proteins, or where supplementation of a particular peptide or protein is needed. Thus, the present invention provides the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention for use in the treatment or prevention of diseases or disorders amenable to treatment by the therapeutic action or effect of peptides, polypeptides or proteins or amenable to treatment

by supplementation of a particular peptide, polypeptide or protein. For example, the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention may be used for the treatment or prevention
5 of genetic diseases, autoimmune diseases, cancerous or tumour-related diseases, infectious diseases, chronic diseases or the like, e.g., by genetic vaccination or gene therapy.

In particular, such therapeutic treatments which benefit from a stable and prolonged presence of therapeutic peptides, polypeptides or proteins in a subject to be treated are
10 especially suitable as medical application in the context of the present invention, since the inventive 3'UTR element provides for a stable and prolonged expression of the ORF of the inventive nucleic acid molecule. Thus, a particularly suitable medical application for the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical
15 composition according to the present invention is vaccination. Thus, the present invention provides the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention for vaccination of a subject, preferably a mammalian subject, more preferably a human subject. Preferred vaccination
20 treatments are vaccination against infectious diseases, such as bacterial, protozoal or viral infections, and anti-tumour-vaccination. Such vaccination treatments may be prophylactic or therapeutic.

Depending on the disease to be treated or prevented, the ORF may be selected. For
25 example, the open reading frame may code for a protein that has to be supplied to a patient suffering from total lack or at least partial loss of function of a protein, such as a patient suffering from a genetic disease. Additionally the open reading frame may be chosen from an ORF coding for a peptide or protein which beneficially influences a disease or the condition of a subject. Furthermore, the open reading frame may code for a peptide or
30 protein which effects down-regulation of a pathological overproduction of a natural peptide or protein or elimination of cells expressing pathologically a protein or peptide. Such lack, loss of function or overproduction may, e.g., occur in the context of tumour and neoplasia, autoimmune diseases, allergies, infections, chronic diseases or the like. Furthermore, the

open reading frame may code for an antigen or immunogen, e.g. for an epitope of a pathogen or for a tumour antigen. Thus, in preferred embodiments, the artificial nucleic acid molecule or the vector according to the present invention comprises an ORF encoding an amino acid sequence comprising or consisting of an antigen or immunogen, e.g. an epitope of a pathogen or a tumour-associated antigen, a 3'UTR element as described above, and optional further components, such as a poly(A) sequence etc.

5 In the context of medical application, in particular, in the context of vaccination, it is preferred that the artificial nucleic acid molecule according to the present invention is RNA,

10 preferably mRNA, since DNA harbours the risk of eliciting an anti-DNA immune response and tends to insert into genomic DNA. However, in some embodiments, for example, if a viral delivery vehicle, such as an adenoviral delivery vehicle is used for delivery of the artificial nucleic acid molecule or the vector according to the present invention, e.g., in the context of gene therapeutic treatments, it may be desirable that the artificial nucleic acid

15 molecule or the vector is a DNA molecule.

The artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention may be administered orally, parenterally, by

20 inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, intracranial, transdermal, intradermal, intrapulmonary, intraperitoneal, intracardial, intraarterial, and sublingual injection or infusion techniques.

25

Preferably, the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention is administered parenterally, e.g. by parenteral injection, more preferably by subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, intracranial, transdermal, intradermal, intrapulmonary, intraperitoneal, intracardial, intraarterial, sublingual injection or via infusion techniques. Particularly preferred is intradermal and intramuscular injection. Sterile injectable forms of the inventive pharmaceutical composition may be

aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.

5 The artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention may also be administered orally in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.

10 The artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, e.g. including diseases of the skin or of any other accessible epithelial tissue. Suitable topical formulations are readily prepared for each of these areas or organs. For topical applications, the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention may be formulated in a 15 suitable ointment suspended or dissolved in one or more carriers.

20 In one embodiment, the use as a medicament comprises the step of transfection of mammalian cells, preferably *in vitro* transfection of mammalian cells, more preferably *in vitro* transfection of isolated cells of a subject to be treated by the medicament. If the use 25 comprises the *in vitro* transfection of isolated cells, the use as a medicament may further comprise the (re)administration of the transfected cells to the patient. The use of the inventive artificial nucleic acid molecules or the vector as a medicament may further comprise the step of selection of successfully transfected isolated cells. Thus, it may be beneficial if the vector further comprises a selection marker. Also, the use as a medicament 30 may comprise *in vitro* transfection of isolated cells and purification of an expression-product, i.e. the encoded peptide or protein from these cells. This purified peptide or protein may subsequently be administered to a subject in need thereof.

The present invention also provides a method for treating or preventing a disease or disorder as described above comprising administering the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention to a subject in need thereof.

Furthermore, the present invention provides a method for treating or preventing a disease or disorder comprising transfection of a cell with an artificial nucleic acid molecule according to the present invention or with the vector according to the present invention. Said 10 transfection may be performed *in vitro* or *in vivo*. In a preferred embodiment, transfection of a cell is performed *in vitro* and the transfected cell is administered to a subject in need thereof, preferably to a human patient. Preferably, the cell which is to be transfected *in vitro* is an isolated cell of the subject, preferably of the human patient. Thus, the present invention provides a method of treatment comprising the steps of isolating a cell from a 15 subject, preferably from a human patient, transfecting the isolated cell with the artificial nucleic acid according to the present invention or the vector according to the present invention, and administering the transfected cell to the subject, preferably the human patient.

20 The method of treating or preventing a disorder according to the present invention is preferably a vaccination method and/or a gene therapy method as described above.

As described above, the inventive 3'UTR element is capable of stabilizing an mRNA molecule and/or of stabilizing and/or prolonging the protein production from an mRNA 25 molecule. Thus, in a further aspect, the present invention relates to a method for stabilizing an RNA molecule, preferably an mRNA molecule, comprising the step of associating the RNA molecule, preferably the mRNA molecule, or a vector encoding the RNA molecule, with a 3'UTR element comprising or consisting of a nucleic acid sequence which is derived from the 3'UTR of an albumin gene or from a variant of the 3'UTR of an albumin gene, 30 preferably with the 3'UTR element as described above.

Furthermore, the present invention relates to a method for increasing protein production from an artificial nucleic acid molecule or from a vector, preferably from an mRNA

molecule, and/or for stabilizing and/or prolonging protein production from an artificial nucleic acid molecule or from a vector, preferably from an mRNA molecule, the method comprising the step of associating the artificial nucleic acid molecule or the vector, preferably the mRNA molecule, with a 3'UTR element which comprises or consists of a nucleic acid sequence which is derived from the 3'UTR of an albumin gene or from a variant of the 3'UTR of an albumin gene, preferably with the 3'UTR element as described above.

The term "associating the artificial nucleic acid molecule or the vector with a 3'UTR element" in the context of the present invention preferably means functionally associating or functionally combining the artificial nucleic acid molecule or the vector with the 3'UTR element. This means that the artificial nucleic acid molecule or the vector and the 3'UTR element, preferably the 3'UTR element as described above, are associated or coupled such that the function of the 3'UTR element, e.g., the RNA and/or protein production stabilizing function, is exerted. Typically, this means that the 3'UTR element is integrated into the artificial nucleic acid molecule or the vector, preferably the mRNA molecule, 3' to an open reading frame, preferably immediately 3' to an open reading frame, preferably between the open reading frame and a poly(A) sequence or a polyadenylation signal. Preferably, the 3'UTR element is integrated into the artificial nucleic acid molecule or the vector, preferably the mRNA, as 3'UTR, i.e. such that the 3'UTR element is the 3'UTR of the artificial nucleic acid molecule or the vector, preferably the mRNA, i.e., such that it extends from the 3'-side of the open reading frame to the 5'-side of a poly(A) sequence or a polyadenylation signal, optionally connected via short linker, such as a sequence comprising or consisting of one or more restriction sites. Thus, preferably, the term "associating the artificial nucleic acid molecule or the vector with a 3'UTR element" means functionally associating the 3'UTR element with an open reading frame located within the artificial nucleic acid molecule or the vector, preferably within the mRNA molecule. The 3'UTR and the ORF are as described above for the artificial nucleic acid molecule according to the present invention, for example, preferably the ORF and the 3'UTR are heterologous, e.g. derived from different genes, as described above.

In a further aspect, the present invention provides the use of a 3'UTR element, preferably the 3'UTR element as described above, for increasing the stability of an RNA molecule,

preferably of an mRNA molecule, wherein the 3'UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'UTR of an albumin gene or from a variant of the 3'UTR of an albumin gene.

5 Furthermore, the present invention provides the use of a 3'UTR element, preferably the 3'UTR element as described above, for increasing protein production from an artificial nucleic acid molecule or a vector, preferably from an mRNA molecule, and/or for stabilizing and/or prolonging protein production from an artificial nucleic acid molecule or a vector molecule, preferably from an mRNA molecule, wherein the 3'UTR element comprises or consists of a 10 nucleic acid sequence which is derived from the 3'UTR of an albumin gene or from a variant of the 3'UTR of an albumin gene as described above.

The uses according to the present invention preferably comprise associating the artificial nucleic acid molecule, the vector, or the RNA with the 3'UTR element as described above.

15 The compounds and ingredients of the inventive pharmaceutical composition may also be manufactured and traded separately of each other. Thus, the invention relates further to a kit or kit of parts comprising an artificial nucleic acid molecule according to the invention, an vector according the invention, a cell according to the invention, and/or a pharmaceutical composition 20 according to the invention. Preferably, such kit or kits of parts may, additionally, comprise instructions for use, cells for transfection, an adjuvant, a means for administration of the pharmaceutical composition, a pharmaceutically acceptable carrier and/or an pharmaceutically acceptable solution for dissolution or dilution of the artificial nucleic acid molecule, the vector, the cells or the pharmaceutical composition.

25 It is to be noted that, throughout the description and claims of this specification, the word 'comprise' and variations of the word, such as 'comprising' and 'comprises', is not intended to exclude other variants or additional components, integers or steps. Modifications and improvements to the invention will be readily apparent to those skilled in the art. Such 30 modifications and improvements are intended to be within the scope of this invention.

Any reference to or discussion of any document, act or item of knowledge in this specification is included solely for the purpose of providing a context for the present invention. It is not suggested or represented that any of these matters or any combination thereof formed at the

priority date part of the common general knowledge, or was known to be relevant to an attempt to solve any problem with which this specification is concerned.

The following Figures, Sequences and Examples are intended to illustrate the invention further.

5 They are not intended to limit the subject matter of the invention thereto.

Fig. 1 shows the effect of the human α -globin 3'UTR, of the human albumin 3'UTR and of the human β -glucuronidase 3'UTR on luciferase expression from an artificial mRNA. Therein, the mRNA comprising the human albumin 3'UTR is an mRNA according to the present invention.

10 It comprises an open reading frame encoding Luciferase of *Photinus pyralis*, followed in 5'-to-3'-direction by a

3'UTR element according to SEQ ID No. 2 and by a poly(A) sequence having a length of 64 adenines. A markedly extended protein expression from the artificial mRNA containing the human albumin 3'UTR corresponding to SEQ ID No. 2 is observable.

5 The effect of the human α -globin 3'-UTR, of the human albumin 3'-UTR, or of the human β -glucuronidase 3'-UTR on luciferase expression from mRNA was examined, compared to Luciferase expression from mRNA lacking a 3'-UTR. Therefore, different mRNAs were electroporated into HeLa cells. Luciferase levels were measured at 6, 24, and 48 hours after transfection. The luciferase level from mRNA lacking a 3'-UTR drops from 6 hours to 48 hours, 10% of the 6-hours-signal remaining at 48 hours. The α -globin 3'-UTR stabilizes luciferase expression from mRNA moderately. Strikingly however, the inventive human albumin 3'-UTR further markedly extends Luciferase expression from mRNA. In contrast, the 3'-UTR of the stable β -glucuronidase mRNA does not extend Luciferase expression to the extent observed for the albumin 3'-UTR, confirming that the albumin 3'-UTR is particularly efficient at extending protein expression from mRNA. Data are graphed as mean RLU \pm SD (relative light units \pm standard deviation) for triplicate transfections. RLU are summarized in Example 5.1.

10

15

Fig. 2 shows the effect of the human albumin 3'-UTR on luciferase expression from mRNA, compared to luciferase expression from mRNA containing the human α -globin 3'-UTR or the 3'-UTR each of several different stable mRNAs. Therefore, different mRNAs were electroporated into HeLa cells. Luciferase levels were measured at 6, 24, and 48 hours after transfection. The luciferase level from mRNA lacking a 3'-UTR drops from 6 hours to 48 hours, 14% of the 6-hours-signal remaining at 48 hours. The α -globin 3'-UTR stabilizes luciferase expression from mRNA moderately. Strikingly however, the inventive human albumin 3'-UTR further markedly extends luciferase expression from mRNA. Compared to the albumin 3'-UTR, the 3'-UTRs of several different stable mRNAs do affect luciferase expression from mRNA in a much less favourable manner: The atp5o and atp5l 3'-UTRs stabilize luciferase expression much less than the albumin 3'-UTR. In addition, atp5o and atp5l 3'-UTRs reduce luciferase levels substantially compared to the albumin 3'-UTR. The 3'-UTR of the stable ndufa1

20

25

30

mRNA does stabilize luciferase expression markedly. However, the *ndufa1* 3'-UTR also reduces luciferase levels substantially. The albumin 3'-UTR is unique at extending protein expression while maintaining total protein expression. Data are graphed as mean RLU \pm SD (relative light units \pm standard deviation) for triplicate transfections. RLU are summarized in Example 5.2.

5

Fig. 3 shows the effect of point mutations to remove either a HindIII and/or an XbaI restriction site and/or a T7 termination signal from the human albumin 3'-UTR on luciferase expression from mRNA containing the human albumin 3'-UTR. Therefore, different mRNAs were electroporated into HeLa cells. Luciferase levels were measured at 6, 24, 48, and 72 hours after transfection. The PpLuc Signal was corrected for transfection efficiency by the signal of cotransfected RrLuc. The α -globin 3'-UTR stabilizes luciferase expression from mRNA only very moderately. In contrast, all variants of the albumin 3'-UTR markedly extend luciferase expression from mRNA. Data are graphed as mean RLU \pm SD (relative light units \pm standard deviation) for triplicate transfections. RLU are summarized in Example 5.4.

10

15

20

25

Fig. 4 shows the mRNA sequence of PpLuc(GC) – A64 lacking a 3'-UTR. Fig. 5 shows the mRNA sequence of PpLuc(GC) – albumin – A64. The 3'-UTR of human albumin was inserted between ORF and poly(A). The sequence was taken from Dugaiczyk et al. 1982; Proc Natl Acad Sci U S A. Jan;79(1):71-5.

Fig. 6 shows the mRNA sequence of PpLuc(GC) – albumin2 – A64. The 3'-UTR of human albumin, with the T7 termination signal removed by a single point mutation, was inserted between ORF and poly(A).

Fig. 7 shows the mRNA sequence of PpLuc(GC) – albumin3 – A64. The 3'-UTR of human albumin, with the T7 termination signal removed by a single point mutation, was inserted between ORF and poly(A).

Fig. 8 shows the mRNA sequence of PpLuc(GC) – albumin4 – A64. The 3'-UTR of human albumin, with the T7 termination signal removed by a single point mutation, was inserted between ORF and poly(A).

Fig. 9 shows the mRNA sequence of PpLuc(GC) – albumin5 – A64. The 3'-UTR of human albumin, with the T7 termination signal removed by two consecutive point mutations, was inserted between ORF and poly(A).

Fig. 10 shows the mRNA sequence of PpLuc(GC) – albumin6 – A64. The 3'-UTR of human albumin, with the HindIII and XbaI restriction sites removed by two single point mutations, was inserted between ORF and poly(A).

Fig. 11 shows the mRNA sequence of PpLuc(GC) – albumin7 – A64. The 3'-UTR of human albumin, with the T7 termination signal as well as the HindIII and XbaI restriction sites removed by three single point mutations, was inserted between ORF and poly(A).

Fig. 12 shows the mRNA sequence of PpLuc(GC) – ag – A64. The center, α -complex-binding portion of the 3'-UTR of human α -globin was inserted between ORF and poly(A).

Fig. 13 shows the mRNA sequence of PpLuc(GC) – gusb – A64. The 3'-UTR of human β -glucuronidase was inserted between ORF and poly(A).

Fig. 14 shows the mRNA sequence of PpLuc(GC) – atp5o – A64. The 3'-UTR of human ATP synthase subunit O was inserted between ORF and poly(A).

Fig. 15 shows the mRNA sequence of PpLuc(GC) – ndufa1 – A64. The 3'-UTR of human NADH dehydrogenase [ubiquinone] 1 α subcomplex subunit 1 was inserted between ORF and poly(A).

Fig. 16 shows the mRNA sequence of PpLuc(GC) – atp5l – A64. The 3'-UTR of human ATP synthase subunit g was inserted between ORF and poly(A).

Fig. 17 illustrates exemplarily the protein production stabilizing and/or protein production prolonging effect of the 3'UTR element according to the present invention. The curves represent the amount of protein produced from nucleic acid molecules, e.g. in mammalian cells, measured over time. The continuous line represents protein production from the artificial nucleic acid molecule according to the present invention, e.g. an artificial mRNA, the dashed line

represents the protein production from a reference nucleic acid molecule, e.g. lacking a 3'UTR or comprising a reference 3'UTR such as a 3'UTR naturally occurring with the ORF encoding the reporter protein. The continuous horizontal bold line represents a threshold value. This may be, for example, the protein amount measured 1, 2, 3, 4, 5, or 6 hours post initiation of expression, such as post transfection of the nucleic acid molecule. It can be seen that the protein amount produced from a reference nucleic acid molecule undercuts the threshold value at about 32 hours post initiation of expression, such as post transfection, whereas the protein amount produced from the artificial nucleic acid molecule according to the present invention undercuts the threshold value at about 68 hours post initiation of expression, such as post transfection. The total amount of protein produced equals the area under the curve (AUC). Preferably, the total amount of protein produced from the artificial nucleic acid molecule according to the present invention is at least the total amount of protein produced from a reference nucleic acid molecule lacking a 3'UTR.

Fig. 18 shows the effect of different albumin 3'-UTRs from primates on luciferase expression from artificial mRNA, compared to luciferase expression from mRNA lacking a 3'-UTR. Therein, the mRNA comprising the human albumin 3'UTR (albumin) and the mRNA comprising the 3'UTR of albumin from *Olive baboon* (albumin8) are mRNAs according to the present invention. They comprise an open reading frame encoding Luciferase of *Photinus pyralis*, followed in 5'-to-3'-direction by a 3'UTR element according to SEQ ID No. 2 or SEQ ID No. 33 and by a poly(A) sequence having a length of 64 adenines. A markedly extended protein expression from the artificial mRNAs containing the albumin 3'UTRs corresponding to SEQ ID No. 2 or SEQ ID No. 33 is observable.

The effect of the human albumin 3'-UTR and the 3'UTR of albumin from *Olive baboon* on luciferase expression from mRNA was examined, compared to Luciferase expression from mRNA lacking a 3'-UTR. To examine the luciferase expression, the different mRNAs were electroporated into human dermal fibroblasts (HDF). Luciferase levels were measured at 6, 24, 48, and 72 hours after transfection. The luciferase level from mRNA lacking a 3'-UTR drops from 6 hours to 72 hours, 5% of the 6-hours-signal remaining at 72 hours. Again, the

inventive human albumin 3'-UTR markedly extends luciferase expression from mRNA. The albumin 3'-UTR from *Olive baboon* (albumin8) extends luciferase expression from mRNA to the same extent as the human albumin 3'UTR sequence. Albumin 3'-UTRs from primates are thus particularly suitable for extending protein expression from mRNA. Data are graphed as mean RLU \pm SD (relative light units \pm standard deviation) for triplicate transfections. RLU are summarized in Example 5.4, table 7.

Fig. 19 shows the effect of different albumin 3'-UTRs from primates on luciferase expression from mRNA, compared to luciferase expression from mRNA lacking a 3'-UTR, using a different method of transfection. Therefore, different mRNAs were lipofected into human dermal fibroblasts (HDF). Luciferase levels were measured at 6, 24, 48, and 72 hours after transfection. The luciferase level from mRNA lacking a 3'-UTR drops from 6 hours to 48 hours to 82% of the 6-hours-signal. Again, the human albumin 3'-UTR markedly extends luciferase expression from mRNA, the 48-hours signal being higher than the 6-hours signal. The albumin 3'-UTR from *Olive baboon* (albumin8) extends luciferase expression from mRNA to a similar extent as the human albumin 3'UTR sequence. Albumin 3'-UTRs from primates are thus particularly suitable for extending protein expression from mRNA. Data are graphed as mean RLU \pm SD (relative light units \pm standard deviation) for triplicate transfections. RLU are summarized in Example 5.4, table 9.

Fig. 20 shows the effect of different albumin 3'-UTRs from primates on luciferase expression from mRNA in mouse cells, compared to luciferase expression from mRNA lacking a 3'-UTR. Therefore, different mRNAs were lipofected into L-929 cells, a murine fibroblast cell line. Luciferase levels were measured at 6, 24, 48, and 72 hours after transfection. The luciferase level from mRNA lacking a 3'-UTR drops from 6 hours to 48 hours, 23% of the 6-hours-signal remaining at 48 hours. Even in the murine cells does the human albumin 3'-UTR markedly extend luciferase expression from mRNA. The albumin 3'-UTR from *Olive baboon* (albumin8) extends luciferase expression from mRNA similarly. Albumin 3'-UTRs from primates are thus particularly suitable for extending protein expression from mRNA in mammalian cell types. Data are graphed as mean

RLU \pm SD (relative light units \pm standard deviation) for triplicate transfections. RLU are summarized in Example 5.5, table 11.

Fig. 21 shows the effect of different albumin 3'-UTRs from mammals on luciferase expression from mRNA, compared to luciferase expression from mRNA lacking a 3'-UTR. Therefore, different mRNAs were lipofected into HeLa cells. Luciferase levels were measured at 6, 24, 48, and 72 hours after transfection. The luciferase level from mRNA lacking a 3'-UTR drops from 6 hours to 48 hours, 49% of the 6-hours-signal remaining at 48 hours. Again, the human albumin 3'-UTR and the albumin 3'-UTR from *Olive baboon* (albumin8) markedly extend luciferase expression from mRNA, the 48-hours signal being higher than the 6-hours signal. Importantly, also the albumin 3'-UTR from mouse (albumin9) extends luciferase expression from mRNA similarly. Albumin 3'-UTRs from mammals are thus particularly suitable for extending protein expression from mRNA. Data are graphed as mean RLU \pm SD (relative light units \pm standard deviation) for triplicate transfections. RLU are summarized in Example 5.6, table 13.

Fig. 22 shows the mRNA sequence of PpLuc(GC) – albumin8 – A64. The 3'-UTR of *Olive baboon* albumin was inserted between ORF and poly(A). The sequence was taken from the NCBI Reference Sequence XM_003898783.1.

Fig. 23 shows the mRNA sequence of PpLuc(GC) – albumin9 – A64. The 3'-UTR of mouse albumin was inserted between ORF and poly(A). The sequence was taken from the NCBI Reference Sequence NM_009654.3.

25

Examples

1. Preparation of DNA-templates

A vector for *in vitro* transcription was constructed containing a T7 promoter followed by a GC-enriched sequence coding for *Photinus pyralis* luciferase (PpLuc(GC)) and an A64 poly(A) sequence. The poly(A) sequence was immediately followed by a restriction site used for linearization of the vector before *in vitro* transcription in order to obtain mRNA ending in an A64 poly(A) sequence. mRNA obtained from this vector accordingly by *in vitro* transcription is designated as „PpLuc(GC) – A64”.

This vector was modified to include untranslated sequences 3' of the open reading frame (3'-UTR). Vectors comprising the following mRNA encoding sequences have been generated (Figures 4 to 16 and Figures 22 and 23):

10 SEQ ID NO. 5 (Fig. 4): PpLuc(GC) – A64

SEQ ID NO. 6 (Fig. 5): PpLuc(GC) – albumin – A64

SEQ ID NO. 7 (Fig. 6): PpLuc(GC) – albumin2 – A64

SEQ ID NO. 8 (Fig. 7): PpLuc(GC) – albumin3 – A64

SEQ ID NO. 9 (Fig. 8): PpLuc(GC) – albumin4 – A64

15 SEQ ID NO. 10 (Fig. 9): PpLuc(GC) – albumin5 – A64

SEQ ID NO. 11 (Fig. 10): PpLuc(GC) – albumin6 – A64

SEQ ID NO. 12 (Fig. 11): PpLuc(GC) – albumin7 – A64

SEQ ID NO. 13 (Fig. 12): PpLuc(GC) – ag – A64

20 SEQ ID NO. 14 (Fig. 13): PpLuc(GC) – gusb – A64

SEQ ID NO. 15 (Fig. 14): PpLuc(GC) – atp5o – A64

SEQ ID NO. 16 (Fig. 15): PpLuc(GC) – ndufa1 – A64

SEQ ID NO. 17 (Fig. 16): PpLuc(GC) – atp5l – A64

SEQ ID NO. 40 (Fig. 22): PpLuc(GC) – albumin8 – A64

SEQ ID NO. 41 (Fig. 23): PpLuc(GC) – albumin9 – A64

mRNAs used in the examples have been obtained by *in vitro* transcription of said vectors.

5 2. *In vitro* transcription

The DNA-template according to Example 1 was linearized and transcribed *in vitro* using T7-Polymerase. The DNA-template was then digested by DNase-treatment. mRNA transcripts contained a 5'-CAP structure obtained by adding an excess of N7-Methyl-Guanosine-5'-Triphosphate-5'-Guanosine to the transcription reaction. mRNA thus obtained was purified 10 and resuspended in water.

3. Transfection of cells

3.1 mRNA electroporation

Cells were trypsinized and washed in opti-MEM. 5x10⁴ or 1x10⁵ cells in 200 µl of opti-MEM 15 each were electroporated with 0.3 or 1 µg of PpLuc-encoding mRNA. As a control, mRNA not coding for PpLuc was electroporated separately. In some experiments, mRNA coding for *Renilla reniformis* luciferase (RrLuc) was electroporated together with PpLuc mRNA to control for transfection efficiency (0.1 µg of RrLuc mRNA). Electroporated cells were seeded in 24-well plates in 1 ml of medium. 6, 24, or 48 hours after transfection (or 72 hours in 20 some experiments), medium was aspirated and cells were lysed in 200 µl of lysis buffer (25 mM Tris, pH 7.5 (HCl), 2 mM EDTA, 10% glycerol, 1% Triton X-100, 2 mM DTT, 1 mM PMSF or alternatively Passive Lysis Buffer, Promega). Lysates were stored at -20°C until luciferase activity was measured.

25 3.2 mRNA lipofection

Cells were seeded in 96 well plates three days before transfection (2500 or 5000 cells per well). Immediately before lipofection, cells were washed in opti-MEM. Cells were lipofected with 25 ng of PpLuc-encoding mRNA per well complexed with Lipofectamine2000. mRNA coding for *Renilla reniformis* luciferase (RrLuc) was cotransfected together with PpLuc mRNA to control for transfection efficiency (2.5 ng of RrLuc mRNA per well). 6, 24, 48, or 5 72 hours after transfection, medium was aspirated and cells were lysed in 100 μ l of lysis buffer (Passive Lysis Buffer, Promega). Lysates were stored at -80°C until luciferase activity was measured.

10 4. Luciferase measurement

Luciferase activity was measured as relative light units (RLU) in a BioTek SynergyHT plate reader. PpLuc activity was measured at 5 seconds measuring time using 50 μ l of lysate and 200 μ l of luciferin buffer (75 μ M luciferin, 25 mM Glycylglycin, pH 7.8 (NaOH), 15 mM MgSO₄, 2 mM ATP). RrLuc activity was measured at 5 seconds measuring time using 50 μ l 15 of lysate and 200 μ l of coelenterazin buffer (40 μ M coelenterazin, 2.2 mM EDTA, 220 mM KH₂PO₄/K₂HPO₄ pH 5.0, 1.1 M NaCl, 1.3 mM NaN₃, 0.44 g/l BSA).

Alternatively, luciferase activity was measured as relative light units (RLU) in a Hidex Chameleon plate reader. PpLuc activity was measured at 2 seconds measuring time using 20 μ l of lysate and 100 μ l of luciferin buffer (Beetle-Juice, PJK GmbH). RrLuc activity was 20 measured at 2 seconds measuring time using 20 μ l of lysate and 100 μ l of coelenterazin buffer (Renilla-Juice, PJK GmbH).

5. Results

5.1 Albumin 3'-UTR extends protein expression from mRNA markedly more than the well-known α -globin 3'-UTR 25

To investigate the effect of 3' untranslated regions on protein expression from mRNA, mRNAs with different 3'-UTRs were synthesized according to Examples 1-2: mRNA contained either the center, α -complex-binding portion of the 3'-UTR of human α -globin

(PpLuc(GC)-ag-A64 according to SEQ ID No. 13), since the α -globin 3'-UTR has been reported to stabilize mRNA independent of coding region sequence (Rodgers, N.D., Wang, Z. & Kiledjian, M., 2002. Regulated alpha-globin mRNA decay is a cytoplasmic event proceeding through 3'-to-5' exosome-dependent decapping. *RNA*, 8(12), S.1526 -1537.). Alternatively, mRNA contained the 3'-UTR of human albumin (PpLuc(GC)-albumin-A64 according to SEQ ID No. 6). Human albumin mRNA has been reported to be stable (Johnson, T.R. et al., 1991. Newly synthesized RNA: simultaneous measurement in intact cells of transcription rates and RNA stability of insulin-like growth factor I, actin, and albumin in growth hormone-stimulated hepatocytes. *Proceedings of the National Academy of Sciences*, 88(12), 5.5287-5291). Finally, mRNA containing the 3'-UTR of human β -glucuronidase (PpLuc(GC)-gusb-A64 according to SEQ ID No. 14) was used. This human β -glucuronidase mRNA has also been reported to be stable (Watson, G. & Paigen, K., 1987. Genetic variations in kinetic constants that describe beta-glucuronidase mRNA induction in androgen-treated mice. *Molecular and Cellular Biology*, 7(3), S.1085 -1090.). For comparison, mRNA lacking a 3'-UTR was also used (PpLuc(GC)-A64 according to SEQ ID No. 5). Luciferase-encoding mRNAs were electroporated into HeLa cells. Luciferase levels were measured at 6, 24, and 48 hours after transfection (see following Table 1 and Figure 1).

Table 1:

mRNA	RLU at 6 hours	RLU at 24 hours	RLU at 48 hours
PpLuc(GC)-A64	299993	162445	29168
PpLuc(GC)-ag-A64	571131	574896	120029
PpLuc(GC)-albumin-A64	364580	476567	277317
PpLuc(GC)-gusb-A64	357513	431134	134463

The luciferase level from mRNA lacking a 3'-UTR dropped from 6 hours to 48 hours, 10% of the 6-hours-signal remaining at 48 hours. The α -globin 3'-UTR stabilized luciferase expression from mRNA only moderately. Strikingly however, the human albumin 3'-UTR further markedly extended luciferase expression from mRNA. In contrast, the 3'-UTR of β -

glucuronidase did not extend luciferase expression to the extent observed for the albumin 3'-UTR.

The ratio of the luciferase level at 48 hours and 6 hours, higher figures indicating stabilization of protein expression, was calculated. These data, indicating how much any 3'-

5 UTR stabilized the time course of protein expression, are summarized in Table 2.

Table 2:

mRNA	48 hours RLU / 6 hours RLU
PpLuc(GC)-A64	0,10
PpLuc(GC)-ag-A64	0,21
PpLuc(GC)-albumin-A64	0,76
PpLuc(GC)-gusb-A64	0,38

The albumin 3'-UTR stabilized protein expression much more than the well-known α -globin 3'-UTR and more than the 3'-UTR of stable β -glucuronidase mRNA. This result

10 demonstrates that the albumin 3'-UTR is particularly efficient at extending protein expression from mRNA.

5.2 Albumin 3'-UTR is unique at extending protein expression while maintaining total protein expression

15 Extension of protein expression by the albumin 3'-UTR might manifest a generic effect of 3'-UTRs of stable mRNAs (even though the very limited effect of the α -globin 3'-UTR observed in Example 5.1 does not attest to this argument). Thus, mRNAs were synthesized containing the 3'-UTR of the stable mRNAs (Friedel, C.C. et al., 2009. Conserved principles of mammalian transcriptional regulation revealed by RNA half-life. Nucleic Acids Research, 37(17), S.e115.) atp5o or ndufa1 or atp5l (human ATP synthase subunit O, human NADH dehydro-
20 genase [ubiquinone] 1 α subcomplex subunit 1, or human ATP synthase subunit g, respec-

tively). Luciferase-encoding mRNAs were electroporated into HeLa cells. Luciferase levels were measured at 6, 24, and 48 hours after transfection (see following Table 3 and Figure 2).

Table 3:

mRNA	RLU at 6 hours	RLU at 24 hours	RLU at 48 hours
PpLuc(GC)-A64	529804	725602	72348
PpLuc(GC)-ag-A64	1065036	1790023	263484
PpLuc(GC)-albumin-A64	548821	1261832	523000
PpLuc(GC)-atp5o-A64	239418	402629	79566
PpLuc(GC)-ndufa1-A64	116139	277149	133723
PpLuc(GC)-atp5l-A64	58610	56553	9728

5

The luciferase level from mRNA lacking a 3'-UTR dropped from 6 hours to 48 hours, 14% of the 6-hours-signal remaining at 48 hours. The α -globin 3'-UTR stabilized luciferase expression from mRNA moderately. Strikingly however, the human albumin 3'-UTR further markedly extended luciferase expression from mRNA. Compared to the albumin 3'-UTR did the 3'-UTRs of several different stable mRNAs affect luciferase expression from mRNA in a much less favourable manner: The atp5o and atp5l 3'-UTRs stabilized luciferase expression much less than the albumin 3'-UTR. In addition reduced the atp5o and the atp5l 3'-UTRs luciferase levels substantially compared to the albumin 3'-UTR. The 3'-UTR of the stable ndufa1 mRNA did stabilize luciferase expression markedly. However, the ndufa1 3'-UTR 10 also reduced luciferase levels substantially.

15 The ratio of the luciferase level at 48 hours and 6 hours, higher figures indicating stabilization of protein expression, was calculated. These data, indicating how much any 3'-UTR stabilized the time course of protein expression, are summarized in Table 4.

Table 4:

mRNA	48 hours RLU / 6 hours RLU
PpLuc(GC)-A64	0,14
PpLuc(GC)-ag-A64	0,25
PpLuc(GC)-albumin-A64	0,95
PpLuc(GC)-atp5o-A64	0,33
PpLuc(GC)-ndufa1-A64	1,15
PpLuc(GC)-atp5l-A64	0,17

The albumin 3'-UTR was unique at extending protein expression while maintaining total protein expression. The albumin 3'-UTR gave rise to substantially higher protein expression at the latest time point compared to the well-known α -globin 3'-UTR and 3'-UTRs of several different stable mRNAs. This result demonstrates that the albumin 3'-UTR is particularly suitable for extending protein expression from mRNA.

5.3 Different variants of the albumin 3'-UTR extend protein expression from mRNA

The human albumin 3'-UTR contains a HindIII restriction site, an XbaI restriction site, and a T7 termination signal. Thus, mRNA was synthesized containing variants of the human albumin 3'-UTR with the HindIII and/or the XbaI restriction site and/or the T7 termination signal removed by point mutation(s) (PpLuc(GC)-albumin2-7 according to SEQ ID Nos. 17-12). Luciferase-encoding mRNAs were electroporated into HeLa cells. Luciferase levels were measured at 6, 24, 48, and 72 hours after transfection. The PpLuc Signal was corrected for transfection efficiency by the signal of cotransfected RrLuc (see following Table 5 and Figure 3).

Table 5:

mRNA	RLU at 6 hours	RLU at 24 hours	RLU at 48 hours	RLU at 72 hours

PpLuc(GC)-A64	382909	576557	122118	20962
PpLuc(GC)-ag-A64	281262	536346	118000	20356
PpLuc(GC)-albumin-A64	199494	499804	282475	134271
PpLuc(GC)-albumin2-A64	258516	655711	351888	186869
PpLuc(GC)-albumin3-A64	219365	547307	292511	124330
PpLuc(GC)-albumin4-A64	236873	576151	298229	139260
PpLuc(GC)-albumin5-A64	223815	576899	289954	131145
PpLuc(GC)-albumin6-A64	180412	455039	240086	99802
PpLuc(GC)-albumin7-A64	174371	417171	216048	68887

The ratio of the luciferase level at 72 hours and 6 hours, higher figures indicating stabilization of protein expression, was calculated. These data, indicating how much any 3'-UTR stabilized the time course of protein expression, are summarized in Table 6.

5

Table 6:

mRNA	72 hours RLU / 6 hours RLU
PpLuc(GC)-A64	0,05
PpLuc(GC)-ag-A64	0,07
PpLuc(GC)-albumin-A64	0,67
PpLuc(GC)-albumin2-A64	0,72
PpLuc(GC)-albumin3-A64	0,57

PpLuc(GC)-albumin4-A64	0,59
PpLuc(GC)-albumin5-A64	0,59
PpLuc(GC)-albumin6-A64	0,55
PpLuc(GC)-albumin7-A64	0,40

The luciferase level from mRNA lacking a 3'-UTR dropped from 6 hours to 72 hours, 5% of the 6-hours-signal remaining at 72 hours. The α -globin 3'-UTR stabilized luciferase expression from mRNA only very moderately. In contrast, all variants of the albumin 3'-UTR markedly extended luciferase expression from mRNA.

5.4 Albumin 3'-UTRs of primates extend protein expression from mRNA

Extension of protein expression by the albumin 3'-UTR might be species-specific. Comparing albumin 3'-UTRs from different primates, the *Olive baboon* albumin 3'-UTR 10 was least homologous to the human albumin 3'-UTR (Common chimpanzee: 99% identity, *Pygmy chimpanzee*: 99% identity, Sumatran orang-utan: 99% identity, *Olive baboon*: 96% identity). Thus, mRNA was synthesized containing the 3'-UTR of the *Olive baboon* albumin gene (PpLuc(GC)-albumin8-A64 according to SEQ ID No. 40). Luciferase-encoding mRNAs 15 were electroporated into human dermal fibroblasts (HDF). Luciferase levels were measured at 6, 24, 48, and 72 hours after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc (see following Table 7 and Figure18).

Table 7:

mRNA	RLU at 6 hours	RLU at 24 hours	RLU at 48 hours	RLU at 72 hours
PpLuc(GC)-A64	130469	72629	26267	6637
PpLuc(GC)-albumin-A64	70661	74152	38209	17648
PpLuc(GC)-albumin8-A64	71463	123361	51361	18373

The ratio of the luciferase level at 72 hours and 6 hours, higher figures indicating stabilization of protein expression, was calculated. These data, indicating how much any 3'-UTR stabilized the time course of protein expression, are summarized in Table 8.

5

Table 8:

mRNA	72 hours RLU / 6 hours RLU
PpLuc(GC)-A64	0,05
PpLuc(GC)-albumin-A64	0,25
PpLuc(GC)-albumin8-A64	0,26

The luciferase level from mRNA lacking a 3'-UTR dropped from 6 hours to 72 hours, 5% of the 6-hours-signal remaining at 72 hours. The human albumin 3'-UTR markedly extended 10 luciferase expression from mRNA. The albumin 3'-UTR from *Olive baboon* extended luciferase expression from mRNA to the same extent as the human sequence. This result demonstrates that albumin 3'-UTRs from primates are particularly suitable for extending protein expression from mRNA.

Extension of protein expression by both the human and the *Olive baboon* albumin 3'-UTR 15 was also observed if mRNAs were lipofected rather than electroporated. Luciferase-encoding mRNAs were lipofected into HDF. Luciferase levels were measured at 6, 24, 48, and 72 hours after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc (see following Table 9 and Figure 19).

20 Table 9:

mRNA	RLU at 6 hours	RLU at 24 hours	RLU at 48 hours	RLU at 72 hours
PpLuc(GC)-A64	3285	7946	2725	1266

PpLuc(GC)-albumin-A64	3743	9525	5466	3381
PpLuc(GC)-albumin8-A64	3259	7367	4044	1892

The ratios of the luciferase level at 48 hours and 6 hours, higher figures indicating stabilization of protein expression, was calculated. These data, indicating how much any 3'-UTR stabilized the time course of protein expression, are summarized in Table 10.

5

Table 10:

mRNA	48 hours RLU / 6 hours RLU
PpLuc(GC)-A64	0,82
PpLuc(GC)-albumin-A64	1,46
PpLuc(GC)-albumin8-A64	1,24

Upon lipofection rather than electroporation, again both human albumin 3'-UTR and the albumin 3'-UTR from *Olive baboon* extended luciferase expression from mRNA markedly.

10 This result confirms that albumin 3'-UTRs from primates are particularly suitable for extending protein expression from mRNA.

5.5 Albumin 3'-UTRs of primates extend protein expression from mRNA in mouse cells

15 Extension of protein expression by the albumin 3'-UTR might be species-specific. Thus, it was tested whether the human albumin 3'-UTR and the albumin 3'-UTR from *Olive baboon* extend luciferase expression from mRNA in mouse cells. Luciferase-encoding mRNAs were lipofected into L-929 cells, a murine fibroblast cell line. Luciferase levels were measured at 6, 24, 48, and 72 hours after transfection. The PpLuc signal was corrected for transfection 20 efficiency by the signal of cotransfected RrLuc (see following Table 11 and Figure 20).

Table 11:

mRNA	RLU at 6 hours	RLU at 24 hours	RLU at 48 hours	RLU at 72 hours
PpLuc(GC)-A64	177805	128658	40414	12593
PpLuc(GC)-albumin-A64	160478	244279	101177	22605
PpLuc(GC)-albumin8-A64	151076	178839	68786	16969

The ratio of the luciferase level at 48 hours and 6 hours, higher figures indicating stabilization of protein expression, was calculated. These data, indicating how much any 3'-

5 UTR stabilized the time course of protein expression, are summarized in Table 12.

Table 12:

mRNA	48 hours RLU / 6 hours RLU
PpLuc(GC)-A64	0,23
PpLuc(GC)-albumin-A64	0,63
PpLuc(GC)-albumin8-A64	0,46

The luciferase level from mRNA lacking a 3'-UTR dropped from 6 hours to 48 hours, 23%

10 of the 6-hours-signal remaining at 48 hours. The human albumin 3'-UTR markedly extended luciferase expression from mRNA in the mouse cell line. The albumin 3'-UTR from *Olive baboon* also extended luciferase expression from mRNA in the mouse cell line. This result demonstrates that albumin 3'-UTRs from primates are particularly suitable for extending protein expression from mRNA in mammalian cell types.

15

5.6 Albumin 3'-UTRs of mammals extend protein expression from mRNA

Extension of protein expression by the albumin 3'-UTR might be species-specific. Comparing albumin 3'-UTRs from different mammals, the mouse albumin 3'-UTR was least homologous to the human albumin 3'-UTR (Horse: 86% identity, Domestic dog: 84% identity, Cattle: 74% identity, Rat: 73% identity, Mouse: 72% identity). Thus, mRNA was synthesized containing the 3'-UTR of the mouse albumin gene (PpLuc(GC)-albumin9-A64 according to SEQ ID No. 41). Luciferase-encoding mRNAs were lipofected into HeLa cells. Luciferase levels were measured at 6, 24, 48, and 72 hours after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc (see following Table 13 and Figure 21).

10

Table 13:

mRNA	RLU at 6 hours	RLU at 24 hours	RLU at 48 hours	RLU at 72 hours
PpLuc(GC)-A64	46533	200168	22702	3001
PpLuc(GC)-albumin-A64	42931	224315	109190	25314
PpLuc(GC)-albumin8-A64	39783	205950	82918	17447
PpLuc(GC)-albumin9-A64	42500	210365	60893	8380

The ratio of the luciferase level at 48 hours and 6 hours, higher figures indicating stabilization of protein expression, was calculated. These data, indicating how much any 3'-UTR stabilized the time course of protein expression, are summarized in Table 14.

Table 14:

mRNA	48 hours RLU / 6 hours RLU
PpLuc(GC)-A64	0,49
PpLuc(GC)-albumin-A64	2,54

PpLuc(GC)-albumin8-A64	2,08
PpLuc(GC)-albumin9-A64	1,43

The luciferase level from mRNA lacking a 3'-UTR dropped from 6 hours to 48 hours, 49% of the 6-hours-signal remaining at 48 hours. The human albumin 3'-UTR and the albumin 3'-UTR from *Olive baboon* markedly extended luciferase expression from mRNA.

5 Importantly, the albumin 3'-UTR from mouse similarly extended luciferase expression from mRNA in the human HeLa cell line. This result demonstrates that albumin 3'-UTRs from mammals are particularly suitable for extending protein expression from mRNA.

10

Sequences:

SEQ ID No. 1:

CATCACATT AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA
 15 AAGCTTATTC ATCTGTTTT CTTTTCGTT GGTGTAAAGC CAACACCCCTG TCTAAAAAAC
 ATAAATTTCT TTAATCATT TGCTCTTT CTCTGTGCTT CAATTAATAA AAAATGGAAA
 GAATCT

SEQ ID No. 2:

CAUCACAUU AAAAGCAUCU CAGCCUACCA UGAGAAUAAG AGAAAGAAAA UGAAGAUCAA
 20 AAGCUUAUUC AUCUGUUUUU CUUUUUCGUU GGUGUAAAGC CAACACCCUG UCUAAAAAAC
 AUAAAUUUCU UUAAUCAUUU UGCCUCUUU CUCUGUGCUU CAAUUAUAA AAAAUGGAAA
 GAAUCU

SEQ ID No. 3:

CATCACATT AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA
 25 AAGCTTATTC ATCTGTTTT CTTTTCGTT GGTGTAAAGC CAACACCCCTG TCTAAAAAAC
 ATAAATTTCT TTAATCATT TGCTCTTT CTCTGTGCTT CAATTAATAA AAAATGGAAA
 GAATCTAGAT CTAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA
 AAAAAAAA AAAAAA

30

SEQ ID No. 4:

CAUCACAUU AAAAGCAUCU CAGCCUACCA UGAGAAUAAG AGAAAGAAAA UGAAGAUCAA
 AAGCUUAUUC AUCUGUUUUU CUUUUUCGUU GGUGUAAAGC CAACACCCUG UCUAAAAAAC
 AUAAAUUUCU UUAAUCAUUU UGCCUCUUU CUCUGUGCUU CAAUUAUAA AAAAUGGAAA
 35 GAAUCUAGAU CUAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA
 AAAAAAAA AAAAAA

SEQ ID No. 5:

GGGAGAAAGCTTGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCGGCGCCCTCTA

CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGGACGATCGCTTCACCGACGCCACATCGAGGTCGACATCACCTACGCGGA
 GTACTTCGAGATGAGCGTGCCTGCCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTCATGCCGTGCTGGCGC
 5 CCTCTTCATCGCGTGGCGTCGCCCGGAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCCACCGTGGTGGTGTGAGCAAGAAGGCCCTGCAGAA
 GATCCTGAACGTGAGAAGACTGCCATCATCCAGAAGATCATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCCAGTCGATGTACACGTTGACCGACGCCACCTCCGCCGG
 10 CTTCAACGAGTACGACTTCGTCGGAGAGCTCGACCCGGACAAGACCATCGCCCTGAT
 CATGAACAGCAGCGCAGCACCGGCTGCCGAAGGGGGTGGCCCTGCCGACCGGACCGC
 CTGCGTGCCTCTCGCACGCCGGGACCCATCTCGGCAACCAGATCATCCGGACAC
 CGCCATCCTGAGCGTGGTGCCTCACCCGGCTCGGATGTCACGACCCCTGGGCTA
 CCTCATCTGCGGCTTCCGGTGGTCTGATGTACCGGTTGAGGAGGAGCTTCCCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCCTGCTGCCGACCCCTGTTCAGCTTCTT
 15 CGCCAAGAGCACCCGTATCGACAAGTACGACCTGTCGAACCTGCACGAGATGCCAGCG
 GGGCGCCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCGGG
 CATCCGCCAGGGCTACGGCCTGACCGAGACCACGAGCGCAGTCCATCACCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCCTTCGAGGCAAGGTGGTGG
 CCTGGACACCGGAAGACCCCTGGCGTGAACCAGCGGGCGAGCTGCGTGCGGGGGCC
 20 GATGATCATGAGCGGCTACGTGAACAAACCCGGAGGCCACCAACGCCCTCATCGACAAGGA
 CGGCTGGCTGCACAGCGGCACATGCCCTACTGGGACGAGGACGAGCACTTCTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCAGCTGGA
 GAGCATCCTGCTCCAGCACCCCAACATCTCGACGCCGGCTGGCCGGCTGCCGGACGA
 CGACGCCGGCAGCTGCCGCCGCGTGGTGGTGTGGAGCACGGAAGACCATGACGGA
 25 GAAGGAGATCGTCACTACGTGCCAGGTGACCAACGCCAAGAAGCTGCCGGGG
 CGTGGTGGTGTGGACGAGGTCCCAGGGCTGACCGGGAAAGCTCGACGCCGGAAAGAT
 CGCGAGATCCTGATCAAGGCAAGAAGGGCGGCAAGATGCCGTGTAAGACTAGTAGAT
 CTAAA
 AAAAAA
 30 SEQ ID No. 6:
 GGGAGAAAGCTGAGGATGGAGGACGCCAAGAACATCAAGAACGGGCCGGCGCCCTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGGACGATCGCTTCACCGACGCCACATCGAGGTCGACATCACCTACGCGGA
 35 GTACTTCGAGATGAGCGTGCCTGCCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTGGAGAACAGCCTGCAGTCTCATGCCGTGCTGGCGC
 CCTCTTCATCGCGTGGCGTCGCCGGCAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCCACCGTGGTGGTGTGAGCAAGAAGGCCCTGCAGAA
 GATCCTGAACGTGAGAAGACTGCCATCATCCAGAAGATCATCATGGACAGCAA
 40 GACCGACTACCAGGGCTTCCAGTCGATGTACACGTTGACCGACGCCACCTCCGCCGG
 CTTCAACGAGTACGACTTCGTCGGAGAGCTCGACCGGGACAAGACCATGCCCTGAT
 CATGAACAGCAGCGCAGCACCGCCTGCCGAAGGGGGTGGCCCTGCCGACCGGACCGC
 CTGCGTGCCTCTCGCACGCCGGGACCCATCTCGGCAACCAGATCATCCGGACAC
 CGCCATCCTGAGCGTGGTGCCTCACCCGGCTCGGATGTCACGACCCCTGGGCTA
 45 CCTCATCTGCGGCTTCCGGTGGTCTGATGTACCGGTTGAGGAGGAGCTTCCCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCCTGCTCGGCCGACCCCTGTTCAGCTTCTT
 CGCCAAGAGCACCCGTATCGACAAGTACGACCTGTCGAACCTGCACGAGATGCCAGCG
 GGGCGCCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCGGG
 CATCCGCCAGGGCTACGGCCTGACCGAGACCACGAGCGCAGTCCATCACCCCCGAGGG
 50 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCCTTCGAGGCAAGGTGGTGG
 CCTGGACACCGGAAGACCCCTGGCGTGAACCAAGCGGGCGAGCTGCGTGCGGGGGCC
 GATGATCATGAGCGGCTACGTGAACAAACCCGGAGGCCACCAACGCCCTCATCGACAAGGA

GGGAGAAAGCTGAGGATGGAGGACGCCAAGAACATCAAGAACGGGCCGGCGCCCTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGGACGATCGCTTCACCGACGCCACATCGAGGTCGACATCACCTACGCGGA
 GTACTTCGAGATGAGCGTGCCTGCCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTGGAGAACAGCCTGCAGTCTCATGCCGTGCTGGCGC
 CCTCTTCATCGCGTGGCGTCGCCGGCAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCCACCGTGGTGGTGTGAGCAAGAAGGCCCTGCAGAA
 GATCCTGAACGTGAGAAGACTGCCATCATCCAGAAGATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCCAGTCGATGTACACGTTGACCGACGCCACCTCCGCCGG
 CTTCAACGAGTACGACTTCGTCGGAGAGCTCGACCGGGACAAGACCATGCCCTGAT
 CATGAACAGCAGCGCAGCACCGCCTGCCGAAGGGGGTGGCCCTGCCGACCGGACCGC
 CTGCGTGCCTCTCGCACGCCGGGACCCATCTCGGCAACCAGATCATCCGGACAC
 CGCCATCCTGAGCGTGGTGCCTCACCCGGCTCGGATGTCACGACCCCTGGGCTA
 CCTCATCTGCGGCTTCCGGTGGTCTGATGTACCGGTTGAGGAGGAGCTTCCCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCCTGCTCGGCCGACCCCTGTTCAGCTTCTT
 CGCCAAGAGCACCCGTATCGACAAGTACGACCTGTCGAACCTGCACGAGATGCCAGCG
 GGGCGCCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCGGG
 CATCCGCCAGGGCTACGGCCTGACCGAGACCACGAGCGCAGTCCATCACCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCCTTCGAGGCAAGGTGGTGG
 CCTGGACACCGGAAGACCCCTGGCGTGAACCAAGCGGGCGAGCTGCGTGCGGGGGCC
 GATGATCATGAGCGGCTACGTGAACAAACCCGGAGGCCACCAACGCCCTCATCGACAAGGA

5 CGGCTGGCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCCGGCGAGCTGGA
 GAGCATCCTGCTCCAGCACCCAAACATCTCGACGCCGGCGTGGCGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGTGGTGGTGTGGAGCACGGCAAGACCATGACGGA
 GAAGGAGATCGTCGACTACGTGGCCAGGCCAGGTGACCACCGCCAAGAAGCTGCGGGCGG
 CGTGGTGGTCTGTCGAGGCTCCGAAGGGCTGACCGGGAAAGCTCGACGCCGGAAAGAT
 CCGCGAGATCCTGATCAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTGCAT
 10 CACATTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAAAG
 CTTATTATCTGTTTCTTCTGTGGTAAAGCCAACACCTGTCTAATTAATAAAAATGGAAAGAA
 AATTTCTTAATCATTTCGCTCTTCTGTGCTTCATTAATTAATAAAAATGGAAAGAA
 TCTAGATCTAA
 AAAAAAAAAAAA

SEQ ID No. 7:

15 GGGAGAAAGCTTGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCGGCGCCCTTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGGACCGATCGCCTTCACCGACGCCACATCGAGGTGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGGCCTGGCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTCATGCCGTGCTGGCGC
 20 CCTCTTCATCGGCGTGGCGTCGCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCCGACCGTGGTGTGAGCAAGAAGGGCTGCAGAA
 GATCCTGAACGTGAGAAGCTGCCATCATCCAGAACATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCAGTCGATGTACACGTTGTCGACCAAGCCACCTCCGCCGG
 CTTCAACGAGTACGACTTCGCTCCGGAGAGCTCGACCCGGACAAGACCATGCCCTGAT
 25 CATGAACAGCAGCGGAGCACGGCCTGCCGAAGGGGTGGCCCTGCCGACCGGACCGC
 CTGCGTGCCTTCGACGCCGGGACCCATCTCGCAACCAGATCATCCGGACAC
 CGCCATCCTGAGCGTGGTGCCTCACCACGGCTTCGGCATGTTACGACCCCTGGGCTA
 CCTCATCTGCGGCTCCGGTGGTCCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGTGCCTGCGACCCCTGTTCAGCTTCTT
 30 CGCCAAGAGCACCCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAGATGCCAGCG
 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCAGCGGCTGGCAAGCGGTTCCACCTCCCGGG
 CATCCGCCAGGGCTACGGCCTGACCGAGACCACGAGCGCAGTCTGATCACCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCGTTCTCGAGGAGCAAGGTGGTGG
 CCTGGACACCGGCAAGACCCCTGGCGTGAACCAGCGGGCGAGCTGTGCGTGCCTGGGCC
 35 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTATCGACAAGGA
 CGGCTGGCTGCACAGCGGAGCATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCGAGCTGGA
 GAGCATCCTGCTCCAGCACCCAAACATCTCGACGCCGGCGTGGCGGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGTGGTGGTGTGGAGCACGGCAAGACCATGACGGA
 40 GAAGGAGATCGTCGACTACGTGGCCAGGCCAGGTGACCACCGCCAAGAAGCTGCGGGCGG
 CGTGGTGGTCTGTCGAGGCTCCGAAGGGCTGACCGGGAAAGCTCGACGCCGGAAAGAT
 CCGCGAGATCCTGATCAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTGCAT
 CACATTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAAAG
 CTTATTCTGCTGTTTCTTCTGTGGTAAAGCCAACACCTGTCTAATTAATAAAAATGGAAAGAA
 45 AATTTCTTAATCATTTCGCTCTTCTGTGCTTCATTAATTAATAAAAATGGAAAGAA
 TCTAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAA

SEQ ID No. 8:

50 GGGAGAAAGCTTGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCGGCGCCCTTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGGACCGATCGCCTTCACCGACGCCACATCGAGGTGACATCACCTACGCCGA

GTACTTCGAGATGAGCGTGCCTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTCATGCCGTGCTGGCGC
 CCTCTTCATCGCGTGGCGTCGCCCCGGCAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCCGACCGTGGTGTGAGCAAGAAGGCCTGCAGAA
 5 GATCCTGAACGTGCAGAAGAAGCTGCCATCATCCAGAAGATCATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCACTCGATGTACACGTTGTCGACCAGCCACCTCCGCCGG
 CTTCAACGAGTACGACTTCGCTCCGGAGAGCTCGACCGGGACAAGAACCATGCCCTGAT
 CATGAACAGCAGCGCAGCACCGCCTGCCGAAGGGGTGGCCCTGCCGACCGGACCG
 10 CTGCGTGCCTCTCGCACGCCGGGACCCATCTCGGCAACCAGATCATCCGGACAC
 CGCCATCTGAGCGTGGTGCCTTCAACCACGGCTTCGGCATGTTACGACCCCTGGGCTA
 CCTCATCTGCGGTTCCGGGTGGTCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCCTGCTCGTGCACCGGACCCCTGTTCA
 15 CGCCAAGAGCACCCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAGATGCCAGCG
 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGCCAAGCGGTTCCACCTCCGGG
 CATCCGCCAGGGTACGCCCTGACCGAGACCACGAGCGCATCTGATCCCCCGAGGG
 20 GGACGACAAGCCGGCGCCGTGGCAAGGGTGGTCCCGTTCTCGAGGCCAAGGTGGTGG
 CCTGGACACCGGCAAGACCCCTGGCGTGAACCAGCGGGCGAGCTGTGCGTGC
 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTATCGACAAGGA
 CGGCTGGCTGCACAGCGCGACATGCCACTGGGACGAGGACGAGCACTCTCATCGT
 25 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGTACCAAGGTGGCGCCGGCGAGCTGG
 GAGCATCTGCTCCAGCACCCAAACATCTCGACGCCGGTGGCGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGGTGGTGTGAGCACGGCAAGAACCATGACGGA
 GAAGGAGATCGTCACTACGTGGCCAGGCCAGGGTGAACCAAGGCCAAGAACGCTGCGGGCG
 CGTGGTGGTCTGAGCGAGGTCCCAGAGGCCCTGACCGGGAAAGCTGACGCCGGAAAGAT
 30 CCGCGAGATCCTGATCAAGGCCAAGAACAGGCCAAGATGCCGTGTAAGACTAGTCAT
 CACATTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAAAAG
 CTTATTATCATCAGTTTTCTTCTGTTGGTAAAGGCCAACACCCTGTCTAAAAAACATA
 AATTCTTAAATCATTTGCCCTTTCTGTGCTCAATTAAATAAAAAATGGAAAGAA
 TCTAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAA

SEQ ID No. 9:

GGGAGAAAGCTTGGAGGATGGAGGACGCCAAGAACATCAAGAACGGCCGCCCTTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 35 GGTGCCGGCACGATGCCCTCACCGACGCCACATCGAGGTGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCCTGCCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTCATGCCGTGCTGGCGC
 CCTCTTCATCGCGTGGCGTCGCCCCGGCAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCCGACCGTGGTGTGAGCAAGAACGCCCTGCAGAA
 40 GATCCTGAACGTGCAGAAGAACAGCTGCCATCATCCAGAAGATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCACTCGATGTACACGTTGTCGACCAGCCACCTCCGCCGG
 CTTCAACGAGTACGACTTCGCTCCGGAGAGCTCGACCGGGACAAGAACCATGCCCTGAT
 CATGAACAGCAGCGCAGCACCGCCTGCCGAAGGGGTGGCCCTGCCGACCGGACCG
 CTGCGTGCCTCTCGCACGCCGGGACCCATCTCGGCAACCAGATCATCCGGACAC
 45 CGCCATCTGAGCGTGGTGCCTTCAACCACGGCTTCGGCATGTTACGACCCCTGGGCTA
 CCTCATCTGCGGTTCCGGGTGGTCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCCTGCTCGTGCACGCCGACCCCTGTTCA
 CGCCAAGAGCACCCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAGATGCCAGCG
 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGCCAAGCGGTTCCACCTCCGGG
 50 CATCCGCCAGGGTACGCCCTGACCGAGACCACGAGCGCATCTGATCCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCGTTCTCGAGGCCAAGGTGGTGG
 CCTGGACACCGGCAAGACCCTGGCGTGAACCAGCGGGCGAGCTGCGTGC
 GGGGGGCC

GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGA
 CGGCTGGCTGCACAGCGGGACATCGCCTACTGGGACGAGGACGAGCACTCTTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCGAGCTGGA
 GAGCATCCTGCTCCAGCACCCCAACATCTTCGACGCCGGCGTGGCCGGCTGCCGGACGA
 5 CGACGCCGGCGAGCTGCCGGCGCGGTGGTGTGGAGCACGGCAAGACCATGACGGA
 GAAGGAGATCGTCACTACGTGGCCAGCCAGGTGACCACCGCCAAGAAGCTGCGGGCGG
 CGTGGTGGTGTGGACGAGGTCCCAGAAGGGCTGACCAGGGAAAGCTCGACGCCCGGAAGAT
 CCGCGAGATCCTGATCAAGGCAAGAAGGGCGGCAAGATCGCCGTGTAAGACTAGTGCAT
 10 CACATTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAAAAG
 CTTATTCATCTTTTCTTTCTGTGGTGTAAAGCCAACACCCCTGTCTAAAAAACATA
 AATTCTTAATCATTTGCCTCTTCTGTGCTTCATTAAATAAAAAATGGAAAGAA
 TCTAGATCTAA
 AAAAAAAAAAAAAA

15 SEQ ID No. 10:

GGGAGAAAGCTTGGAGGATGGAGGACGCCAAGAACATCAAGAACGGCCGGCGCCCTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGCACGATCGCCTCACCGACGCCACATCGAGGTGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCCTGGCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 20 CCACCGGATCGTGGTGTGCTCGAGAACAGCCTGCAGTTCTCATGCCGGTGTGGCGC
 CCTCTTCATCGCGTGGCGTCGCCCGAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCCGACCGTGGTGTGAGCAAGAACGGCTGCAGAA
 GATCCTGAACGTGCAGAAGAACGCTGCCCATCATCCAGAACGATCATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCAGTCGATGTACACGTTGACCGAGCCACCTCCGCCGG
 25 CTTCAACGAGTACGACTCGTCCCAGAGAGCTCGACCGGGACAAGACCATGCCCTGAT
 CATGAACAGCAGCGGAGCACCCTGCGAACGGGGTGGCCCTGCCGACCGGACCGC
 CTGCGTGCCTCTCGCACGCCGGGACCCATCTCGGCAACCAGATCATCCGGACAC
 CGCCATCCTGAGCGTGGTGCCTCACCGGCTTCGGCATGTTCACGACCCCTGGGCTA
 CCTCATCTCGGGCTTCCGGGTGGTCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 30 GAGCCTGCAGGACTACAAGATCCAGAGCGCGTGCCTCGAACCGGACCGTGTGCTT
 CGCCAAGAGCACCCCTGATCGACAAGTACGACCTGTCGAACCTGACGAGATGCCAGCG
 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCGGG
 CATCCGCCAGGGTACGGCCTGACCGAGACCACGAGCGCAGCTGATCACCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCGTTCTCGAGGCAAGGTGGTGG
 35 CCTGGACACCGGAAGACCCCTGGCGTGAACCAAGCAGCGGGCGAGCTGTGCGTGGGGGCC
 GATGATCATGAGCGGCTACGTGAACAAACCCGGAGGCCACCAACGCCCTCATCGACAAGGA
 CGGCTGGCTGCACAGCGGCACATCGCCTACTGGGACGAGGACGAGCACTCTTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCGAGCTGGA
 GAGCATCCTGCTCCAGCACCCCAACATCTTCGACGCCGGCGTGGCCGGCTGCCGGACGA
 40 CGACGCCGGCGAGCTGCCGGCGCGTGGTGTGGAGCACGGCAAGACCATGACGGA
 GAAGGAGATCGTCACTACGTGGCCAGCCAGGTGACCACCGCCAAGAACGCTGCGGGCGG
 CGTGGTGGTGTGGACGAGGTCCCAGAAGGGCTGACCAGGGAAAGCTCGACGCCCGGAAGAT
 CCGCGAGATCCTGATCAAGGCAAGAACGGCGCAAGATCGCCGTGTAAGACTAGTGCAT
 CACATTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAAAAG
 45 CTTATTCATCTGGTGTCTTTCTGTGGTGTAAAGCCAACACCCCTGTCTAAAAAACATA
 AATTCTTAATCATTTGCCTCTTCTGTGCTTCATTAAATAAAAAATGGAAAGAA
 TCTAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAA

50 SEQ ID No. 11:

GGGAGAAAGCTTGGAGGATGGAGGACGCCAAGAACATCAAGAACGGCCGGCGCCCTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT

GGTGCCGGGCACGATGCCCTCACCGACGCCACATCGAGGTCGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCCTGGCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGAGAACAGCCTGCAGTTCTCATGCCGGTGTGGCGC
 CCTCTTCATCGCGTGGCGTGCACCGCGAACGACATCTACAACGAGCGGGAGCTGCT
 5 GAACAGCATGGGATCAGCCAGCCAGCGACCGTGGTGTGAGCAAGAAGGCCCTGCAGAA
 GATCCTGAACGTGCAGAAGAAGCTGCCCATCATCCAGAACAGATCATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCCAGTCGATGTACACGTTCGTGCACGCCACCTCCGCCGG
 10 CTTCAACGAGTACGACTTCGTCGGAGAGCTTCGACCCGGACAAGACCATGCCCTGAT
 CATGAACAGCAGCGCAGCACCGGCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGC
 15 CTGCGTGCCTCTCGCACGCCGGGACCCATCTCGCAACCAGGCTTCGGCATGTTACGACCCCTGGGCTA
 CCTCATCTCGGGCTTCCGGGTGGTCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCTGCTCGTGCACGCCCTGTCAGCTTCTT
 CGCCAAGAGCACCCGTATCGACAAGTACGACCTGTCGAACCTGCACGAGATGCCAGCGG
 20 GGGCGCCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGCCAACGGGTTCCACCTCCCGGG
 CATCCGCCAGGGTACGCCCTGACCGAGACCACGAGCGCAGTCTGATCACCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGGTGGTCCCTCGAGGCAAGGTGGTGG
 CCTGGACACCGGAAGACCCCTGGCGTGAACCAAGCGGGCGAGCTGTGCGTGGGGGCC
 GATGATCATGAGCGGCTACGTGAACAAACCGGAGGCCACCAACCCCTCATCGACAAGGA
 25 CGGCTGGCTGCACAGCGGCACATGCCCTACTGGGACGAGGACGAGCACTTCTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGTACCCAGGTGGGCCGGCGAGCTGGA
 GAGCATCTGCTCCAGCACCCAAACATCTCGACGCCGGCGTGGCCGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGTGGTGGTGTGGAGCACGGCAAGACCATGACGGA
 GAAGGGAGATCGTCACTACGTGCCAGGGTGAACCCGCCAACAGCAAGCTGCGGGCG
 30 CGTGGTGGTGTGGACGAGGTCCCAGGGCCTGACCGGGAAAGCTCGACGCCGGAAAGAT
 CCGCGAGATCCTGATCAAGGCAAGAAGGGCGCAAGATGCCGTGAAGACTAGTGCAT
 CACATTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAATAG
 CTTATTATCTGTTTTCTTCTGTTGGTGTAAAGCCAACACCCCTGTCTAAAAAACATA
 AATTCTTAAATCTTCTGCTCTCTGTGCTTCATTAATAAAAAATGGAAAGAA
 CCTAGATCTAA
 AAAAAAAAAAAA

SEQ ID No. 12:

GGGAGAAAGCTTGAGGATGGAGGACGCCAACATCAAGAACGCCCTTCTA
 35 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGGCACGATGCCCTCACCGACGCCACATCGAGGTCGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCCTGGCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGAGAACAGCCTGCAGTTCTCATGCCGGTGTGGCGC
 CCTCTTCATCGCGTGGCGTGCACCGCGAACGACATCTACAACGAGCGGGAGCTGCT
 40 GAACAGCATGGGATCAGCCAGCCAGCGACCGTGGTGTGAGCAAGAAGGCCCTGCAGAA
 GATCCTGAACGTGCAGAACAGCTGCCCATCATCCAGAACAGATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCCAGTCGATGTACACGTTCGTGCACGCCACCTCCGCCGG
 CTTCAACGAGTACGACTTCGTCGGAGAGCTTCGACCCGGACAAGACCATGCCCTGAT
 CATGAACAGCAGCGCAGCACCGGCTGCCAACGGGGTGGCCCTGCCGCACCGGACCGC
 45 CTGCGTGCCTCTCGCACGCCGGGACCCATCTCGCAACCAGATCATCCGGACAC
 CGCCATCTGAGCGTGGTGCCTCACCGGCTTCGGCATGTTACGACCCCTGGGCTA
 CCTCATCTCGGGCTCCGGGTGGTCTGATGTACCGGTTGCTCGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGTGTGCGACCCCTGTCAGCTTCTT
 CGCCAAGAGCACCCGTATCGACAAGTACGACCTGTCGAACCTGCACGAGATGCCAGCGG
 50 GGGCGCCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGCCAACGGGTTCCACCTCCCGGG
 CATCCGCCAGGGTACGCCCTGACCGAGACCACGAGCGCAGTCTGATCACCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCTCGAGGCAAGGTGGTGG

CCTGGACACCGGCAAGACCCCTGGCGTGAACCAGCGGGCGAGCTGTGCGTGCAGGGGCC
 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTATCGACAAGGA
 CGGCTGGCTGCACAGCGGCACATGCCACTGGGACGAGGACGAGCACTTCTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCGAGCTGGA
 5 GAGCATCTGCTCCAGCACCCAAACATCTCGACGCCGGTGGCGGGCTGCCGGACGA
 CGACGCCGGAGCTGCCGCCGCGGTGGTGTGGAGCACGGCAAGACCATGACGGA
 GAAGGAGATCGTCACTACGTGGCCAGGCCAGGTGACCACCGCCAAGAAGCTGCGGGCG
 CGTGGTGGTGTGGACGAGGTCCCAGAAGGGCTGACCGGGAAAGCTCGACGCCCGGAAGAT
 10 CCGCGAGATCCTGATCAAGGCAAGAAGGGCGCAAGATCGCCGTGTAAGACTAGTGCAT
 CACATTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAATAG
 CTTATTATCTCTTTCTTTCTGTGGTGTAAAGCCAACACCCTGTCTAAACATA
 AATTCTTAAATCATTTGCCTCTTCTGTGCTCAATTAAATAAAAGAA
 CCTAGATCTAA
 15 AAAAAAAAAAAAAA

15 SEQ ID No. 13:

GGGAGAAAGCTGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCCGGCCCTTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGCACGATGCCCTCACCGACGCCACATCGAGGTGACATCACCTACGCCGA
 20 GTACTTCGAGATGAGCGTGCCTGCCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTCATGCCGTGCTGGCG
 CCTCTTCATCGCGTGGCGTCGCCCGGAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCGACCGTGGTGTGAGCAAGAAGGGCTGCAGAA
 GATCCTGAACGTGAGAACAGCTGCCATCATCCAGAACATCATCATGGACAGCAA
 25 GACCGACTACCAGGGCTTCAGTCGATGTACACGTTGTGACCAAGCCACCTCCGCCGG
 CTTCAACGAGTACGACTTCGCTCCGGAGAGCTCGACCGGGACAAGACCATGCCCTGAT
 CATGAACAGCAGCGGACGCCCTGCCGAAGGGGTGGCCCTGCCGACCGGACCGC
 CTGCGTGCCTCTCGCACGCCGGGACCCATCTCGGCAACCAGATCATCCGGACAC
 CGCCATCCTGAGCGTGGTGCCTCACCAACGGCTTCGGCATGTCACGACCCCTGGGCTA
 30 CCTCATCTCGGGCTTCCGGGTGGTCTGATGTACCGGTTGCTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGTGTGCGACCGGACCCCTGTTCAGCTTCTT
 CGCCAAGAGCACCCCTGATCGACAAGTACGACCTGTCGACGAGATGCCAGCG
 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCGG
 CATCCGCCAGGGTACGCCCTGACCGAGACCACAGCGCGATCTGATCACCCCCGAGGG
 35 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCCTTCGAGGCCAAGGTGGTGG
 CCTGGACACCGGCAAGACCCCTGGCGTGAACCAGCGGGCGAGCTGTGCGTGCAGGGGCC
 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTATCGACAAGGA
 CGGCTGGCTGCACAGCGGCACATGCCACTGGGACGAGGACGAGCACTTCTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCGAGCTGGA
 40 GAGCATCTGCTCCAGCACCCAAACATCTCGACGCCGGTGGCGGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGCCGCGGTGGTGTGGAGCACGGCAAGACCATGACGGA
 GAAGGAGATCGTCACTACGTGGCAGGCCAGGTGACCACGCCAAGAACAGCTGCCAGCG
 CGTGGTGGTGTGGACGAGGTCCCAGAAGGGCTGACCGGGAAAGCTCGACGCCCGGAAGAT
 CCGCGAGATCCTGATCAAGGCAAGAACAGGGCGCAAGAACATCGCCGTGTAAGACTAGTTATA
 45 AGACTGACTAGCCCAGATGGGCCTCCAAACGGGCCCTCCCTCCCTTGCACCGAGATTA
 ATAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAA

SEQ ID No. 14:

GGGAGAAAGCTGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCCGGCCCTTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGCACGATGCCCTCACCGACGCCACATCGAGGTGACATCACCTACGCCGA

GTACTTCGAGATGAGCGTGCCTGCCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGGGTGTGCTCGGAGAACAGCCTGCAGTTCTCATGCCGTGCTGGCGC
 CCTCTTCATCGCGTGGCGTCGCCCGGCAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCCGACCGTGGTGTGAGCAAGAAGGCCTGCAGAA
 5 GATCCTGAACGTGAGAAGAGCTGCCATCATCCAGAAGATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCCAGTCGATGTACACGTTGTGACCAGCCACCTCCGCCGG
 CTTCAACGAGTACGACTTCGCTCCGGAGAGCTCGACCAGGACAAGAACCATGCCCTGAT
 CATGAACAGCAGCGGCAGCACCGCCTGCCGAAGGGGTGGCCCTGCCGACCGGACCG
 10 CTGCGTGCCTCTCGCACGCCGGACCCATCTCGGCAACCAGATCATCCGGACAC
 CGCCATCCTGAGCGTGGTGCCGTTCCACACGGCTTCGGCATGTTACGACCCCTGGGCTA
 CCTCATCTGCGGCTTCGGGTGGTCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGTGTGCGACCCTGTTCAGCTTCTT
 CGCCAAGAGCACCCCTGATGACAAGTACGACCTGTCGAACTGCACGAGATGCCAGCG
 15 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCAAGCGGTTCCACCTCCGGG
 CATCCGCCAGGGTACGCCCTGACCGAGACCAGAGCGCATCTGATCACCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCTTCGAGGCCAAGGTGGTGG
 CCTGGACACCGGCAAGACCCCTGGCGTGAACCAAGCAGGGCGAGCTGTGCGTGC
 GATGATCATGAGCGGCTACGTGAAACAACCGGAGGCCACCAACGCCCTATGACAAGGA
 CGGCTGGCTGCACAGCGGCACATGCCACTGGGACGAGGACGAGCACTCTTATCGT
 20 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGTACCAAGGTGGCGCCGGCGAGCTGG
 GAGCATCCTGCTCCAGCACCCAAACATCTCGACGCCGGTGGCGGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGGTGGTGTGAGCACGGCAAGACCATGACGGA
 GAAGGAGATCGTCACTACGTGGCCAGCCAGGGTGAACCAAGGCCAAGAAGCTGCCGG
 CGTGGTGGTGTGAGGCTCCGAAGGGCTGACCGGGAAAGCTCGACGCCGGAAAGAT
 25 CCGCGAGATCCTGATCAAGGCCAAGAAGGGCGCAAGATGCCGTGTAAGACTAGTCAA
 GACTGATAACCACCTCGTGTCCCTTCCCTCCCGAGTCAGGGCAGTCCACAGCAGCAGA
 ACAAGTGCCTCTGGACTGTTACGAGCAGACGAGCTTCTGCCCTGGGTTTGTGGT
 CATCTATTCTAGCAGGAAACACTAAAGGTGGAAATAAAAGATTTCTATTATGAAATAA
 AGAGTTGGCATGAAAGTGGCTACTGAGATCTAAAAAAAAAAAAAAAAAAAAAAA
 30 AAAAAAAAAAAAAAAAAAAAAAAA

SEQ ID No. 15:

GGGAGAAAGCTTGGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCGGCCCTTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 35 GGTGCCGGCACGATGCCCTCACCGACGCCACATCGAGGTGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCCTGCCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGGGTGTGCTCGGAGAACAGCCTGCAGTTCTCATGCCGTGCTGGCGC
 CCTCTTCATCGCGTGGCGTCGCCCGGCAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCCGACCGTGGTGTGAGCAAGAAGGCCTGCAGAA
 40 GATCCTGAACGTGAGAAGCTGCCATCATCCAGAAGATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCCAGTCGATGTACACGTTGTGACCAGCCACCTCCGCCGG
 CTTCAACGAGTACGACTTCGCTCCGGAGAGCTCGACCAGGACAAGAACCATGCCCTGAT
 CATGAACAGCAGCGCAGCACGCCGTGCCGAAGGGGTGGCCCTGCCGACCGGACCG
 CTGCGTGCCTCTCGCACGCCGGACCCATCTCGGCAACCAGATCATCCGGACAC
 45 CGCCATCCTGAGCGTGGTGCCGTTCCACACGGCTTCGGCATGTTACGACCCCTGGGCTA
 CCTCATCTGCGGCTTCGGGTGGTCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGTGTGCGGCCACCCCTGTTCAGCTTCTT
 CGCCAAGAGCACCCCTGATGACAAGTACGACCTGTCGAACTGCACGAGATGCCAGCG
 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCGGG
 50 CATCCGCCAGGGTACGCCCTGACCGAGACCACGAGCGCATCTGATCACCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCGTTCTGAGGCCAAGGTGGTGG
 CCTGGACACCGGCAAGACCCCTGGCGTGAACCAGCGGGCGAGCTGTGCGTGC
 GGGGCC

5 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGA
 CGGCTGGCTGCACAGCGGCACATGCCCTACTGGGACGAGGACGAGCACTCTTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCGAGCTGGA
 GAGCATCCTGCTCCAGCACCCAAACATCTTCGACGCCGGCGTGGCCGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGGTGGTGTGGAGCACGGCAAGACCATGACGGA
 10 GAAGGAGATCGTCGACTACGTGGCCAGGCCAGGTGACCACCGCCAAGAAGCTGCCGGCG
 CGTGGTGGCTGAGGCTCCGAAGGGCTGACCGGGAAAGCTCGACGCCGGAAAGAT
 CCGCGAGATCCTGATCAAGGCAAGAAGGGCGGCAAGATGCCGTGTAAGACTAGTAAGT
 GTTGGTTTCTGCCATCAGTAAAATTCTTAAACTTGGAGCAACAATAAAAAGCTTCCAG
 AACAGATCAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAA

SEQ ID No. 16:

15 GGGAGAAAGCTTGGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCCGGCCCTTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGCACCGATGCCCTCACCGACGCCACATCGAGGTGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCCTGGCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTGGAGAACAGCCTGCAGTTCTCATGCCGTGCTGGCGC
 CCTCTTCATGCCGTGGCGTCGCCCGGCAACGACATCTACAACGAGCGGGAGCTGCT
 20 GAACAGCATGGGATCAGCCAGCCGACCGTGGTGTGCTGAGCAAGAAGGGCTGCAGAA
 GATCCTGAACGTGCAAGAACAGCTGCCATCATCCAGAACATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCCAGTCGATGTACACGTTGTCGACCGACCCCTCCGCCGG
 CTTCAACGAGTACGACTTCGCTCCGGAGAGCTCGACCCGGACAAGACCATGCCCTGAT
 CATGAACAGCAGCGGCAACCGCCTGCCGAAGGGGGTGGCCCTGCCGACCGGACCGC
 25 CTGCGTGCCTTCGACGCCGGGACCCATCTCGCAACCAGATCATCCGGACAC
 CGCCATCTGAGCGTGGTGCCTCACCGCCTCGGCATGTTACGACCCCTGGGCTA
 CCTCATCTGCCGCTCCGGTGGTCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGTGCCTGCGACCCCTGTTAGCTTCTT
 CGCCAAGAGCACCCCTGATCGACAAGTACGACCTGTCGAACCTGCAAGAACGAGATGCCAGCG
 30 GGGCGCCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCGG
 CATCCGCCAGGGTACGCCGTGACCGAGACCACAGAGCGCATCTGATACCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCGTTCTGAGGCCAAGGTGGTGG
 CCTGGACACCGGCAAGACCCCTGGCGTGAACCAAGCAGGGCGAGCTGTGCGTGC
 GAGCTGGG
 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGA
 35 CGGCTGGCTGCACAGCGGCACATGCCCTACTGGGACGAGGACGAGCACTCTTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCGAGCTGGA
 GAGCATCCTGCTCCAGCACCCAAACATCTTCGACGCCGGCGTGGCCGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGGTGGTGTGGAGCACGGCAAGACCATGACGGA
 GAAGGAGATCGTCGACTACGTGGCAGCCAGGTGACCACGCCAAGAACGCTGCCGGCG
 40 CGTGGTGGCTGAGGCTCCGAAGGGCTGACCGGGAAAGCTCGACGCCGGAAAGAT
 CCGCGAGATCCTGATCAAGGCAAGAACAGGGCGCAAGATGCCGTGTAAGACTAGTGGAA
 GCATTTCTGATTGATGAAAAAAATAACTCAGTTATGCCATCTACCCCTGCTAGAAGG
 TTACAGTGTATTATGTAGCATGCAATGTGTTATGAGCTTAATAAAAATAAAATGAAA
 45 AAAATGCAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAA

SEQ ID No. 17:

GGGAGAAAGCTTGGAGGATGGAGGACGCCAAGAACATCAAGAAGGGCCCGGCCCTTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 50 GGTGCCGGCACCGATGCCCTCACCGACGCCACATCGAGGTGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCCTGGCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTGGAGAACAGCCTGCAGTTCTCATGCCGTGCTGGCGC

CCTCTTCATGGCGTGGCCGTGCCCGCGAACGACATCTACAACGAGCGGGAGCTGCT
 5 GAACAGCATGGGATCAGCCAGCGACCGTGGTGTGAGCAAGAAGGGCCTGCAGAA
 GATCCTGAACGTGCAGAAGAAGCTGCCATCATCCAGAAGATCATCATGGACAGCAA
 GACCGACTACCAGGGCTCCAGTCATGTACACGTTGTGACCAGCCACCTCCGCCGGG
 10 CTTCAACGAGTACGACTCGTCCCAGAGAGCTCGACCAGGACAAGACCATCGCCCTGAT
 CATGAACAGCAGCGCAGCACCGGCCTGCCGAAGGGGTGGCCCTGCCGCACCGGACCGC
 CTGCGTGCCTCTCGCACGCCGGACCCATCTCGGCAACCAGATCATCCCGGACAC
 CGCCATCCTGAGCGTGGTGCCTCACCCAGGCTTCGGCATGTCAGCACGACCTGGGCTA
 CCTCATCTGCGGCTCCGGTGGTCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 15 GAGCCTGCAGGACTACAAGATCCAGAGCGCCTGCTCGTGCACGAGATGCCAGCG
 CGCCAAGAGCACCCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAGATGCCAGCG
 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCAGCGTGGCCAAGCGGTTCCACCTCCCGG
 CATCCGCCAGGGTACGGCTGACCGAGACACGAGCGCAGCTGATCACCCCCGAGGG
 GGACGACAAGCGGGCGCCGTGGCAAGGTGGTCCGAGGCCAGGTGGTGGGA
 20 CCTGGACACCAGGCAAGACCCCTGGCGTGAACCAGCGGGCGAGCTGTGCGTGCAGGG
 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGA
 CGGCTGGCTGCACAGCGCGACATCGCCTACTGGGACGAGGACGAGCACTCTTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAAGGTGGCGCCGGAGCTGGA
 GAGCATCCTGCTCCAGCACCCAAACATCTCGACGCCGGTGGCCGGCTGCCGGACGA
 25 CGACGCCGGAGCTGCCGGCGCGTGGTGGTGTGGAGCACGGCAAGACCATGACGGA
 GAAGGAGATCGCACTACGTGGCAGCCAGGTGACCACGCCAGAAGCTGCCGGCG
 CGTGGTGGTCTGGACGAGGTCCCAGAGGGCTGACCGGGAGCTCGACGCCGGAGAT
 CCGCGAGATCCTGATCAAGGCCAGAAGGGCGCAAGATGCCGTGTAAGACTAGTAGAC
 CAATCTTAACATCTGATTATTTGATTATTTGAGTGTGTTGGACCATGTGTGA
 30 TCAGACTGCTATCTGAATAAAATAAGATTGCAAAACTCAGTGTGTTCTCCATCAGACA
 CTCCATGAAAGGTACAATTCTCTGATATTAAAGCTGGTTGTCTTAAACAACCTAA
 ATACACGTCTGTTAGCCCGCAATTGGAAAGGATATATGTGGCAATATTAACCTGGTACA
 TGAATATATGGGATAACATTAAATTGAAGGTTGGAATATATATATTAAAGCTTTAT
 TTCCAGAACAGTGAGGGTTAGGTCTGGAAAAGTACATTGCAAAAGTAGAAGAAATA
 35 GTAGTACCATATGCCAAAGTGTAGAGATGAATCATGTCAGTAGTTAGAATAAACATTCA
 ACTGTTTCTTGCTAAACACAGAAAGACCCATTGACAACATCTATGTCTGTAAAAA
 TGTTAGAGTACTGTCATCTGAATATAGCCCTCCAAAGAGAGAACAGGGTGGTATTCTA
 AGTATGTTCTTGTAACATCTTAGCAGTAGGACAGAGCCATACATGTGAAATCTGATT
 TTTATGTGTTATTGCTGTGTTACTACCTTGCAAAACAAAATACCCAAA
 GATATTAAACAAGGTTATAATTAGCATCTCCCTGGATCTAAATAGTATATTATATCC
 TGAAATAAATGAAATGATTGCTATAGATCTAAAAAAAAAAAAAAAAAAAAAAA
 40 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 SEQ ID No. 18:
 AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA AAGCTTATT
 ATCTGTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCCTG TCTAAAAAAC ATAAATTCT
 TTAATCATTT TGCCTCTTT CTCTGTGCTT CAATT

SEQ ID No. 19:
 45 CATCACATTT AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA
 AAGCTTATTTC ATCTGTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCCTG
 TCTAAAAAAC

SEQ ID No. 20:
 AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA AAGCTTATT
 50 ATCTGTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCCTG TCTAAAAAAC

SEQ ID No. 21:

CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA AAGCTTATTC ATCTGTTTT
CTTTTCGTT GGTGTAAAGC CAACACCCCTG TCTAAAAAAC ATAAATTCT

SEQ ID No. 22:

5 TGAGAATAAG AGAAAGAAAA TGAAGATCAA AAGCTTATTC ATCTGTTTT CTTTTTCGTT
GGTGTAAAGC CAACACCCCTG TCTAAAAAAC ATAAATTCT TTAATCATT

SEQ ID No. 23:

10 AGAAAGAAAA TGAAGATCAA AAGCTTATTC ATCTGTTTT CTTTTTCGTT GGTGTAAAGC
CAACACCCCTG TCTAAAAAAC ATAAATTCT TTAATCATT TGCCTCTTT

SEQ ID No. 24:

TGAAGATCAA AAGCTTATTC ATCTGTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCCTG
TCTAAAAAAC ATAAATTCT TTAATCATT TGCCTCTTT CTCTGTGCTT

15

SEQ ID No. 25:

AAGCTTATTC ATCTGTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCCTG TCTAAAAAAC
ATAAATTCT TTAATCATT TGCCTCTTT CTCTGTGCTT CAATTAATAA

20

SEQ ID No. 26:

ATCTGTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCCTG TCTAAAAAAC ATAAATTCT
TTAATCATT TGCCTCTTT CTCTGTGCTT CAATTAATAA AAAATGGAAA

SEQ ID No. 27:

25 CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA AAGCTTATTC ATCTGTTTT
CTTTTCGTT GGTGTAAAGC CAACACCCCTG TCTAAAAAAC ATAAATTCT TTAATCATT
TGCCTCTTT CTCTGTGCTT CAATTAATAA A

SEQ ID No. 28:

30 TGAAGATCAA AAGCTTATTC ATCTGTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCCTG
TCTAAAAAAC ATAAATTCT TTAATCATT TGCCTCTTT CTCTGTGCTT CAATTAATAA
A

SEQ ID No. 29:

35 CTTTTTCGTT GGTGTAAAGC CAACACCCCTG TCTAAAAAAC ATAAATTCT TTAATCATT
TGCCTCTTT CTCTGTGCTT CAATTAATAA A

SEQ ID No. 30:

40 AAGCTTATTC ATCTGTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCCTG TCTAAAAAAC

SEQ ID No. 31:

CAAAGGCTTTCAAGAGCCACCA

SEQ ID No. 32:

AAACATCACCA ATTAAGAACCA TCTCAGCCTA CCATGAGAAC AAGAGAAATA AAATGAAGAT
CAAAAGCTTA TTCATCTGTT TTTCTTTTC ATTGGTATAA AGCCAACACC CTGTCTAAAA
AACTATAAAT TTCTTAATC ATTTGCCTC TTTCTCTGT GCTTCAATTA ATAAAAAATG
GAAAGAATCT AGATCTAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA
AAAA

SEQ ID No. 33:

AAACAUCACA AUUAAGAACA UCUCAGCCUA CCAUGAGAAC AAGAGAAUA AAAUGAAGAU
CAAAAGCUUA UUCAUCUGUU UUUUUUUUUC AUUGGUUAAA AGCCAACACC CUGUCUAAA
AACUUAAAAU UUCUUUAAUC AUUUUGCCUC UUUUCUCUGU GCUUCAUUA AUAAAAAAU
GAAAGAAUCU AGAUCUAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA
AAAA

SEQ ID No. 34:

ACACATCACA ACCACAACCT TCTCAGGCTA CCCTGAGAAA AAAAGACATG AAGACTCAGG
ACTCATCTT TCTGTTGGTG TAAAATCAAC ACCCTAAGGA ACACAAATTT CTTAAACAT
TTGACTTCTT GTCTCTGTGC TGCAATTAAAT AAAAAATGGA AAGAATCTAC AGATCTAAA
AAAA

SEQ ID No. 35:

ACACAUCACA ACCACAACCU UCUCAGGCUA CCCUGAGAAA AAAAGACAUG AAGACUCAGG
ACUCAUUU UCUGUUGGUG UAAAAUCAAC ACCCUAAGGA ACACAAUUUU CUUUAACAU
UUGACUUUU GUCUCUGUGC UGCAAUUUAA AAAAAAUGGA AAGAAUCUAC AGAUCUAAA
AAAA

SEQ ID No. 36:AAACATCACA ATTAAGAACA TCTCAGCCTA CCATGAGAAC AAGAGAAATA
AAATGAAGAT CAAAAGCTTA TTCATCTGTT TTTCTTTTC ATTGGTATAAA AGCCAACACC
CTGTCTAAAAAACTATAAAAT TTCTTAATC ATTTGCCTC TTTTCTCTGT GCTTCAATTA
ATAAAAAAATG GAAAGAATCT AGATCTAAA AAAAAAAA AAAAAAAA AAAAAAAA
AAAAAAA AAAAAAAA AAAAAAAA

SEQ ID No. 37:

AAACAUCACA AUUAAGAACA UCUCAGCCUA CCAUGAGAAC AAGAGAAUA AAAUGAAGAU
CAAAAGCUUA UUCAUCUGUU UUUUUUUUUC AUUGGUUAAA AGCCAACACC CUGUCUAAA
AACUUAAAAU UUCUTTAATC ATTTGCCTC TTTTCTCTGT GCTTCAATTA ATAAAAAAATG
GAAAGAATCT AGATCTAAA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAAA
AAAAAAA AAAAAAAA

SEQ ID No. 38:

ACACATCACA ACCACAACCT TCTCAGGCTA CCCTGAGAAA AAAAGACATG AAGACTCAGG
ACTCATCTT TCTGTTGGTG TAAAATCAAC ACCCTAAGGA ACACAAATTT CTTAAACAT

TTGACTTCTT GTCTCTGTGC TGCAATTAAT AAAAAATGGA AAGAATCTAC AGATCTAAA
AAAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

SEQ ID No. 39:

ACACAUCA CAC ACCACAACCU UCUCAGGCUA CCCUGAGAAA AAAAGACAUG AAGACUCAGG
ACUCAUCUU UCUGUUGGUG UAAAAUCAAC ACCCUAAGGA ACACAAUUCUU CUUUAACAU
UUGACUUCUU GUCUCUGUGC UGCAAUUAU AAAAAAUGGA AAGAAUCUAC AGAUCUAAA
AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

SEQ ID No. 40:

GGGAGAAAGC TTGAGGATGG AGGACGCCAA GAACATCAAG AAGGGCCCGG CGCCCTTCTA
CCCGCTGGAG GACGGGACCG CCGGCGAGCA GCTCCACAAG GCCATGAAGC GGTACGCCCT
GGTGCCTGGC ACGATCGCCT TCACCGACGC CCACATCGAG GTCGACATCA CCTACGCGGA
GTACTTCGAG ATGAGCGTGC GCCTGGCCGA GGCCATGAAG CGGTACGGCC TGAACACCAA
CCACCGGATC GTGGTGTGCT CGGAGAACAG CCTGCAGTTC TTCATGCCGG TGCTGGCGC
CCTCTTCATC GGC GTGGCCCG TCGCCCCGGC GAACGACATC TACAACGGAGC GGGAGCTGCT
GAACAGCATG GGGATCAGCC AGCCGACCGT GGTGTTCGT AGCAAGAAGG GCCTGCAGAA
GATCCTGAAC GTGCAGAAGA AGCTGCCAT CATCCAGAAG ATCATCATCA TGGACAGCAA
GACCGACTAC CAGGGCTTCC AGTCGATGTA CACGTTCGT ACCAGCCACC TCCCGCCGGG
CTTCAACGAG TACGACTTCG TCCCGGAGAG CTTCGACCGG GACAAGACCA TCGCCCTGAT
CATGAACAGC AGCGGCAGCA CCGGCCTGCC GAAGGGGGTG GCCCTGCCGC ACCGGACCGC
CTGCGTGCAC TTCTCGCACG CCCGGGACCC CATCTCGGC AACCAAGATCA TCCCGGACAC
CGCCATCCTG AGCGTGGTGC CGTCCACCA CGGCTTCGGC ATGTTCACGA CCCTGGGCTA
CCTCATCTGC GGCTTCCGGG TGGTCCTGAT GTACCGGTTG GAGGAGGAGC TGTTCCTGCG
GAGCCTGCAG GACTACAAGA TCCAGAGCGC GCTGCTCGT CCGACCCGT TCAGCTTCTT
CGCCAAGAGC ACCCTGATCG ACAAGTACGA CCTGTCGAAC CTGCACGAGA TCGCCAGCGG
GGGCGCCCCG CTGAGCAAGG AGGTGGCGA GGCGTGGCC AAGCGGTTCC ACCTCCCAGGG
CATCCGCCAG GGCTACGGCC TGACCGAGAC CACGAGCGC ATCCTGATCA CCCCCGAGGG
GGACGACAAG CCGGGCGCCG TGGGCAAGGT GGTCCCGTTC TTCGAGGCCA AGGTGGTGG
CCTGGACACC GGCAAGACCC TGGCGTGAA CCAGCGGGC GAGCTGTGCG TGCGGGGGCC
GATGATCATG AGCGGCTACG TGAACAACCC GGAGGCCACC AACGCCCTCA TCGACAAGGA
CGGCTGGCTG CACAGCGGCG ACATCGCCTA CTGGGACGAG GACGAGCACT TCTTCATCGT
CGACCGGCTG AAGTCGCTGA TCAAGTACAA GGGCTACCAAG GTGGCGCCGG CCGAGCTGGA
GAGCCTGCAG CTCCAGCACC CCAACATCTT CGACGCCGGC GTGGCCGGC TGCCGGACGA
CGACGCCGGC GAGCTGCCGG CCGCGGTGGT GGTGCTGGAG CACGGCAAGA CCATGACGGA
GAAGGAGATC GTCGACTACG TGGCCAGCCA GGTGACCA GCGCAAGAAGC TGCGGGGCGG

CGTGGTGTTC GTGGACGAGG TCCCGAAGGG CCTGACCGGG AAGCTCGACG CCCGGAAGAT
CCCGCAGATC CTGATCAAGG CCAAGAAGGG CGGCAAGATC GCCGTGTAAG ACTAGTAAAC
ATCACACAATTA AGAACATCTC AGCCTACCAT GAGAACAAAGA GAAATAAAAT GAAGATCAA
AGCTTATTCA TCTGTTTTC TTTTCTATTG GTATAAAGCC AACACCTGT CTAAAAAAACT
ATAAAATTCT TTAACATTT TGCCTCTTT CTCTGTGCTT CAATTAATAA AAAATGGAAA
GAATCTAGAT CTAAAAAAA AAAAAAA AAAAAAA AAAAAAA AAAAAAA
AAAAAAA AAAAAA

SEQ ID No. 41:

GGGAGAAAGC TTGAGGATGG AGGACGCCAA GAACATCAAG AAGGGCCCGG CGCCCTTCTA
CCCGCTGGAG GACGGGACCG CGGGCGAGCA GCTCCACAAG GCCATGAAGC GGTACGCCCT
GGTGCCGGC ACGATCGCCT TCACCGACGC CCACATCGAG GTCGACATCA CCTACGCGGA
GTACTTCGAG ATGAGCGTGC GCCTGGCCGA GGCCATGAAG CGGTACGGCC TGAACACCAA
CCACCGGATC GTGGTGTGCT CGGAGAACAG CCTGCAGTTC TTCATGCCGG TGCTGGCGC
CCTCTTCATC GGCGTGGCCG TCGCCCCGGC GAACGACATC TACAACGAGC GGGAGCTGCT
GAACAGCATG GGGATCAGCC AGCCGACCGT GGTGTTCGTG AGCAAGAAGG GCCTGCAGAA
GATCCTGAAC GTGCAGAAGA AGCTGCCAT CATCCAGAAG ATCATCATCA TGGACAGCAA
GACCGACTAC CAGGGCTTCC AGTCGATGTA CACGTTCGTG ACCAGCCACC TCCCGCCGGG
CTTCAACGAG TACGACTTCG TCCCGGAGAG CTTCGACCGG GACAAGACCA TCGCCCTGAT
CATGAACAGC AGCGGCAGCA CGGGCCTGCC GAAGGGGGTG GCCCTGCCGC ACCGGACCGC
CTGCGTGCCTC TTCTCGCACG CCCGGGACCC CATCTCGGC AACCAGATCA TCCCGGACAC
CGCCATCCTG AGCGTGGTGC CGTCCACCA CGGCTCGGC ATGTTACGA CCCTGGGCTA
CCTCATCTGC GGCTTCCGGG TGGTCCTGAT GTACCGGTTG GAGGAGGAGC TGTTCTGCG
GAGCCTGCAG GACTACAAGA TCCAGAGCGC GCTGCTCGTG CCGACCTGT TCAGCTTCTT
CGCCAAGAGC ACCCTGATCG ACAAGTACGA CCTGTCGAAC CTGCACGAGA TCGCCAGCGG
GGGCGCCCCG CTGAGCAAGG AGGTGGCGA GGCGTGGCC AAGCGGTTCC ACCTCCCAGGG
CATCCGCCAG GGCTACGGCC TGACCGAGAC CACGAGCGC ATCCTGATCA CCCCCGAGGG
GGACGACAAG CGGGCGCCG TGGCAAGGT GGTCCCGTTC TTCGAGGCCA AGGTGGTGG
CCTGGACACC GGCAAGACCC TGGCGTGAA CCAGCGGGC GAGCTGTGCG TGCGGGGGCC
GATGATCATG AGCGGCTACG TGAACAACCC GGAGGCCACC AACGCCCTCA TCGACAAGGA
CGGCTGGCTG CACAGCGCG ACATCGCTA CTGGGACGAG GACGAGCACT TCTTCATCGT
CGACCGGCTG AAGTCGCTGA TCAAGTACAA GGGCTACCAAG GTGGCGCCGG CCGAGCTGGA
GAGCATCCTG CTCCAGCACC CCAACATCTT CGACGCCGGC GTGGCCGGGC TGCCGGACGA
CGACGCCGGC GAGCTGCCGG CGCGGGTGGT GGTGCTGGAG CACGGCAAGA CCATGACGGA
GAAGGAGATC GTCGACTACG TGGCCAGCCA GGTGACCAACC GCCAAGAAGC TGCGGGGGCC

100

CGTGGTGTTC GTGGACGAGG TCCCGAAGGG CCTGACCGGG AAGCTCGACG CCCGGAAGAT
CCGCGAGATC CTGATCAAGG CCAAGAAGGG CGGCAAGATC GCCGTGTAAG ACTAGTACAC
ATCACAAACCA CAACCTTCTC AGGCTACCCT GAGAAAAAAA GACATGAAGA CTCAGGACTC
ATCTTTCTG TTGGTGTAAA ATCAACACCC TAAGGAACAC AAATTTCTTT AAACATTTGA
CTTCTTGTCT CTGTGCTGCA ATTAATAAAA AATGGAAAGA ATCTACAGAT CTAAAAAAA
AAAAAAA AAAA AAAA

The claims defining the invention are as follows:

1. An artificial nucleic acid molecule comprising
 - a. at least one open reading frame (ORF);
 - b. at least one 3'-untranslated region element (3'UTR element) comprising a nucleic acid sequence which is derived from the 3'UTR of an albumin gene or from a variant of the 3'UTR of an albumin gene, and
 - a histone stem-loop.
2. The artificial nucleic acid molecule according to claim 1, wherein the open reading frame does not code for β -globulin or human factor IX.
3. The artificial nucleic acid molecule according to claim 1 or 2,

wherein the at least one 3'UTR element comprises a nucleic acid sequence which is derived from the 3'UTR of a vertebrate albumin gene or from a variant thereof; or

wherein the 3'-UTR element is derived from the 3'-UTR of the rat albumin gene or the human albumin gene; or wherein the 3'UTR of a vertebrate albumin gene or a variant thereof, is from a mammalian albumin gene, a mouse albumin gene or from a variant thereof, a primate albumin gene, a human albumin gene or an albumin gene from *Olive baboon*, or the 3'UTR of the human albumin gene or from a variant thereof
4. The artificial nucleic acid molecule according to any one of claims 1-3, wherein the at least one 3'UTR element comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 99% to the nucleic acid sequence according to SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 32, SEQ ID NO. 33, SEQ ID No. 34, or SEQ ID No. 35, or wherein the at least one 3'UTR element comprises or consists of a fragment of a nucleic acid sequence which has an identity of at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 99% to the nucleic acid sequence according to SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 32, SEQ ID NO. 33, SEQ ID No. 34, or SEQ ID No. 35.

5. The artificial nucleic acid molecule according to any one of claims 1-4 further comprising at least one of a poly(A) sequence and a polyadenylation signal.
6. The artificial nucleic acid molecule according to any one of claims 1-5, wherein the open reading frame does not code for albumin.
7. The artificial nucleic acid molecule according to any one of claims 1-6, further comprising at least one of a 5'-cap structure, a poly(C) sequence, and an IRES-motif.
8. The artificial nucleic acid molecule according to any one of claims 1-7, wherein the nucleic acid comprises an additional 5'-element, wherein the additional 5'-element is a 5'UTR, a promoter, or a 5'UTR and a promoter containing-sequence.
9. The artificial nucleic acid molecule according to any one of claims 1-8, wherein the artificial nucleic acid molecule is at least partially G/C modified.
10. The artificial nucleic acid molecule according to any one of claims 1-9, wherein the open reading frame comprises a codon-optimized region or wherein the open reading frame is codon-optimized.
11. The artificial nucleic acid molecule according to any one of claims 1-10, which is an RNA molecule or mRNA molecule.
12. A vector comprising the artificial nucleic acid according to any one of claims 1-11.
13. The vector according to claim 12, wherein the vector is a DNA vector, plasmid vector or a viral vector.
14. A cell comprising the artificial nucleic acid molecule according to any one of claims 1-11 or the vector according to claim 12 or 13.
15. A pharmaceutical composition comprising the artificial nucleic acid molecule according to any one of claims 1-16, the vector according to claim 12 or 13, or the cell according to claim 14.
16. The pharmaceutical composition according to claim 15, further comprising one or more pharmaceutically acceptable diluents, excipients and adjuvants.
17. Use of the artificial nucleic acid molecule according to any one of claims 1-11, the vector according to claim 12 or 13, the cell according to claim 14, or the

pharmaceutical composition according to claim 15 or 16 for the manufacture of a medicament for use as a vaccine or in gene therapy.

18. A method for treating or preventing a disorder comprising administering the artificial nucleic acid molecule according to any one of claims 1-11, the vector according to claim 12 or 13, the cell according to claim 14, or the pharmaceutical composition according to claim 15 or 16 to a subject in need thereof.
19. A method of treating or preventing a disorder comprising transfection of a cell with an artificial nucleic acid molecule according to any one of claims 1-11 or with the vector according to claim 12 or 13.
20. The method according to claim 19, wherein transfection of a cell is performed *in vitro* or *ex vivo* and the transfected cell is administered to a subject in need thereof.
21. The method according to any one of claims 18-20, wherein the method is a vaccination method or a gene therapy method.
22. A method for stabilizing and/or prolonging protein production from a nucleic acid molecule, the method comprising the step of associating the nucleic acid molecule, with a 3'UTR element and a histone stem-loop, wherein the 3'UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'UTR of an albumin gene or from a variant of the 3'UTR of an albumin gene.
23. Use of a 3'UTR element and a histone stem-loop for stabilizing and/or prolonging protein production from a nucleic acid molecule, wherein the 3'UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'UTR of an albumin gene or from a variant of the 3'UTR of an albumin gene.
24. The method according to claim 22 or the use according to claim 23, wherein the 3'UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'UTR of a vertebrate albumin gene or from a variant thereof.
25. The method or use according to claim 24, wherein the 3'UTR of a vertebrate albumin gene or a variant thereof, is from a mammalian albumin gene, a mouse albumin gene or from a variant thereof, a primate albumin gene, a human albumin gene or an albumin gene from *Olive baboon*, or the 3'UTR of the human albumin gene or from a variant thereof.

26. The method or the use according to any one of claims 22-25, wherein the 3'UTR element comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 99% to the nucleic acid sequence according to SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 32, SEQ ID NO. 33, SEQ ID No. 34, or SEQ ID No. 35, or wherein the 3'UTR element comprises or consists of a fragment of a nucleic acid sequence that has an identity of at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 99% to the nucleic acid sequence according to SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 32, SEQ ID NO. 33, SEQ ID No. 34, or SEQ ID No. 35.
27. A kit comprising an artificial nucleic acid molecule according to any one of claims 1-11, a vector according to claim 12 or 13, a cell according to claim 14, and/or a pharmaceutical composition according to claim 15 or 16.
28. The kit according to claim 27 further comprising instructions for use, cells for transfection, an adjuvant, a means for administration of the pharmaceutical composition, a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable solution for dissolution or dilution of the artificial nucleic acid molecule, the DNA-vector or the pharmaceutical composition.

PpLuc from mRNAs with different 3'-UTRs (HeLa)

PpLuc(GC)..




Fig. 1

PpLuc from mRNAs with different 3'-UTRs (HeLa)

PpLuc(GC) ..




Fig. 2

PpLuc from mRNA with different albumin 3'-UTR variants (HeLa)

PpLuc(GC)..




Fig. 3

PpLuc(GC) – A64 lacking a 3'-UTR

5'-GGGAGAAAGCTGAGGATGGAGGACGCCAAGAACATCAAGAACGGCCGGCGCCCTTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGCACGATGCCCTCACCGACGCCACATCGAGGTCGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCGCCTGGCCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTGGAGAACAGCCTGCAGTTCTCATGCCGTGCTGGCGC
 CCTCTTCATCGCGTGGCCGTGCCCGCGAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCCGACCGTGGTGTGCTGAGCAAGAACGGCCTGCAGAA
 GATCCTGAACGTGAGAACAGCTGCCATCATCCAGAACGATCATCATGGACAGCAA
 GACCGACTACCAGGGCTCCAGTCGATGTACACGTTGTCGACCGACCTCCCGCCGG
 CTTCAACGAGTACGACTTCGTCGGAGAGCTTCGACCGGACAAGAACCATCGCCCTGAT
 CATGAACAGCAGCGGCAGCACCGGCTGCCGAAGGGGTGGCCCTGCCGACCGGACCGC
 CTGCGTGCCTCTCGCACGCCCGGGACCCATCTCGGCAACCAGATCATCCCGGACAC
 CGCCATCTGAGCGTGGTGCCTCACCGGCTTCGGCATGTTACGACCCCTGGGCTA
 CCTCATCTGCCGCTCCGGGTGGTCCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGCTGCTGCGACCCCTGTTCAGCTTCTT
 CGCCAAGAGCACCCCTGATCGACAAGTACGACCTGTCGAACCTGCACGAGATGCCAGCG
 GGGCGCCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCGG
 CATCCGCCAGGGTACGCCCTGACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCTTCGAGGCCAAGGTGGTGG
 CCTGGACACCGCAAGACCCCTGGCGTGAACCAGCGGGCGAGCTGTGCGTGCAGGG
 GATGATCATGAGCGGCTACGTGAACAACCGGAGGCCACCAACGCCCTCATCGACAAGGA
 CGGCTGGCTGCACAGCGCGACATGCCCTACTGGGACGAGGACGAGCACTCTTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAGGTGGCGCCGGCAGCTGGA
 GAGCATCTGCTCCAGCACCCAAACATCTCGACGCCGGCGTGGCCGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGTGGTGGTGTGGAGCACGGCAAGACCATGACGGA
 GAAGGGAGATCGTCAACTACGTGGCCAGCCAGGTGACCACCGCCAAGAACGTCGAGGG
 CGTGGTGGTGTGGACGAGGTCCCGAAGGGCTGACCGGGAAAGCTGACGCCGGAAAGAT
 CCGCGAGATCTGATCAAGGCCAAGAACGGCGCAAGATGCCGTGTAAGACTAGTAGAT
 CTAAA
 AAAAAA-3'

Fig. 4

PpLuc(GC) – albumin – A64

5'-GGGAGAAAGCTT GAGGA TGGAGGACGCCAAGAACATCAAGAACGGGCCGGCGCCCTTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGCACGATCGCCTCACCGACGCCACATCGAGGTGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCCTGGCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGAGAACAGCCTGCAGTTCTCATGCCGGTGTGGCGC
 CCTCTTATCGCGTGGCGTCGCCCGAAGCAGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCGACCGTGGTGTGAGCAAGAACGGCCTGCAGAA
 GATCCTGAACGTGAGAACAGCTGCCATCATCCAGAACATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCAGTCATGTACAGCTCGTGAACAGCCACCTCCCGCCGG
 CTTCAACGAGTACGACTTCGCTCCGGAGAGCTTCGACCCGGACAAGAACATGCCCTGAT
 CATGAACAGCAGCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGC
 CTGCGTGCCTTCGACGCCGGGACCCATCTCGGCAACCAGATCATCCGGACAC
 CGCCATCCTGAGCGTGGTGCCGTTCCACCACGGCTTCGGCATGTTCACGACCCCTGGGCTA
 CCTCATCTGCGGTTCCGGTGGTCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGTGCCTGCGACCCCTGTTAGCTTCTT
 CGCCAAGAGCACCCGTATCGACAAGTACGACCTGTCGAACCTGCAAGGAGATGCCAGCGG
 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCGGG
 CATCCGCCAGGGTACGGCCTGACCGAGACCACGAGCGCGATCCTGATCACCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCTTGTGAGGCCAAGGTGGTGG
 CCTGGACACCGCAAGACCCCTGGCGTGAACCAGCAGCGGGCGAGCTGTGCGTGC
 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATGACAAGGA
 CGGCTGGCTGCACAGCGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAAGGTGGCGCCGGGAGCTGGA
 GAGCATCCTGCTCCAGCACCCAAACATCTCGACGCCGGCGTGGCGGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGTGGTGGTGTGAGCACGGCAAGACCATGACGGA
 GAAGGAGATCGTCACTACGTGGCCAGCCAGGTGACCACGCCAAGAACGCTGCCGG
 CGTGGTGGTGTGGACGAGGTCCCGAAGGGCCTGACCGGGAGCTCGACGCCCGGAAGAT
 CCGCGAGATCCTGATCAAGGCCAAGAACGGCGCAAGATGCCGTGTAAGACTAGTGCAT
CACATTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAAAG
CTTATTATCTGTTTTCTTCTGTTGGTGTAAAGCCAACACCTGTCTAAAAAACATA
AATTCTTAATCATTTGCCTTTCTGTGCTTCAATTAAAGAAAATGGAAAGAA
TCTAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAA-3'

Fig. 5

6/23

PpLuc(GC) – albumin2 – A64

5'-GGGAGAAAGCTT GAGGATGGAGGACGCCAAGAACATCAAGAACGGGCCGGCGCCCTTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGGACGATCGCCTTCACCGACGCCACATCGAGGTCGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCGCCTGGCCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTCATGCCGTGCTGGCGC
 CCTCTTCATCGGCGTGGCGTCGCCCGGGAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCCGACCGTGGTGTGAGCAAGAACGGCCTGCAGAA
 GATCCTGAACGTGCAAGAACAGCTGCCATCATCCAGAACATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCCAGTCGATGTACACGTTGTGACCAGCCACCTCCCGCCGG
 CTTCAACAGAGTACGACTTCGCTCCGGAGAGCTTCGACCGGGACAAGAACCATCGCCCTGAT
 CATGAACAGCAGCGGAGCACC GGCTGCCGAAGGGGTGGCCCTGCCGACCGGACCGC
 CTGCGTGCCTCTCGCACGCCGGGACCCATCTCGGCAACCAGATCATCCGGACAC
 CGCCATCTGAGCGTGGTGCGTTCCACCACGGCTTCGGCATGTTCACGACCCCTGGGCTA
 CCTCATCTGCGGCTTCCGGGTGGTCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGTGTGCGTGGCACCCCTGTTCAGCTTCTT
 CGCCAAGAGCACCCCTGATCGACAAGTACGACCTGTCGAACCTGCAAGAACATGCCAGCG
 GGGCGCCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCGGG
 CATCCGCCAGGGTACGCCCTGACCGAGACCACGAGCGCGATCCTGATCACCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGGTGGTCCCGTTCTCGAGGCCAAGGGTGGTGG
 CCTGGACACCGGCAAGACCCCTGGCGTGAACCAGCGGGCGAGCTGTGCGTGCCTGGGCC
 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTATCGACAAGGA
 CGGCTGGCTGCACAGCGCGACATCGCCTACTGGGACGAGGACGAGCACTCTTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGTACCCAGGTGGCGCCGGCGAGCTGGA
 GAGCATCTGCTCCAGCACCCCAACATCTCGACGCCGGCGTGGCGGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGGTGGTGTGGAGCACGGCAAGAACATGACGGA
 GAAGGGAGATCGTCACTACGTGGCCAGCCAGGTGACCACGCCAAGAACCTGCGGGCG
 CGTGGTGGTGTGGACGAGGTCCGAAGGGCTGACCGGGAAAGCTGACGCCGGAAAGAT
 CCGCGAGATCCTGATCAAGGCCAAGAACGGCGCAAGATGCCGTGTAAGACTAGTGCAT
CACATTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAAAG
CTTATTCTGTGTTTTCTTTCTGTGGTGTAAAGCCAACACCTGTCTAAAAAACATA
AATTCTTAAATCATTTGCCCTTTCTGTGCTTCAATTAAATAAAAATGGAAAGAA
TCTAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAA-3'

Fig. 6

7/23

PpLuc(GC) – albumin3 – A64

Fig. 7

8/23

PpLuc(CC) – albumin4 – A64

5'-GGGAGAAAGCTTGAGGATGGAGGACGCCAAGAACATCAAGAACGGGCCGGCGCCCTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGGCACGATGCCCTCACCGACGCCACATCGAGGTCGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCCTGGCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGAGAACAGCCTGCAGTTCTCATGCCGGTGCTGGCGC
 CCTCTTCATCGCGTGGCGTCGCCCGAAGCAGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCGACCGTGGTGTGAGCAAGAACGGGCTGCAGAA
 GATCCTGAACGTGCAGAACAGCTGCCATCATCCAGAACATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCCAGTCGATGTACACGTTCGTGAACCAGCCACCTCCCGCCGG
 CTTCAACGAGTACGACTTCGTCGGAGAGCTTCGACCCGGACAAGACCATGCCCTGAT
 CATGAACAGCAGCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCGACCGGACCGC
 CTGCGTGCCTTCGCACGCCCGGGACCCATCTCGCAACCAGATCATCCCGGACAC
 CGCCATCCTGAGCGTGGTGCCTCCACCACGGCTTCGCGATGTTACGACCCCTGGGCTA
 CCTCATCTGCCGCTTCCGGTGGTCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGTGCCTGCGAACCTGAGATGCCAGCG
 CGCCAAGAGCACCCCTGATCGACAAGTACGACCTGTCGAACCTGACGAGATGCCAGCG
 GGGCGCCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGG
 CATCCGCCAGGGCTACGGCCTGACCGAGAACACGAGCGCATCCTGATCACCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCGTTCTCGAGGCCAAGGTGGTGG
 CCTGGACACCGGCAAGACCCCTGGCGTGAACCAGCGGGCGAGCTGTGCGTGC
 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATGACAAGGA
 CGGCTGGCTGCACAGCGCGACATGCCCTACTGGGACGGAGGACGAGCACTTCTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAAGGTGGCGCCGGCGAGCTGGA
 GAGCATCCTGCTCCAGCACCCCAACATCTCGACGCCGGCGTGGCGGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGGTGGTGTGGAGCACGGCAAGAACCATGACGGA
 GAAGGAGATCGTCACTACGTGGCCAGCCAGGTGACCACGCCAAGAACGCTGCGGGCG
 CGTGGTGGTGTGGACGAGGTCCCGAAGGGCTGACCCGGAAAGCTGACGCCGGAAAGAT
 CCGCGAGATCCTGATCAAGGCCAAGAACGGCGGCAAGATGCCGTGAAGACTAGTGCAT
 CACATTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAAAG
 CTTATTATCCTTTTCTTTCTGTTGGTGTAAAGCCAACACCCCTGTCTAAAAAACATA
 AATTCTTAATCATTTGCCTTTCTCTGTGCTCAATTAAATAAAAGGAAAGAA
 TCTAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAA-3'

Fig. 8

9/23

PpLuc(GC) – albumin5 – A64

5'-GGGAGAAAGCTTGAGGATGGAGGACGCCAAGAACATCAAGAACGGGCCGGGCCCTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGGCACGATGCCCTCACCGACGCCACATCGAGGTCGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCCTGGCCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTCATGCCGTGCTGGCGC
 CCTCTCATGCCGTGGCCGTCGCCCGAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGGATCAGCCAGCCGACCGTGGTGTGAGCAAGAACGGCCTGCAGAA
 GATCCTGAACGTGCAGAAGAACGCTGCCATCATCCAGAACGATCATCATGGACAGCAA
 GACCGACTACCAGGGCTCCAGTCGATGTACACGTTGACCGGCCACCTCCCGCCGG
 CTTCAACGAGTACGACTTCGTCGGAGAGCTTCGACCCGGACAAGAACCATGCCCTGAT
 CATGAACACGAGCCGGCAGCACCGGCTGCCGAAGGGGTGGCCCTGCCGACCGGACCGC
 CTGCGTGCCTTCGACGCCGGGACCCATCTCGGCAACCAGAACATCCCAGACAC
 CGCCATCCTGAGCGTGGTGCCGTTCCACCACGGCTTCGACGAGCTGGCT
 CCTCATCTGCCGTTCCGGGTGGTCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGCTGCTGCGACCCCTGTCAGCTTCTT
 CGCCAAGAGCACCCGTATGACAAGTACGACCTGTCGACGAGATGCCAGCGG
 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCGG
 CATCCGCCAGGGCTACGCCCTGACCGAGAACACGAGCGCAGTCGATCACCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCGTTCTCGAGGCAAGGTGGTGG
 CCTGGACACCGGAAGACCCCTGGCGTGAACCAAGCGGGCGAGCTGTCGTCGGGG
 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATGACAAGGA
 CGGCTGGCTGCACAGCGGCACATGCCCTACTGGGACGAGGACGAGCACTCTTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAAGGTGGCGCCGGGAGCTGGA
 GAGCATCCTGCTCCAGCACCCCAACATCTCGACGCCGGCGTGGCCGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGCCGCGGTGGTGTGGAGCACGGCAAGAACATGACGGA
 GAAGGGAGATCGTCACTACGTGGCCAGGCCAGGTGACCAACGCCAAGAACGCTGCCGG
 CGTGGTGGTGTGGACGAGGTCCCGAAGGGCTGACCGGGAGCTCGACGCCGGAAAGAT
 CCGCGAGATCTGATCAAGGCCAAGAACGGGGCAAGATGCCGTGTAAGACTAGTGCAT
 CACATTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAAAG
CTTATTATCTGTTGGTCTTTCTGTTGTTAAAGCCAACACCTGTCTAAAAAACATA
AATTCTTAATCATTGCTCTTCTGTGCTCAATTAAATAAAAATGGAAAGAA
TCTAGATCTAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAA-3'

Fig. 9

10/23

PpLuc(GC) – albumin6 – A64

5'-GGGAGAAAGCTTGAGGATGGAGGACGCCAAGAACATCAAGAACGGGCCGGCGCCCTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGCACGATGCCCTCACCGACGCCACATCGAGGTCGACATCACCTACGCCA
 GTACTTCGAGATGAGCGTGCCTGGCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGAGAACAGCCTGCAGTTCTCATGCCGGTGTGGCGC
 CCTCTCATCGCGTGGCCGTCGCCCGCGAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCGACCGTGGTGTGAGCAAGAACGGCTGCAGAA
 GATCCTGAACGTGCAGAAGAACGCTGCCATCATCCAGAACGATCATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCAGTCGATGTACACGTTGTGACCAAGCCACCTCCGCCGG
 CTTCAACGAGTACGACTCGTCCCAGAGAGCTTCGACCCGGACAAGACCATCGCCCTGAT
 CATGAACAGCAGCGCAGCACCGGCTGCCGAAGGGGTGGCCCTGCCGACCGGACCGC
 CTGCGTGCCTTCGACGCCGGGACCCATCTCGGCAACCAGATCATCCGGACAC
 CGCCATCTGAGCGTGGTGCCTCACCACGGCTTCGGCATGTTCACGACCCCTGGGCTA
 CCTCATCTCGGGCTTCGGTGGTCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGTGCCTGCGACCCCTGTTAGCTTCTT
 CGCCAAGAGCACCCCTGATCGACAAGTACGACACTGTCGAACCTGACGAGATCGCCAGCG
 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCGG
 CATCCGCCAGGGCTACGGCCTGACCGAGACCACGAGCGCGATCCTGATCACCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCTCGAGGCCAAGGTGGTGG
 CCTGGACACCGCAAGACCCCTGGCGTGAACCAAGCAGCGGGCGAGCTGTGCGTGC
 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGA
 CGGCTGGCTGCACAGCGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAAGGTGGCGCCGGCGAGCTGGA
 GAGCATCCTGCTCCAGCACCCAAACATCTCGACGCCGGCGTGGCGGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGTGGTGGTGTGGAGCACGGCAAGACCATGACGGA
 GAAGGGAGATCGTCGACTACGTGGCCAGCCAGGTGACCAACGCCAAGAACGCTGCGGGCG
 CGTGGTGGTGTGGACGAGGTCCCGAAGGGCTGACCGGGAAAGCTCGACGCCCGAAGAT
 CGCGAGAGATCCTGATCAAGGCCAAGAACGGCGCAAGATGCCGTGTAAGACTAGTGCAT
CACATTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAATAG
CTTATTACATCTTTTCTTTCTGTTGGTGTAAAGCCAACACCTGTCTAAAAAACATA
AATTCTTAATCATTTGCCTCTTCTGTGCTTCAATTAAAGAAAATGGAAAGAA
CCTAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAA-3'

Fig. 10

11/23

PpLuc(GC) – albumin7 – A64

5'-GGGAGAAAGCTTGAGGATGGAGGACGCCAAGAACATCAAGAACGGGCCGGCGCCCTTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGCACGATGCCCTCACCGACGCCACATCGAGGTCGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCCTGGCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGAGAACAGCCTGCAGTTCTCATGCCGGTGTGGCGC
 CCTCTCATGCCGTGGCGTCGCCCGGAAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCCGACCGTGGTGTGAGCAAGAACGGCTGCAGAA
 GATCCTGAACGTGAGAACAGCTGCCATCATCCAGAACATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCCAGTCGATGTACACGTTGTCGACCAAGCCACCTCCCACCGG
 CTTCAACGAGTACGACTCGTCCCAGAGAGCTCGACCCGGACAAGAACATCGCCCTGAT
 CATGAACAGCAGCGCAGCACCGGCTGCCGAAGGGGTGGCCCTGCCGACCGGACCGC
 CTGCGTGCCTCTGCACGCCGGGACCCATCTCGGCAACCAGATCATCCCAGACAC
 CGCCATCCTGAGCGTGGTGCCTCACACCGGCTTCGGCATGTTCACGACCCCTGGGCTA
 CCTCATCTGCGGCTTCCGGTGGTCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGTCTGCGTGGCACCCCTGTTAGCTTCTT
 CGCCAAGAGCACCCGTACGACAAGTACGACCTGTCGAACCTGACGAGATCGCCAGCGG
 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCAGGG
 CATCCGCCAGGGTACGCCGTGACCGAGACCACGAGCGCGATCTGATCACCCCCAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCTCGAGGCCAAGGTGGTGGGA
 CCTGGACACCGCAAGACCCCTGGCGTGAACCAGCGGGCGAGCTGTCGTGCGGGGCC
 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGA
 CGGCTGGCTGCACAGCGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAAGGTGGCGCCGGCGAGCTGGA
 GAGCATCCTGCTCCAGCACCCAAACATCTCGACGCCGGCGTGGCGGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGTGGTGGTGTGGAGCACGGCAAGACCATGACGGA
 GAAGGGAGATCGTCGACTACGTGGCCAGCCAGGTGACCAACGCCAAGAACGCTGCCGGCG
 CGTGGTGGTGTGGACGAGGTCCCGAAGGGCTGACCGGGAAAGCTCGACGCCGGAAAGAT
 CCGCGAGATCTGATCAAGGCCAAGAACGGCGCAAGATGCCGTGTAAGACTAGTGCAT
CACATTAAAAGCATCTCAGCCTACCATGAGAATAAGAGAAAGAAAATGAAGATCAATAG
CTTATTACATCTTTTCTTTCTGTTGGTGTAAAGCCAACACCTGTCTAAAAAACATA
AATTCTTAATCATTTGCCTTTCTGTGCTTCAATTAAATAAAAATGGAAAGAA
CCTAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAA-3'

Fig. 11

12/23

PpLuc(GC) – ag – A64

5'-GGGAGAAAGCTT GAGGA TGGAGGACGCCAAGAACATCAAGAACGGGCCGGCGCCCTTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGCACGATCGCCTTCACCGACGCCACATCGAGGTCGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCGCCTGGCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGAGAACAGCCTGCAGTTCTCATGCCGGTGTGGCGC
 CCTCTTCATCGCGTGGCGTCGCCCGAAGCAGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCGACCGTGGTGTGAGCAAGAACGGCCTGCAGAA
 GATCCTGAACGTGAGAACAGCTGCCCATCATCCAGAACATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCCAGTCGATGTACAGCTCGTACCAGCCACCTCCCGCCGG
 CTTCAACGAGTACGACTCGTCCCAGAGAGCTCGACCCGGACAAGAACATCGCCCTGAT
 CATGAACAGCAGCGGCAGCACCGGCTGCCGAAGGGGGTGGCCCTGCCGCACCGGACCGC
 CTGCGTGCCTCTCGCACGCCGGGACCCATCTCGGCAACCAGATCATCCGGACAC
 CGCCATCCTGAGCGTGGTGCCGTTCAACCACGGCTTCGGCATGTTCACGACCCCTGGGCTA
 CCTCATCTCGGGCTTCCGGTGGTCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGTCTCGTGCACCGGACCCCTGTTAGCTTCTT
 CGCCAAGAGCACCCCTGATCGACAAGTACGACCTGTCGAACCTGCAACGAGATGCCAGCGG
 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCGGG
 CATCCGCCAGGGTACGGCCTGACCGAGACCACGAGCGCATCTGATCACCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCTTGAGGCAAGGTGGTGGGA
 CCTGGACACCGCAAGACCCCTGGCGTGAACCAGCGGGCGAGCTGTGCGTGCAGGGGCC
 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTATCGACAAGGA
 CGGCTGGCTGCACAGCGCGACATCGCCTACTGGGACGAGGACGAGCACTCTTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAAGGTGGCGCCGGCGAGCTGGA
 GAGCATCCTGCTCCAGCACCCAAACATCTCGACGCCGGCGTGGCGGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGTGGTGGTGTGGAGCACGGCAAGACCATGACGGA
 GAAGGAGATCGTCACTACGTGGCCAGCCAGGTGACCACCGCCAAGAACGCTGCCGGCG
 CGTGGTGGTGTGGACGAGGTCCCAGGGCTGACCGGGAAAGCTCGACGCCGGAAAGAT
 CCGCGAGATCCTGATCAAGGCCAAGAACGGCGCAAGATGCCGTGTAAGACTAGTTATA
 AGACTGACTAGCCCGATGGCCTCCAACGGCCCTCCCTCCCTTGCACCGAGATTA
 ATAGATCTAAA
 AAAAAAAA-3'

Fig. 12

PpLuc(CC) – gusb – A64

5' -GGGAGAAAGCTT GAGGATGGAGGACGCCAAGAACATCAAGAACGGGCCGGCGCCCTTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGCACGATGCCCTCACCGACGCCACATCGAGGTCGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCCTGGCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTCATGCCGGTGTGGCGC
 CCTCTCATCGCGTGGCCGTCGCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCGACC GTGGTGTGAGCAAGAACGGCCTGCAGAA
 GATCCTGAACGTGCAGAACAGCTGCCATCATCCAGAACATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCCAGTCATGTACACGTTGTGACCAGCCACCTCCCGCCGG
 CTTCAACGAGTACGACTCGTCCCAGAGAGCTTCGACCCGGACAAGACCATCGCCCTGAT
 CATGAACAGCAGCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCGACCGGACCGC
 CTGCGTGCCTTCGACGCCGGGACCCCATCTCGGCAACCAGATCATCCCGGACAC
 CGCCATCCTGAGCGTGGTGCCGTTCCACCAACGGCTTCCGATGTTACGACCCCTGGGCTA
 CCTCATCTGCGGTTCCGGGTGGTCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGTCTCGTCCGACCCCTGTCAGCTTCTT
 CGCCAAGAGCACCCGTATCGACAAAGTACGACCTGTCGAACCTGCACGAGATCGCCAGCGG
 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCCGGG
 CATCCGCCAGGGTACGGCTGACCGAGAACACGAGCGCAGTCTGATCACCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCTTCGAGGCCAAGGTGGTGGGA
 CCTGGACACCGGCAAGACCCCTGGCGTGAACCAGCGGGCGAGCTGTGCGTGGGGGCC
 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGA
 CGGCTGGCTGCACAGCGCGACATCGCCTACTGGGACGAGGACGAGCACTCTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCGAGGTGGCGCCGGCGAGCTGG
 GAGCATCCTGCTCCAGCACCCAAACATCTCGACGCCGGCGTGGCCGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGGTGGTGTGGAGCAGGCCAAGAACCATGACGGA
 GAAGGAGATCGTCACTACGTGGCCAGCCAGGTGACCACGCCAAGAACGCTGCGGGCG
 CGTGGTGTGTCGAGGAGTCCGAAGGGCTGACCGGGAAAGCTCGACGCCGGAAAGAT
 CCGCGAGATCCTGATCAAGGCCAAGAACGGCGCAAGATCGCCGTGAAGACTAGTGC
 GAAACTGATACCACCTGCGTGTCCCTCCCTCCCGAGTCAGGGCGACTTCCACAGCAGC
 ACAAGTGCCTCCTGGACTGTTACGGCAGACCAACGTTCTGGCTGGTTTGTTGTGG
 CATCTATTCTAGCAGGAAACACTAAAGGTGGAAATAAAAGATTTCTATTATGGAAATAA
 AGAGTTGGCATGAAAGTGGCTACTGAGATCTAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA-3'

Fig. 13

PpLuc(GC) – atp50 – A64

5'-GGGAGAAAGCTT GAGGATGGAGGACGCCAAGAACATCAAGAACGGGCCGGCGCCCTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGGACAGATGCCCTCACCGACGCCACATCGAGGTCGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCCTGGCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTCATGCCGGTGTGGCGC
 CCTCTTCATCGCGTGGCGTCGCCCGAAGCAGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCCAGCGACCGTGGTGTGAGCAAGAACGGCCTGCAGAA
 GATCCTGAACGTGCAGAACAGCTGCCCATCATCCAGAACAGATCATCATATGGACAGCAA
 GACCGACTACCAGGGCTTCCAGTCATGTACACGTTGACCGACGCCACCTCCCGCCGG
 CTTCAACGAGTACGACTTCGTCGGAGAGCTTCGACCCGGACAAGACCATCGCCCTGAT
 CATGAACACGAGCAGCCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCGACCGGACCGC
 CTGCGTGCCTCTCGCACGCCGGGACCCATCTCGGCAACCAGATCATCCCGGACAC
 CGCCATCTGAGCGTGGTGCCTCACCCAGGCTTCGGCATGTTACGACCCCTGGGCTA
 CCTCATCTGCCGCTTCCGGGTGGTCCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGCTGCTCGTGCACCCCTGTCAGCTCTT
 CGCCAAGAGCACCCGTACGACAAGTACGACCTGTCGAACCTGCAAGGAGATGCCAGCGG
 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCGG
 CATCCGCCAGGGTACGGCCTGACCGAGACCACGAGCGCGATCCTGATCACCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCGTTCTCGAGGCAAGGTGGTGGGA
 CCTGGACACCGGAAGACCCCTGGCGTGAACCAAGCAGCGGGCGAGCTGTGCGTGGGGCC
 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATGACAAGGA
 CGGCTGGCTGCACAGCGCGACATGCCCTACTGGGACGGAGGACGAGCACTCTTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGTACCAAGGTGGCGCCGGCGAGCTGGA
 GAGCATCTGCTCCAGCACCCCAACATCTCGACGCCGGCGTGGCGGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGTGGTGGCTGGAGCAGGCCAAGAACCATGACCGGA
 GAAGGGAGATCGTCGACTACGTGGCCAGCCAGGTGACCAAGGCCAAGAAGCTGCGGGCG
 CGTGGTGGTGTGGACGGAGGTCCGAAGGGCCTGACCGGGAGCTCGACGCCGGAGAT
 CCGCGAGATCCTGATCAAGGCCAAGAACGGCGCAAGATGCCGTGAAGACTAGTAAGT
GTTGGTTTCTGCCATCAGTGAAAATTCTAAACTTGAGCAACAATAAAAGCTTCCAG
AACAGATCAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAA-3'

Fig. 14

PpLuc(GC) – ndufa1 – A64

5'-GGGAGAAAGCTT GAGGATGGAGGACGCCAAGAACATCAAGAACGGGCCGGCGCCCTTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGCACGATGCCCTCACCGACGCCACATCGAGGTCGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCCTGGCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTCATGCCGGTGTGGCGC
 CCTCTCATCGCGTGGCCGTCGCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCGACCCTGGTGTGAGCAAGAACGGCCTGCAGAA
 GATCCTGAACGTGCAGAAGAACGCTGCCCATCATCCAGAAGATCATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCAGTCATGTACACGTTGTGACCAGCCACCTCCCGCCGG
 CTTCAACGAGTACGACTCGTCCCAGAGAGCTTCGACCCGGACAAGAACCATGCCCTGAT
 CATGAACAGCAGCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCGACCGGACCGC
 CTGCGTGCCTTCGACGCCGGGACCCATCTCGGCAACCAGATCATCCGGACAC
 CGCCATCCTGAGCGTGGTGCCGTTCCACCAACGGCTTCGGCATGTTCACGACCCCTGGGCTA
 CCTCATCTCGGGCTCCGGGTGGTCCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGCTGCTCGTGCACCGGACCCCTGTTAGCTTCTT
 CGCCAAGAGCACCCGTATCGACAAGTACGACCTGTCGAACCTGCACGAGATGCCAGCGG
 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCGG
 CATCCGCCAGGGTACGGCCTGACCGAGACCACGAGCGCAGTCTGATCACCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCTTCTCGAGGCCAAGGTGGTGGGA
 CCTGGACACCGCAAGACCCCTGGCGTGAACCAGCAGCGGGCGAGCTGTCGTGCGGGGCC
 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATGACAAGGA
 CGGCTGGCTGCACAGCGCGACATCGCCTACTGGGACGAGGACGAGCACTCTTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAAGGTGGCGCCGGAGCTGGA
 GAGCATCTGCTCCAGCACCCAAACATCTCGACGCCGGCGTGGCGGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGTGGTGGTGTGGAGCACGGCAAGACCATGACGGA
 GAAGGAGATCGTCACTACGTGGCCAGCCAGGTGACCACCGCCAAGAACGCTGCCGGCG
 CGTGGTGTGACGAGGTCCCGAAGGGCCTGACCGGGAGCTCGACGCCGGAAAGAT
 CCGCGAGATCTGATCAAGGCCAAGAACGGCGCAAGATGCCGTGTAAGACTAGTGGAA
GCATTTCTGATTGATGAAAAAAATAACTCAGTTATGCCATCTACCCCTGCTAGAAGG
TTACAGTGTATTATGTAGCATGCAATGTGTTATGTAGTGCTTAATAAAATAAAATGAAA
AAAATGCAGATCTAAAAAAAAAAAAAA
AAAAAAAAAAAAAAA-3'

Fig. 15

PpLuc(CC) – atp51 – A64

5'-GGGAGAAAGCTT GAGGATGGAGGACGCCAAGAACATCAAGAACGGGCCGGCGCCCTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGGACAGATGCCCTCACCGACGCCACATCGAGGTCGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCCTGGCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGAGAACAGCCTGCAGTTCTCATGCCGGTGTGGCGC
 CCTCTCATGCCGTGGCGTCGCCCGAAGCAGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCCACCGTGGTGTGAGCAAGAACGGCCTGCAGAA
 GATCCTGAACGTGCAGAACAGCTGCCCATCATCCAGAACAGATCATCATGGAACAGCAA
 GACCGACTACCAGGGCTTCCAGTCGATGTACACGTTGACCGAGCCACCTCCGCCGG
 CTTCAACGAGTACGACTTCGTCGGAGAGCTTCGACCCGGAACAGACCATGCCCTGAT
 CATGAACAGCAGCGGCAGCACCGGCCTGCCGAAGGGGGTGGCCCTGCCGACCCGGACCG
 CTGCGTGCCTCTCGCACGCCGGGACCCATCTCGGCAACCAGATCATCCGGACAC
 CGCCATCTGAGCGTGGTGCCTCACCGGCTTCGGCATGTTACGACCCCTGGGCTA
 CCTCATCTGCCGTTCCGGGTGCTGATGTACCGGTCGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCCTGCTGCGCACCTGTTCAGCTTCTT
 CGCCAAGAGCACCCATGACAGAACAGTACGACCTGTCGAACCTGACGAGATGCCAGCG
 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCGG
 CATCCGCCAGGGCTACGGCCTGACCGAGACCACGAGCGCAGTCCTGATCACCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCGTTCTCGAGGCAAGGTGGTGG
 CCTGGACACCGCAAGACCCCTGGCGTGAACCAGCGGGCGAGCTGTGCGTGGGGGCC
 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATGACAAGGA
 CGGCTGGCTGCACAGCGGCACATGCCCTACTGGGACGAGGACGAGCACTCTTACATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGTACCAAGGTGGCGCCGGAGCTGGA
 GAGCATCTGCTCCAGCACCCCAACATCTCGACGCCGGCTGGCGGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGTGGTGGTGTGGAGCACGGCAAGACCATGACGGA
 GAAGGGAGATCGTCACTACGTGGCCAGCCAGGTGACCACGCCAAGAACGCTGCCGG
 CGTGGTGGTGTGGACGAGGTCCCGAAGGGCCTGACCGGGAGCTCGACGCCGGAGAT
 CCGCGAGATCTGATCAAGGCCAAGAACGGCGCAAGATGCCGTGAAGACTAGTAGAC
 CAATCTTAACATCTGATTATTTGATTATTGAGTGTGGACCATGTGTGA
 TCAGACTGCTATCTGAATAAAATAAGATTGCAAAACTCAGTGTGTTCTCCATCAGACA
 CTCCATGAAAGGTACAATTCTCTGATATTAGCTGGTTGTCTTAAACAACCTAA
 ATACACGTCTGTTAGCCCGAATTGGAAAGGATATATGTGGCAATATTACCTGGTACA
 TGAATATATGGGATAACATTAAATTGAAAGGTTGGAATATATATATTAAAGCTTTAT
 TTCCAGAACAGTGGGTTAGGTCTGGAAAATATAACTTGCAAAAGTAGAAGAAATA
 GTAGTACCATATGCCAAAGTGTGATAGAGATGAATCATGTCAGTAGTTAGAATAACATTCA
 ACTGTTTCTTGCTAAATCACAGAAAGACCCATTGACAACATCTATGTCTGAAAAAA
 TGTTAGAGTACTTGTCACTTGAAATATAGCCTCCCAAGAGAGAACAGGGTGGTATTCTA
 AGTATGTTCTTGTAACATCTTAGCAGTAGGACAGAGCCATACATGTGAAATCTGATT
 TTTATGTTGTTATTGCTGTTACTACCTTGCAAAACAAACCCAAA
 GATATTAAACAAGGTATAATTAGCATCTCCCTGGATCTAAATAGTATATTATATCC
 TGAAATAAAATGAAATGATTGCTATAGATCTAAAAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAA-3'

Fig. 16




Fig. 17

PpLuc from mRNA with albumin 3'-UTR from different species (HDF)

PpLuc(GC)..





Fig. 18

PpLuc from mRNA with albumin 3'-UTR from different species (HDF)

PpLuc(GC)..

**PpLuc/RrLuc [RLU]**

mean, SD

Fig. 19

PpLuc from mRNA with albumin 3'-UTR from different species (L-929)

PpLuc(GC)..




Fig. 20

PpLuc from mRNA with albumin 3'-UTR from different species (HeLa)

PpLuc(GC)..




Fig. 21

22/23

PpLuc(GC) – albumin8 – A64

5'-GGGAGAAAGCTTGAGGATGGAGGACGCCAAGAACATCAAGAACGGGCCGGCGCCCTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGGACGATGCCCTCACCGACGCCACATCGAGGTCGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCCTGGCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGGAGAACAGCCTGCAGTTCTCATGCCGGTGCCTGGCGC
 CCTCTCATCGCGTGGCGTCGCCCGAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGGATCAGCCAGCGACCCTGGTGTGAGCAAGAACGGCCTGCAGAA
 GATCCTGAACGTGCAGAAGAACGCTGCCATCATCCAGAACGATCATCATGGAACAGCAA
 GACCGACTACCAGGGCTTCCAGTCGATGTACACGTTCGTGAACAGCCACCTCCCGCCGG
 CTTCAACGAGTACGACTCGTCCCAGAGAGCTTCGACCCGGACAAGACCATCGCCCTGAT
 CATGAACAGCAGCGGAGCACCAGCGCTGCCGAAGGGGGTGGCCCTGCCGACCGGACCGC
 CTGCGTGCCTCTCGCACGCCGGGACCCATCTCGGCAACCAGATCATCCGGACAC
 CGCCATCCTGAGCGTGGTCCGTTCCACCAACGGCTTCGATGTTCACGACCCCTGGGCTA
 CCTCATCTCGGGCTTCCGGGTGGTCTGATGTACCGGTTCGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGCTGCTCGTGCACCGCTGTCAGCTTCTT
 CGCCAAGAGCACCCGTATCGACAAGTACGACCTGTCGAACCTGACGAGATGCCAGCGG
 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCAAGCGGTTCCACCTCCGG
 CATCCGCCAGGGCTACGGCTGACCGAGACACGAGCGCAGCTGATCACCCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCTTCGAGGCCAAGGTGGTGGGA
 CCTGGACACCGCAAGACCCCTGGCGTAACCGAGCGGGCGAGCTGTCGTGCGGGGCC
 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGA
 CGGCTGGCTGCACAGCGCGACATCGCCTACTGGGACGGAGGACGAGCACTCTTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAAGGTGGCGCCGGAGCTGGA
 GAGCATCCTGCTCCAGCACCCAAACATCTCGACGCCGGCTGGCGGGCTGCCGGACGA
 CGACGCCGGCGAGCTGCCGGCGCGTGGTGGTGCAGCAGGCCAAGAACCATGACGGA
 GAAGGGAGATCGTCACTACGTGGCCAGCCAGGTGACCACGCCAAGAACGCTGCCGGCG
 CGTGGTGGTCTGAGGCTCCGAAGGGCTGACCCGGAAAGCTCGACGCCCGGAAGAT
CCGCGAGATCTGATCAAGGCCAAGAACGGCGCAAGATGCCGTGTAAGACTAGTAAAC
ATCACAAATTAAAGAACATCTCAGCCTACCATGAGAACAAAGAGAAATAAAATGAAGATCAA
AGCTTATTCTGTTTCTTTCTGGTATAAAGCCAACACCCCTGTCTAAAAAAACT
ATAAATTCTTAATCATTGCTCTTCTGTGCTTCATAATAAAATGGAAA
GAATCTAGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAA-3'

Fig. 22

23/23

PpLuc(GC) – albumin9 – A64

5'-GGGAGAAAGCTT GAGGATGGAGGACGCCAAGAACATCAAGAACGGGCCGGCGCCCTTCTA
 CCCGCTGGAGGACGGGACCGCCGGCGAGCAGCTCCACAAGGCCATGAAGCGGTACGCCCT
 GGTGCCGGGACGATGCCCTCACCGACGCCACATCGAGGTGACATCACCTACGCCGA
 GTACTTCGAGATGAGCGTGCGCCTGGCGAGGCCATGAAGCGGTACGCCCTGAACACCAA
 CCACCGGATCGTGGTGTGCTCGAGAACAGCCTGCAGTTCTCATGCCGGTGTGGCGC
 CCTCTCATCGCGTGGCCGTCGCCCCGGCGAACGACATCTACAACGAGCGGGAGCTGCT
 GAACAGCATGGGATCAGCCAGCGACCGTGGTGTGAGCAAGAACGGCCTGCAGAA
 GATCCTGAACGTGAGAACAGCTGCCCATCATCCAGAACATCATCATGGACAGCAA
 GACCGACTACCAGGGCTTCAGTCATGTACACGTTGTGACCAGCCACCTCCGCCGG
 CTTCAACGAGTACGACTCGTCCCAGAGAGCTTCGACCCGGACAAGACCATCGCCCTGAT
 CATGAACAGCAGCGGAGCACCAGCGCTGCCGAAGGGGTGGCCCTGCCGACCGGACCGC
 CTGCGTGCCTTCGACGCCGGGACCCCATCTCGGCAACCAGATCATCCGGACAC
 CGCCATCCTGAGCGTGGTGCCGTTCCACCAACGGCTTCGGCATGTTCACGACCCCTGGGCTA
 CCTCATCTCGGGCTTCCGGTGGTCCTGATGTACCGGTTGAGGAGGAGCTGTTCTGCG
 GAGCCTGCAGGACTACAAGATCCAGAGCGCGCTGCTCGTCCGACCCCTGTCAGCTTCTT
 CGCCAAGAGCACCCGTATCGACAAGTACGACCTGTCGAACCTGACGAGATGCCAGCGG
 GGGCGCCCGCTGAGCAAGGAGGTGGCGAGGCCGTGGCCAAGCGGTTCCACCTCCGG
 CATCCGCCAGGGTACGGCTGACCGAGACCAACGAGCGCGATCCTGATCACCCCGAGGG
 GGACGACAAGCCGGCGCCGTGGCAAGGTGGTCCCTTCGAGGCCAAGGTGGTGGGA
 CCTGGACACCGGAAGACCCCTGGCGTGAACACAGCGGGCGAGCTGTGCGTGCAGGGCC
 GATGATCATGAGCGGCTACGTGAACAACCCGGAGGCCACCAACGCCCTCATCGACAAGGA
 CGGCTGGCTGCACAGCGCGACATCGCCTACTGGGACGAGGACGAGCACTCTTCATCGT
 CGACCGGCTGAAGTCGCTGATCAAGTACAAGGGCTACCAAGGTGGCGCCGGAGCTGGA
 GAGCATCCTGCTCCAGCACCCAAACATCTCGACGCCGGCGTGGTGGCTGGAGCACGGCAAGAACCATGACGGA
 CGACGCCGGCGAGCTGCCGGCGCGTGGTGGCTGGAGCACGGCAAGAACCATGACGGA
 GAAGGAGATCGTCACTACGTGGCCAGCCAGGTGACCACGCCAAGAACGCTGCCGGCG
 CGTGGTGTGACGAGGTCCGAAGGGCTGACCGGGAAAGCTCGACGCCGGAAAGAT
 CCGCGAGATCCTGATCAAGGCCAAGAACGGCGCAAGATGCCGTGTAAGACTAGTACAC
ATCACAAACACACACCTCTCAGGCTACCCCTGAGAAAAAAAGACATGAAGACTCAGGACTC
ATCTTTCTGTTGGTGTAAAATCAACACCCCTAAGGAACACAAATTCTTAAACATTGA
CTTCTTGTCTGTGCTGCAATTAAATAAAAATGGAAAGAATCTACAGATCTAAAAAAA
AAA-3'

Fig. 23